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Chapter I
Introductlon
and
Outline of Investigations
INTRODUCTION
History
For a very long period it was generally accepted that ac- 
tivities in the body were entirely co-ordinated by the nervous 
system. The discovery of s e c r e t m  in 1902 by Bayliss & Star- 
ling (1) therefore, can be considered as a t u r m n g - o o i n t  in 
history of co-ordinating functions. Secretin is a "chemical 
messenger" s h a n n g  with the nervous system the quality of co- 
ordinating functions in other organs than the place were the 
stimulus is rece i v e d . Bayliss & Starling realized, that ït 
was unlikely that secretin was the only endogenous substance 
that acted as a "chemical messenger" between different organs, 
and that others would soon be found. They created a new word 
to d e s e n b e  such messengers: hormone, derived from the Greek 
and meaning "to excite" (2). Bayliss & Starling were cor­
rect in assuming that many hormones would soon be discovered.
In 1904, Fleig discovered that acid and soap were able to re­
lease a hormone from the duodenum stimulating bile secretion 
(3). In 1905, Ekins discovered g a s t n n ,  a hormone o n g i n a t i n g  
from the antral mucosa, g i v m g  g a s t n c  acid secretion when ïn- 
]ected intravenously into anaesthetized cats (4). Further evi- 
dence that gallbladder contraction was regulated bv a hormone 
was found by Ivy & Oldberg in 1928 (5). This hormone was named 
cholecystokinin. In 1943, Harper & Raper (9) discovered a hor­
mone giving pancreatic enzyme secretion, which they named oan- 
creozymin. Although other gastrointestinal hormones, like mo- 
tilin (6) and substance P (7) were discovered in that period 
too, secretin, g a s t n n  and cholecystokinin constitute the clas- 
sical triad of gut hormones, because for a long period, these
3 hormones were considered sufficiënt to explain the entire 
e n d o e n n e  regulation of digestive functions (8).
Half a century elapsed before the ïmolications of the gas- 
trointestinal hormones were realized. The reasons for such slow 
progress included controversy over the very existance of seve- 
ral hormones on one hand, and difficulties in ï s o l a t m g  them
8
on the other. Only in the 60's, biochemical techniques became 
solid enough to purify tissue extracts for structural work (12, 
13,14). During purification of the cholecystokinetic substance 
from porcine small intestine, Jorpes & Mutt discovered that 
this cholecystokinetic substance was also responsible for the 
pancreozymin activity, and that cholecystokinin and pancreo- 
zymin were in fact the same hormone (10). In view of antece- 
dence in discovery, this polypeptide is now named cholecysto­
kinin (11). After 1960 the development in biochemical techni­
ques advanced in a way that nowadays many polypeptides are 
purified and structurally characterized, before their biologi- 
cal functions are elucidated (15,16,17,18).
Recently, a dramatic new period in the history of chole­
cystokinin started, due to the development of radioimmunoassay 
and immunohistochemical techniques. In 1975, Vanderhaeghen et 
al discovered a gastrin-like substance in the central nervous 
system (19), that turned out to be mainly cholecystokinin-like. 
(20,21,22). It became clear that cholecystokinin was not only 
confined to the gastrointestinal tract, but was also widely 
distributed throughout the central and periferal nervous sys­
tem (21,23) .
Heterogeneity
Like many other polypeptide hormones, cholecystokinin is 
heterogeneous.This means that peptide hormones exist in a num- 
ber of different molecular forms all containing the biologic-ally 
active region (size-heterogeneity)(24,25,26,27), while between 
species amino acid variations may occur (species-heterogenei- 
ty) (28, 29, 30) . In mammalian species, at least 5 molecular var- 
iants of cholecystokinin have been demonstrated in small intes- 
tinal mucosa extracts (31). So far 3 of these molecular forms 
have been isolated and structurally characterized from m amma­
lian intestinal mucosa: The originally isolated porcine tria- 
contatriapeptide (CCK 33) (14), a molecular variant extended by 
a further 6 amino acid residues at the amino-terminus, porcine 
triacontanonapeptide (CCK 39) (32), and a molecular form contai-
9
ning 58 a n n o  acid residues (CCK 58), probably comparable with 
porcine component I cholecystokinin (31), which has recently 
been isolated from canine small m t e s t i n a l  mucosa (33). Al- 
though at present only larger molecular forms of cholecystoki­
nin have been isolated from upper small m t e s t i n a l  mucosa, ït 
is believed from radioimmunoassay data, that smaller molecular 
forms predominate (31,34,35). However, until now none of these 
small molecular v a n a n t s  have been structurally c h a r a c t e n z e d  
from small intestine. Although ït is generally believed, that 
smaller molecular forms of cholecystokinin, like the octapep- 
tide, predominate in small m t e s t i n a l  mucosa (31, 34,35), the 
correct proportion between the different molecular v a n a n t s  is 
still questionable, and some recent studies even show ratios 
in favour of larger molecular forms (71,72). A major reason 
for this controversy is the difference in antibody affinity 
for the v a n o u s  molecular forms of cholecystokinin. Many anti- 
sera raised against small forms of cholecystokinin may show 
diminished binding to larger molecular v a n a n t s  (36), while 
some antisera raised against larger molecular forms may show 
diminished binding to smaller molecular variants (78). This 
problem can be related to differences m  amino acid chain 
lenght and charge between v a n o u s  molecular cholecystokinin 
variants, promoting conformational changes between smaller and 
larger molecular forms. Although the complete antibody binding 
site is present in different molecular forms of a peptide, con­
formational changes may result in differences in antibody af­
finity (91).
The heterogeneity is the more important, because different 
molecular forms may possess different biological activities.
It has been reported that sulphated cholecystokinin octapeptide 
is 2 - 1 0  times more potent on a molar base than cholecysto­
kinin t n a c o n t a t n a p e p t i d e  in several systems, including gall- 
bladder contraction in vivo and vitro (85,89,90). In contrast 
to small molecular variants, large molecular forms of cholecys­
tokinin like the t n a c o n t a t n a  and triacontanonapeptide have 
positively charged amino acid residues in excess. This is not
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only important for extraction procedures (83), but it also ma- 
kes larger molecular forms of cholecystokinin very susceptible 
to adhere to plastic surfaces like radioimmunoassay tubes and 
infusion materials (84). However, when sufficiënt amounts of 
albumin were added to infusates to prevent adherence, cholecys­
tokinin octapeptide and triacontatriapeptide turned out to be 
equipotent in contracting guinea pig gallbladder in vitro (87) 
and in stimulating pancreatic enzyme secretion in vivo and in 
vitro
In nervous tissue, cholecystokinin is heterogeneous too. 
Smaller molecular forms predominate even more (22,31,36). A 
small form of cholecystokinin containing the carboxyl-terminal 
octapeptide is the only molecular form structurally characte­
rized in brain, hitherto (37). However, there is strong immu- 
nological evidence, that larger molecular variants of cholecys­
tokinin are present in brain too (31,38). The exact biological 
functions of these molecular variants in the nervous system 
still have to be elucidated, but it is generally accepted, that 
larger molecular forms of cholecystokinin in brain are precur­
sors of smaller ones, like the octapeptide and possibly the 
tetrapeptide (31).
The messenger-RNA of cholecystokinin has not yet been 
isolated, but it can be derived from studies on the related 
peptide gastrin, where messenger-RNA codes for a peptide of 
some 110 - 140 amino acid residues (39,40) that there is room 
for additional heterogeneity and extensions of the known m o ­
lecular forms, not only at the amino-terminus, but also at the 
carboxyl-terminus (32).
Cholecystokinin in the nervous system
Cholecystokinin is widely distributed throughout the ner­
vous system (40) . Both in central and peripheral nervous tissue, 
cholecystokinin occurs not only in cell bodies, but also in 
nerve endings. There is immunocytochemical evidence, that cho­
lecystokinin is mainly concentrated in nerve terminals espec- 
ially in synaptosomes and synaptic vesicules (42). It has also
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been shown that depolarization of nerves in rats induces a cal­
cium dependent cholecystokinin release (42). Furthermore, cho­
lecystokinin octapeptide and tetrapeptide apnlicated to the 
postsynaptic membrane in the hippocampes were able to excitate 
neurones (43). Taken together, these experiments fullfill the 
major criteria for cholecystokinin to be accepted as a neuro­
transmitter in the nervous system (44). The exact functions of 
cholecystokinin in central and p e n f e r a l  nervous tissue have 
still to be elucidated and are challenges for research in the 
futu r e .
Cholecystokinin in the small m t e s t i n a l  mucosa
It is generally accepted, that cholecystokinin acts as a 
hormone. However, this concept has so far been based on stud­
ies in which the evidence has been indirect (45,46,47,48). In 
summary, n u t n e n t s  perfused intraduodenally are able to cause 
gallbladder contraction (45,46,48) and pancreatic enzyme se- 
cretion (45,46,47,48). From these experiments it was concluded 
that intraduodenal administration of n u t n e n t s  act by relea- 
sing cholecystokinin from the duodenal mucosa. However, it has 
also been shown, that cholinergic reflexes were able to cause 
pancreatic enzyme secretion d u n n g  intraduodenal perfusion of 
sodium oleate and amino acids and that cholecystokinin was not 
of necessity for this action (51,49,50). Whether neural or 
hormonal mechanisms are the major physiological stimulus for 
pancreatic enzyme secretion after a meal has still to be e l u ­
cidated. Furthermore, conflictang results have been published 
about the action of cholecystokinin on target organs. For ïn- 
stance, it has been shown that low doses of cholecystokinin 
lead to musculus sphincter Oddi relaxation, but high doses to 
contraction (52). These problems can only be u n n d d l e d  by de- 
monstration that target cell responses can be mimicked be exo- 
genous infusion of cholecystokinin in amounts that produce 
plasma concentrations similar to those observed d u n n g  the en- 
dogenous release of cholecystokinin by meal stimulation (53, 
54). The only suitable technique available for this purpose at
12
TABLE I
peripheral biological actions of cholecystokinin
- I n c r e a s e s  p a n c r e a t i c  e n z y m e  s e c r e t i o n
- G a l l b l a d d e r  c o n t r a c t i o n
- R e l a x a t i o n  of m u s c u l u s  s p h i n c t e r  Odd i
- A u g m e n t a t i o n  of the a c t i o n  of s e c r e t i n
- I n h i b i t i o n  of g a s t r i c  e m p t y i n g
- I n c r e a s e s  i n t e s t i n a l  p e r i s t a l s i s
- D e c r e a s e s  l o w e r  o e s o p h a g e a l  p r e s s u r e
- I n h i b i t i o n  of g a s t r i n  s t i m u l a t e d  g a s t r i c  a c i d  s e c r e t i o n
- I n h i b i t i o n  of i n t e s t i n a l  w a t e r  and e l e c t r o l y t e  a b s o r p t i o n
- T r o p h i c  e f f e c t  on p a n c r e a s
- T r o p h i c  e f f e c t  on i n t e s t i n a l  m u c o s a
- E f f e c t s  on s a t i e t y
TABLE II
amino acid sequence of the gastrin-cholecystokinin family
P y r o - L e u - G l y - P r o - G l n - G l y -  
1-39: H j N - T y r - I l e - G l n - G l n - A l a - A r g - L y s - A l a - P r o - S e r - G l y -
hGastrin 1-34 =
pCCK
hGastrin 1-34:
pCCK 1-39:
hGastrin 1-34:
pCCK 1-39:
hGastrin 1-34:
PCCK 1-39:
A r g - V a l - S e r - M e t - I l e - L y s - A s n - L e u - G l n - S e r - L e u - A s p -
(s o 3 h )
G l y - P r o - T r p - L e u - G l u - G l u - G l u - G l u - G l u - A l a - T y r - G l y -
SO^H
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the moment is radioimmunoassay. All reported pharmacological 
actions of cholecystokinin (table I ) , have to be validated for 
this criterium to be considered of physiological significance. 
However, radioimmunoassay of cholecystokinin has proven to be 
extremely difficult and conflicting data have been published 
(55,56,57,58).
PROBLEMS IN CHOLECYSTOKININ RADIOIMMUNOASSAY 
Antibodies
Many problems in the radioimmunoassay of cholecystokinin 
can be related to the structure of the peptide, displaying 
some remarkable features (table I I ) . Most striking is the si- 
milarity of the biologically active part of cholecystokinin and 
gastrin. Cholecystokinin and gastrin share an identical carbo- 
xyl-terminal pentapeptide amide. This similarity suggests a com- 
mon ancestor (63) . The amino-terminal extension of this penta­
peptide therefore governs the biologie activity of these pep- 
tides towards different target organs. In this way, gastrin is 
responsible for gastric acid secretion, while cholecystokinin 
causes gallbladder contraction and pancreatic enzyme secretion. 
Because this biologically active pentapeptide is highly immuno- 
genic, it turned out that this similarity displayed considera- 
ble problems in raising specific antisera, especially for cho­
lecystokinin. Antisera for cholecystokinin directed towards 
this biologically active region of the molecule are unspecific, 
because they show full cross-reactivity with gastrin (58,64,65). 
Since gastrin probably circulates in higher concentrations 
than cholecystokinin, cross-reactivity between these two 
peptides is highly undesirable. This problem was tried to 
overcome by separating plasma cholecystokinin from gastrin 
using chromatographic techniques in combination with these un ­
specific antibodies (58,64,65). However, these techniques tur­
ned out to be insufficiënt in separating larger forms of cho­
lecystokinin from gastrin and therefore only allowed estima- 
feions on smaller molecular forms of cholecystokinin. Using
14
these methods, it appeared that infusion of cholecystokinin 
octapeptide resulting in plasma concentrations comparable to 
those found after a mixed meal were insufficiënt to account 
for full physiological regulation of pancreatic enzyme secre­
tion (65). A major hormonal role for cholecystokinin octapep­
tide is also discutable because there is evidence that this 
peptide is cleared to a large extent from the circulation when 
it passes the liver (66,67,68). Data on cholecystokinin in 
plasma should therefore be based on radioimmunoassays using 
antibodies binding to all biologically active cholecystokinin 
variants present in circulation, without cross-reactivity with 
g a s t n n .  These data can only be obtained using antisera not 
directed towards the region that cholecystokinin and g a s t n n  
have in common. However, because these antibodies are not di ­
rected towards the biologically active part of the molecule, the 
possibility is m t r o d u c e d  that biologically inactive fragments 
may be bound. In order to exclude this possibility, these an ­
tisera have to be c h a r a c t e n z e d  with great care, using tissue 
extracts adequately separated on molecular weight and charge, 
in combination with antibodies directed towards the biologically 
active pentap e p t i d e . Furthermore, antisera directed towards re- 
gions outside the biologically active pentapeptide do not bind 
to small biologically active variants missing the amino acid 
sequence against which the antiserum is raised (69). The more 
this binding region in cholecystokinin is located in distant 
from the biologically active pentapeptide, the less biologically 
active fragments of cholecystokinin are bound. Fortunately, it 
turned out that the sulphated tyrosyl region in vicinity to 
the c a r b o x y l - t e r m m a l  pentapeptide, is one of the regions out­
side the bioactive pentapeptide with the highest immunoreacti- 
vity (70,71,72). This sulphated tyrosyl residue is not only 
highly immunoreactive, but also governs biological activity of 
cholecystokinin (73,74). Antisera directed towards this region 
have the advantage of binding to sulphated cholecystokinin oc ­
tapeptide. However, because this sulphated tyrosyl region in 
cholecystokinin also shows s t n k i n g  s i m i l a n t i e s  with sulpha-
15
ted molecular forms of gastrin, these antisera have to be cha- 
racterized with sulphated and not only with unsulphated mol e ­
cular variants of gastrin, in order to determine antibody spe- 
cificity (70,71,72,88). It has also been shown that some anti­
sera directed towards as yet uncharacterized biologically inac- 
tive regions in porcine cholecystokinin may show diminished 
binding to cholecystokinin in other species (75) , suggesting 
species differences in this region of cholecystokinin. Consi- 
dering these data, most reliable results on cholecvstokinin can 
be obtained by using a panel of well characterized antisera.
Radioiodination of cholecystokinin
The response parameter in radioimmunoassays is percentage
antibody binding and displacement of labelled peptide. Intro- 
125
duction of I into the peptide will change the antigenetic
properties of the peptide in one way or another. This may re-
sult in diminished immunoreactivity of the antigen by the la-
belling technique, masking the true quality of antisera. Con-
ventional labelling techniques are based on oxidation using
125
chloramine T or lactoperoxidase to introducé I into the
peptide, preferably into an unsulphated tyrosyl residue of a
polypeptide. However, the originally isolated triacontatria-
peptide, in contrast to the triacontanonapeptide, does not
possess such an unsulphated tyrosyl residue, hindering the 
125
introduction of I into the molecule by this method. Further- 
more, both gastrin and cholecystokinin contain 1 and 2 methi- 
onyl residues in the biologically active part of the molecule. 
These residues are highly sensitive to oxidation, resulting in 
diminished bioactivity for cholecystokinin (70,76) as well as 
for gastrin (77) . It has been reported that oxidative radio­
iodination techniques also abolish cholecystokinin immunore­
activity (70). This may be an explanation for the lack of sen- 
sitivity in a few preliminary reported radioimmunoassays (55, 
56,57). However, in other studies, labels prepared by oxidative 
methods were successfully employed in radioimmunoassays of 
both cholecystokinin (69,64,65,78,79) and gastrin (80). In or­
16
der to prevent oxidative labelling damage, Rehfeld (70) intro-
125
duced a conjugation technique using I-hydroxyphenylpropion- 
ic acid-succinimide ester (Bolton-Hunter reagent, 81) for io- 
dination of cholecystokinin. This ester binds to one of the 
free amino groups in cholecystokinin, preferably to lysyl side 
chains. However, it has been shown in albumin, that this con­
jugation technique interferes with protein conformation, re- 
sulting in diminished immunoreactivity for some antisera (82). 
In analogy, this technique may also result in diminished im­
munoreactivity for some cholecystokinin antisera. Therefore, 
antisera raised against cholecystokinin should be characteri­
zed using both labels prepared by oxidative and conjugation 
techniques, in order to detect the most suitable cholecysto­
kinin antibodies. A special problem in the development of ra- 
dioimmunoassay for cholecystokinin, concerns the quality of 
peptides used. The peptide required as Standard and tracer has 
to be pure and therefore, preferably synthetic fragments have 
to be used. However, larger molecular forms of cholecystokinin 
are only available in limited amounts as highly purified por­
cine extracts (14,32). This problem may also account for the 
difficulties experienced in some preliminary reported chole­
cystokinin radioimmunoassays.
Considering these data, it has to be emphasized that con- 
formational changes between molecular variants of cholecysto­
kinin and conformational changes introduced by labelling tech­
niques may be involved in differences in cholecystokinin 
immunoreactivity.
OUTLINE OF INVESTIGATIONS
The aim of this study was to develop a specific and sen- 
sitive radioimmunoassay for cholecystokinin.
Data about the production and evaluation of antisera are
presented in chapter II.
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Introduction of I into a polypeptide may result in
changes in immunoreactivity. The evaluation of antisera tested 
with cholecystokinin labels prepared by different techniques 
is presented in chapters III and IV.
It appeared that one of the antisera was specific for the 
triacontanonapeptide of cholecystokinin (CCK 39). This urged 
us to investigate whether or not cholecystokinin-39 immunoreac­
tivity could be demonstrated in porcine brain. These data are 
presented in chapter V.
The reliability of a highly sensitive and specific chole­
cystokinin radioimmunoassay for measurements in human tissue 
and blood is extensively evaluated in chapter VI.
In chapters II and IV it was shown that oral and intra­
duodenal administration of fat stimulated plasma cholecystoki­
nin secretion. In chapters VII and VIII the effect of other 
stimuli for pancreatic protein secretion on plasma cholecvsto- 
kinin concentrations are presented.
In chapter VII the effect of insulin-hypoglycaemia and in 
chapter VIII the effect of infusion of bombesin on plasma cho­
lecystokinin were studied.
To determine the roles of gastrin and gastric acid in the 
effect of bombesin on plasma CCK, both normal subjects and pa­
tients with previous partial gastrectomy were investigated.
The molecular forms of cholecystokinin in plasma during 
infusion of bombesin in man are reported in chapter IX.
In chapters X and XI plasma cholecystokinin is measured 
in patients with clinical conditions, in which previously ab- 
normal CCK values have been suggested.
In chapter X patients with pancreatic insufficiency, due 
to alcohol or cystic fibrosis are studied, while in chapter 
XI the effect of intraduodenal fat on plasma CCK and on gall- 
bladder contraction in patients with coeliac disease is repor­
ted.
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Summary: In order to produce antibodies for the radioimmunoassay of cholecystokinin the following animals 
were immunized 10 rabbits and 3 guinea pigs with cholecystokinin 1-33 coupled to bovine serum albumin, 9 
rabbits and 2 guinea pigs with uncoupled cholecystokinin 1-33, 5 rabbits with cholecystokinin 10-20 
coupled to bovine serum albumin and 4 rabbits with sulphated cholecystokinin 26—33 coupled to bovine 
serum albumin The titer, the binding energy and the specificity of the antibodies were evaluated Cholecysto­
kinin 1-33, coupled to [l25I]hydroxyphenylpropiomc acid-succinimide ester (Bolton-Hunter reagent) to a 
specific activity of 8 1-14 7 MBq/(ig (219-398 nCi/^g) (n = 8), was used as label After the fourth ïmmuni- 
zation 5 rabbits immunized with albumin coupled cholecystokinin 1-13 had antibody titers between 1 22500 
and 1 80000, while one rabbit immunized with uncoupled cholecystokinin 1-33 had a titer of 1 52000 The 
affinity constant of these 6 antibodies ranged from K = 2 0 x 10'° to 72 3 x 10"’ 1/mol One antibody was 
specific for all sulphated forms of cholecystokinin, while the other 5 antibodies were specific for the large 
molecular forms of cholecystokinin In the guinea pigs immunized with cholecystokinin 1-33 and in the 
rabbits immunized with cholecystokinin fragments antibody titers were less than 1 500 Concentrations of 
cholecystokinin in an aqueous-acid extract of human and hog upper small intestme were 48 7 ± 6 7 pmol/g 
and 46 2 ± 3 4 pmol/g, when measured with antibody T204 specific for sulphated forms of cholecystokinin, 
and 49 7 ± 1 9 pmol/g and 39 2 ± 1 6 pmol/g, when measured with antibody 1703 specific for largc forms of 
cholecystokinin After ingestion of 60 ml corn oil in 6 normal subjects, plasma cholecystokinin increased from 
2 7 ± 0 5 pmol/1 to 6 8 ± 17 pmol/1 (p <  0 05) when measured with antibody T204, and from 1 0 ± 0 3 
pmol/1 to 5 7 ± 1 0 pmol/1 (p <  0 05) when measured with antibody 1703
In conclusion, immunization of rabbits with cholecystokinin 1-33 resulted in high titer antibodies which 
could be used in sensitive and specific radioimmunoassays for cholecystokinin
Radioimmunassay fur Cholecystokinin Cewinnung und Bewertung von Antikorpern
Zusanunenfassung: Zur Gewinnung von Antikorpern fur einen Radioimmunoassay fur Cholecystokinin 
wurden immunisiert 10 Kamnchen und 3 Meerschweinchen mit an Rinderserumalbumin gekoppcltcm 
Cholecystokinin 1-33, 9 Kamnchen und 2 Meerschweinchen mit ungekoppeltem Cholecystokinin 1-33, 
5 Kamnchen mit an Rinderserumalbumin gekoppeltem Cholecystokinin 10-20 und 4 Kamnchen mit an Rin­
derserumalbumin gekoppeltem, sulfatiertem Cholecystokinin 26-33 Titer, Bindungsenergie und Spezifitat 
der Antikorper wurden bestimmt Cholecystokinin 1-33, gekoppelt an [l25I]Hydroxyphenylpropionsaure- 
succimmid ester (Bolton-Hunter-Reagenz) mit einer spezifischen Aktivital von 8,1-14,7 MBq/|xg (219-398 
nCi/(ig) (n = 8), wurde als Label benutzt Nach der vierten Immumsierung hatten 5 der mit an Rinderserum­
albumin gekoppeltem Cholecystokinin 1-33 immumsierten Kamnchen Antikorpertiter zwischen 1 22500 
und 1 80000, wahrend ein mit ungekoppéltem Cholecystokinin 1-33 ïmmumsiertes Kamnchen einen Titer
') Supported by the Foundation for Medical Research FUNGO (grant No 13-37 32)
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von 1 *52000 aufwies Die Affinitatskonstante dieser 6 Antikorper lag zwischen K = 2,0 x 10'° und 72,3 x 
10"' l/mol Ein Antikorper war spezifisch fur alle sulfatierten Cholecystokinine, wahrend die anderen 5 Anti­
korper spezifisch fur die groBmolckularen Cholecystokinine waren Bei den mit Cholecystokinin 1-33 ïmmu- 
msicrten Meerschweinchcn und bei den mit Cholecystokinm-Fragmenten immunisierten Kamnchen waren 
die Antikorpertiter kleiner als 1 500
Die Cholecvstokimn-Konzcntrationen in einem waBng-sauren Extrakt aus Schlcimhaut des oberen Dunn- 
darms vom Menschen und vom Schwcin betrugen 48,7 ± 6,7 pmol/g bzw 46,2 ± 3,4 pmol/g, wenn sic mit 
Antikorper T204 bestimmt wurden, der fur die sulfatierten Cholecystokinine spezifisch ïst Wenn sie mit dem 
fur die groOmolekularen Cholecystokinine spezifischen Antikorper 1703 gemessen wurden, lagen sie bei 49,7 
+ 1,9 pmol/g bzw 39,2 ± 1,6 pmol/g Nach Emnahme von 60 ml Maisol stieg bei 6 gesunden Probanden die 
Konzentration von Cholecystokinin ïm Plasma von 2,7 ± 0,5 pmol/1 auf 6,8 ± 1,7 pmol/1 (p <  0 05, Messung 
mit Antikorper 1204), und von 1,0 ± 0,3 auf 5,7 ± 1,0 pmol/1 (p <  0 05, Messung mit Antikorper 1703)
Wir folgern, daB die Immunisierung von Kamnchen mit Cholecystokinin 1 -33 zur Bildung von hohen Anti- 
korpertitern fuhrt, die fur empfindliche und spezifische Radioimmunoassays fur Cholecystokinin benutzt 
werden konnen
Introduction
Cholecystokinin is one of the classical gut hormones 
(1) This peptide hormone stimulatcs gall bladder 
contrattion and secretion of cnzymes from the pan­
creas (2, 3) In extracts of gut and brain cholecysto­
kinin was found to be present in several molecular 
forms (4) Onginally cholecystokinin was isolated 
from acid extracts of hog small intestine as a basic 
molecule containing 33 amino acid residues (chole­
cystokinin 1-33) with the chemical structure Lys- 
Ala-Pro-Ser-Gly-Arg-Val-Ser-Met-lle-Lys-Asn- 
Leu-Gln-Ser-Leu-Asp-Pro-Ser-His-Arg-Ile-Ser- 
Asp-Arg-Asp-Tyr(SOi)-Met-Gly-Trp-Met-Asp- 
Phe (4, 5) A molecular form extended at the NH 2- 
terminus by 6 amino acid residues, Tyr-Ile-Gln-GIn- 
Ala-Arg (cholecystokinin 1-39), was desenbed 
some years later (6) Recently, it was shown that in 
neutral extracts of sheep brain a smaller molecular 
form containing 8 amino acid residues (cholecysto­
kinin 26-33) predominates (4, 7)
Even though the first radioimmunoassay of chole­
cystokinin was reported as early as 1969 (8), only 
few radioimmunoassays have so far been developed, 
despite much effort Several factors contnbute to the 
difficulties in developing a rcliable radioimmunoas­
say for cholecystokinin
1 difficulties in producing antibodies duc to the low 
immunogemcity (9),
2 an unacceptably high degree of cross-reactivity of 
COOH-terminal antibodies with gastnn, because 
both peptides share the same COOH-terminal 
pentapeptide sequence,
3 suspected species diffcrcnccs in the NHi-terminal 
sequence of cholecystokinin 1—33 resulting in 
antibodies reacting with porcine cholecystokinin 
but not with cholecystokinin from other species 
(10 , 11),
4 availability of only limited amounts of pure 
cholecystokinin, and
5 difficulties in preparing ïmmuno-reactive chole­
cystokinin labels It has been shown that the con- 
ventional oxidizing labelling methods, such as the 
chloramine T method and the lactoperoxidase 
method, result in cholecystokinin labels of poor 
immunoreactivity, probably due to the delete- 
rious effects of oxidation of the methiomne re­
sidues in cholecystokinin (12) Recently, the la­
belling problem has been overcome by using a 
non-oxidizing labelling method Using 
[12<I]hydroxyphenylpropionic acid-succinimide 
ester (Bolton-Hunter reagent) Rehfeld was able 
to produce highly ïmmunoreactive cholecysto­
kinin 1-33 labels, and he suggested that chole­
cystokinin 1-33 was a good immunogen (12, 
13)
In this report we present our experience with the 
production of antibodies to cholecystokinin in rab- 
bits and guinea pigs Furthermore, the titer, the 
binding energy and the specificity of the antibodies 
were evaluated in radioimmunoassays using Bolton- 
Hunter labelled cholecystokinin 1-33 In addition, 
we have measured cholecystokinin concentrations in 
extracts of human and hog upper small intestine and 
in human plasma after ingestion of fat, using ra­
dioimmunoassays employing an antibody specific for 
sulphated forms of cholecystokinin and an antibody 
specific for large forms of cholecystokinin
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Materials and Methods
peptides
99% pure porcine cholecystokinin 1-19 and 30% and 99% pure 
poreme cholecystokinin 1-33 were obtained from Professor 
Muti, Karolinska Institutc. Stockholm, Sweden, synthetic sulphat­
ed and unsulphated cholecystokinin 26-33 from the Squibb Insti- 
tute Pnncetown N J , USA, synthetic unsulphated human gastnn 
1-17 from lmpenal Chemical Industries, ('heshire Fngland, va- 
soactive intestinal polypcptide from Penmsula Laboratories, San 
Carlos, Ca, USA, gastric inhibitory polypcptide from Professor 
Brown, Vancouver Canada, sulphated human gastnn 1-17 and 
sulphated and unsulphated gastnn 1-34 from Professor Gross- 
man Los Angeles, Ca, USA, secretin synthesized by the Squibb 
Institutc, Princetown, N J USA. through the courtesy of Profes­
sor Groisman caerulein from Farmitalia, Milan, Italy. synthetic 
cholecystokinin 10—20 from UCB Brussels. Bclgium, porcine 
pancreatic polypeptide porcine glucagon and monocomponent 
insulin from Novo Industry ('openhagen. Denmark, synthetic 
cholecystokinin 30-33 (tetragastnn) from Sigma, St Louis, Mo, 
USA
Other reagents
(l2SI)hydroxvphenylpTopionic acid succinimide ester (Bolton 
Hunter reagent) was purchased from New bngland Nuclcar Bos­
ton Ma. USA. Sephadex G 50 SF and SP-Sephadex C 25 from 
Pharmacia, Uppsala Sweden, 1 -ethyl 3 (3 dimethylaminoprop 
yl) carbodumide hydrothJonde from JCN, Plainview. NY, USA, 
hreund's complete and incomplete adjuvant from Difco l aborato- 
nes, Detroit, Mi, USA, Bordetella pertussis vaccine from RIV, 
Bilthovcn. Fhe Netherlands, human and bovinc scrum albumin 
from Behnngwerke AG, Marburg/I ahn West Germany, dextran 
T 70 and bovine serum albumin (RIA-grade) from Sigma St 
Louis, Mo, USA, trypsin IPCK from Worthington Biochcmical 
Corporation, Freehold, NJ. USA. sodium ethylmercunthiosalicy- 
late from Aldnch-Turope. Beerse, Belgium, double antibody sol- 
id phase from Organon, Oss. The Netherlands, all other reagents 
from E Merck. Darmstadt, FRG
Animals
28 randomly bred rabbits and 5 randomly bred guinea pigs were 
immumzcd
Apparatus
Automatic y-scintillation counter Philips PW 4800, Philips, Eind­
hoven, The Netherlands, digital dilutcr dispenser, Hamilton, Bo- 
naduz, Switzerland
Production of antibodies
Uncouplcd cholecystokinin 1-33 30% pure porcine cholecysto­
kinin I -33 dissolved in 0 05 mol/1 sodium phosphate buffer pH
7 5 was uscd without modification
Albumin coupled peptides
30% pure porcine cholecystokinin 1 -33. synthetic cholecystokin- 
in 10-20, and synthetic sulphated cholecystokinin 26-33 were 
dissolved in 0 05 mol/1 sodium phosphate buffer pH 7 5 and con- 
jugated to bovine serum albumin by reacting with 1 -ethyl- 3-(3-di- 
mcthylammopropyl) carbodumide hydrochloride for 2 hours at 
room temperature and a further 20 hours at 4 °C The ratio be- 
tween peptide, bovine serum albumin and l-ethyl-3-(3-dimethyl 
aminopropyl) carbodumide hydrochtonde on a molar base was
1 0 2 462 The antigen solution was emulsified with equal vo­
lumes of Freund's adjuvant for the initial immumzations and with 
equal volumes of Freund's incomplete adjuvant for booster injec- 
tions At the initial immunization 0 5 ml Bordetella pertussis vac­
cine was admimstered intramuscularly Fach rabbit was immun- 
tzcd with 2 ml and each guinea pig with 1 ml of the emulsified 
antigen The initial injections were given intracutaneously on mul-
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tiple sites into the back of the animals, while booster tnjections 
were given subcutaneously with four weeks intervals on 4 sites 
The doses of antigen injected are givcn in table 1 Seven days after 
each booster injection blood was drawn from an ear vein in rabbits 
and by cardiac puncture in guinea pigs
Tab 1 Type (BSA = bovine serum albumin coupled) and 
amount of antigen used for production of antibodies to 
cholecystokinin (CCK) in rabbits and guinea pigs
Animal Num-Antigen Doseof
species ber antigen
of (nmol) 
ani~
mals initial boost­
er
Rabbit 10 30% CCK 1-33-BSA 20 10
Rabbit 9 30% CCK 1-33 20 10
Rabbit 5 CCK 10-20-BSA 120 60
Rabbit 4 sulphated CCK 26-33-BSA 120 60
(fuinea pig 3 30% CCK 1-33-BSA 10 5
Guinea pig 2 30% CCK 1-33 10 5
Rad io iod ina iion
37 MBq (1 mCi) (12,iI]hydroxyphenyIpropiomc acid-succimmide 
ester (Bolton-Hunter reagent) was dned under a gentle stream of 
mtrogen according to the instructions of the manufacturer Five 
Hg 99% pure cholecystokinin 1-33 dissolved in 5 \i\ 0 05 mol/l 
acetic acid was added to the bot lom of the vial After addition of
15 ul 0 05 mol/1 sodium borate pH 10. the vial was gently agitated 
for 30 minutes in an ice bath To remove excess unreacted 
[l2Sï]hydroxyphenylpropiomc acid-succimmtde ester, 0 2 mol/l 
glycine in 500 1^ 0 05 mol/l sodium borate pH 8 5 was added to 
the mixture and the vial was agitated for 5 minutes The reaction 
mixture was chromatographed at 4°C on a Sephadex G 50 SF 
column, 100 x 0 9 cm. using 0 5 mol/1 acetic acid containmg 2 g/1 
gelatine as eluant Every hour 5 fractions of 1 ml were collected 
The elution profile of the radioactivity is shown in figure 1 Only 
the second radioactive peak showed immunoreactivity The frac- 
tion with the highest radioactivity in peak 11 was diluted in the 
elutmg buffer and stored at -20°C This label retained its immu­
noreactivity for at least 3 months Label damage was between 2
F ra c tio n n u m b e r
Fig 1 Elution profile of l25l radioactivity after application of 
reaction mixture of cholecystokinin 1-33 with 
[ l2Sl|hydroxyphenylpropiomc acid-succimmide ester 
(Bolton-Hunter reagent) to a Sephadex G 50 SF column 
Peak II represents labelled cholecystokinin 1 -33 For de­
tails see lexl
Jansen and Lamers Radioimmunoassay of cholecystokinin
and 7% The specific activity of the label, determmed according to 
Stadil & Rehfeld (14), ranged from 8 1 to 14 7 MBq/jig (219 to 
198 nCi/|ig) (n = 8) When the label was rcchromatographed on 
SP-Sephadex C 25 using a 0 OS to 1 0 mol/l acetic acid gradiënt, 
the radioactivuy elutcd as a single peak
Incubation condilions
Antibody titers were determmed as follows The assays were set 
up in plastic tubes in an ite bath using 0 02 mol/l sodium barbital 
buffer pH 8 4 containing 0 01 mmol/1 human serum albumin and 
0 1)6 mmol/1 sodium ethylmercunthiosdhcylatc The 2 2 ml ïncu- 
bation volume consisted of 1 0 ml of approximately 2000 counts/ 
min label 0 2 ml Standard solution, and I 0 ml diluted antiserum 
The tubes were incubated for 96 hours at 4 °C To determine the 
binding cnergy and cross-reactivity of the antibodies a pre-equih- 
brium method was used 0 2 ml Standard solution was incubated 
with 0 l ml diluted antiserum for 72 hours at 4 °C After addition 
of approximately 2000 counts/min Holton-Hurtter labelled chole- 
cystokinin 1-33 in 0 2 ml buffer, the mixture was incubated for 
another 48 hours at 4°C All dilutions in this pre-equilibnum as- 
say were made in 0 0S mol/l sodium phosphate buffer pH 7 4 con­
taining 0 08 mmoll human serum albumin and 0 06 mmol/l sodi­
um ethylmercurithiosahc>late
Separation procedure
Antibody-bound radioactivuy was separated from free label by 
addition of a 1 S ml suspension of 0 05 mol/l sodium phosphate 
buffer pH 7 4 containing 25 mg activatcd charcoal, 2 5 mg dex- 
tran T 70 and 16 mg bovine serum albumin The tubes were vor- 
texed and immediately ccntrifuged (3000 g for 10 minutcs) In the 
double-antibod> separation techmque 1 ml of 1 20 diluted sheep 
and rabbil immunoglobulm was added to the tube and incubated 
for 4 to 8 hours at 4 "C before ccntnfugation Both the supernat- 
ant and the pellet were counted in an automatic y-scintillation 
counter
Tryptic cleavage
230 (imol/1 99% pure cholecystokinin 1-33 was incubated with 5 
g/l trypsin for 60 minutcs at 37 °C The action of trypsm was ter- 
minated by boiling for 10 minutcs The completeness of cleavage 
of cholecystokinin 1 -33 to the COOH-terminal octapeptide (sul­
phated cholecystokinin 26-33) was assessed by gel filtration of 
cholecystokinin 1 33 before and after trypsmization on a Se- 
phadex G 50 SF column. 200 x I 5 cm, using 0 02 molA sodium 
barbital buffer pH 8 4 as eluant at 4 eC The eluate was measured 
by radioimmunoassay using a COO II terminal cholecystokinin 
antibody and l2SI labelled non-sulphatcd cholecystokinin 26-33 
(15)
Tissue extraction
Pieces of freshly obtained human (n = 3) and hog (n = 3) upper 
small intcstinc were extracted in boiling water (1 g/10 ml) for 10 
minutes After homogenization and ccntnfugation the supernat- 
ant was decanted and the pellet was re-extracted in 0 5 mol/l acct- 
ic acid (1 g/10 ml) for 10 minutes After centrifugation the super- 
natant was added to the supernatant of the aqueous extraction, 
rapidly frozen. lyophilized, dissolved in 0 05 mol/l sodium phos­
phate buffer and measured by radioimmunoassay
Measurement of cholecystokinin in plasma
Blood samples were collected in ice-chilled glass tubes containing
2 g/i cthylenediammetetraaceiale (EDTA) After centrifugation 
the plasma was frozen at — 20 °C Cholecystokinin was extracted 
from plasma by addition of 2 volumes of 960 ml/1 ethanol to 1 
volume of plasma After mixing and centrifugation the supernat- 
ant was evaporatcd to dryness under a stream of nitrogen at 37 °C
The dned supernatant was reconstituted in assay buffer a n d  200 
|xl were incubated with 100 fil diluted antiserum for 72 hours at
4 °C After addition of 200 1^ labelled cholecystokinin 1 -33 con> 
taining approximately 2000 counts/min and incubation for anoth- 
er 20 hours at 4°C, free and antibody-bound peptide were separ- 
ated and counted tn a y-sciniiJJation counter Cholecysfokmin 
1-33 was used as S tan d ard , and antibodies 1703 and T204 as 
antisera 0 05 mol/l sodium phosphate buffer pH 7 4 containing
0 08 mmol/1 human serum albumin and 0 06 mmol/1 sodium 
ethylmercunthiosalicylate was used as assay buffer Recovery of 
cholecystokinin added to hormone-free plasma was 85 4 ± 2 0% 
(mean ± SD, n = 11) Separation using plasma-coated charcoal 
or the double-antibody solid phase technique gave identical re- 
sults The delection limit of the assays was between 0 5 and 1 0 
pmol/1 plasma Intra-assay vanation ranged from 4 6-8 4% and 
intcr-assay vanation from 11 3-15 4%
Human studies
After an ovcmight fasl 6 normal subjects (4 males and 2 fcmales, 
mean age 30 years, range 23 — 38 vears) ingested 60 ml corn oil 
Blood samples were obtained at -5, 0, 5, 10, 15, 20, 30, 40, 50, 
60, 75 and 90 minutes
Statistics
Results were expressed as mean ± SEM, unless otherwise stated 
Student's t-test for paircd data was used for analysis of the plasma 
cholecystokinin results
Results
The titers of the antibodies after the second, third 
and fourth immunization are presented in table 2. 
Antibodies with titers greatcr than 1:10000 were not 
detected after the second immunization, while after 
the third immunization 3 ammals and after the 
fourth immunization 6 ammals had produced antibo­
dies with titers of more than 1:10000. O f the 10 rab­
bits immunized with albumin-coupled cholecysto­
kinin 1-33, 5 had antibody titers of more than 
1:10000 ranging from 1:22500 to 1:80000. O f the 9 
rabbits immunized with uncoupled cholecystokinin 
1-33, one produced a high titer antibody, 1:100000 
after the third and 1:52000 after the fourth immuni­
zation. Immunization with synthetic cholecystokinin 
fragments (cholecystokinin 10—20 and sulphated 
cholecystokinin 26-33) did not result in antibodies 
detectable in radioimmunoassays employing Bolton- 
Hunter labelled cholecystokinin 1-33. None of the 
guinea pigs produced cholecystokinin antibodies 
with titers of more than 1:500.
In radioimmunoassays using Bolton-Hunter labelled 
cholecystokinin 1-33 the binding energy of 6 high 
titer antibodies after the fourth immunization and of 
one antibody after the third immunization (1703) 
were determmed. The affinity constants indicating 
the binding cnergy between the antibodies and 
cholecystokinin 1-33 (16) are presented in table 3.
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Four antibodies had very high affimty constants of 
more than 5 x 10" 1/mol. These high binding ener- 
gies were reflected in low IDjo’s (inhibition doseso)
Tab 2 The dilution of antibodies to cholecystokinin (CCK) in 
the incubation mixture binding 50% of 1 fmol Bolton- 
Hunter labelled cholecystokinin 1-33
Animal number Reciprocal of antibody dilution 
aftcr
immuni- immum- ïmmum- 
zationll 7ation III zation IV
Rabbit
30% CCK 1 —33-BSA
11 1000 1800 2750
12 5000 6000 27000
13 2000 10000 75000
14 2000 60000 50000
Tl <500 <500 22500
12 n t 3700 80000
T3 through T6 <500 <500 <500
30% CCK 1-33
15 <500 1700 <500
16 <500 2400 1500
17 2000 100000 52000
18 <500 1800 2500
T7 <500 <500 2600
T8 through Tl 1 <500 <500 <500
CCK 10-20-BSA
1 through 5 <500 <500 <500
Sulphated CCK 26-33-BSA
7 through 10 <500 <500 <500
Cutnea ptg
30% CCK 1-33-BSA
G1 through G3 <500 <500 <500
30% CCK 1-33
G4 and G5 <500 <500 <500
n t = not tesled
BSA = bovine serum albumin coupled
between 2.8 and 5.0 pmol/1 in the radioimmunoas­
says. With these sensitive radioimmunoassays for 
cholecystokinin 1-33, very low detection limits 
ranging from 0.5 to 3 pmol/1 sample were obtained.
All antibodies cross-reacted with cholecystokinin 
1-39 (table 3). Five antibodies (1204, 1304, 1404, 
T104 and 1703/1704) did not cross-react with either 
synthetic cholecystokinin fragments or cholecysto­
kinin fragments produced by trypsinization (table 3). 
Furthermore, these antibodies did not show any 
binding to sulphated or non-sulphated gastrms, to 
COOH-terminal tetragastrin (cholecystokinin 
30-33), to caerulein or to structurally unrelatcd 
peptides such as insulin, glucagon, pancreatic poly­
peptide, gastnc inhibitory polypeptide, vasoactive 
intestinal polypeptide or secretin. Antibody T 204 
bound to cholecystokinin 33, cholecystokinin 39, 
sulphated cholecystokinin 26-33, caerulein and to 
trypsinized cholecystokinin 33 (table 3). Binding to 
sulphated gastrin 1-17 and sulphated gastrin 1-34 
was low, while binding to non-sulphated forms of 
cholecystokinin or gastrin and to unrelated peptides 
was absent. All 6 antibodies did not only bind to por­
cine cholecystokinin, bul also to cholecystokinin in 
human tissue extracts.
Standard curves for both types of antibodies are 
shown in figures 2 and 3.
Concentrations of cholecystokinin in an aqueous 
acid extract of human (n = 3) and hog (n = 3) upper 
small intestine were 48.7 ± 6.7 pmol/g and 46.2 ± 
3.4 pmol/g, when measured with antibody T204, and 
49.7 ± 1 .9  pmol/g and 39.2 ± 1.6  pmol/g, when 
measured with antibody 1703.
Tab 3. Binding energy, inhibition dose 50 and cross-reactivity of high titer cholecystokinin (CCK) antibodies***
Anti- K* IDW"  CCK CCK CCK Caerulein
body 1-33 1-39 10-20
number
Sul­ Non-sul- Trypsin- CCK Sul­ Sul­
phated phated ïzcd 30-33 phated phated
CCK CCK CCK gastrin gastrin
26-33 26-33 1-33 1-17 1-34
1204 20 26.0 1 0 0.00 <0 001 <0 001 <0.001 <0 001 <0 001 <0 001 <0.001 <0 001
1304 72 3 45 I 0 0.49 <0 001 <0.001 <0 001 <0 001 <0 001 <0 001 <0 001 <0 001
1404 2 8 24 0 I 0 0 80 <0 001 <0 001 <0 001 <0 001 <0 001 <0 001 <0 001 <0 001
Tl 04 55 4 5 0 1 0 0 50 <0 001 <0 001 <0 001 <0 001 <0 001 <0 001 <0.001 <0 001
T204 52 2 33 1 0 1 12 <0 001 0 20 0 93 <0 001 0 88 <0 001 0016 0018
1703 59 4 2.8 1 0 0 89 <0 001 <0 001 <0 001 <0 001 <0 001 <0 001 <0 001 <0 001
1704 31 6 5 1 1 0 0 88 <0 001 <0 001 <0 001 <0 001 <0 001 <0.001 <0 001 <0 001
* Affinity constant K (x 1010 l/mol)
”  Inhibition dose 50- dose of cholecystoktnm 1-33 which reduces binding between label and antibody by 50% (pmol/1)
None of the antibodies showed cross-reactivity with non-sulphated gastrin 17. non-sulphated gastrin 34 or unrelated regulatory pep­
tides
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c [pmol/ll
Fig 2 Standard curves of antibody 1703 using Bollon-Hunter la­
belled cholecystokinin 1-33 The antibody binds to 
cholecystokinin 1 -33 ( • )  and cholecystokinin 1 -39 (A), 
but not to sulphated gastnn (▲), unsulphated gastnn (V), 
sulphatcd cholecystokinin 26-33 (x), unsulphated chole­
cystokinin 26—33 (O), trypsinized cholecystokinin 1-33 
(■) or caerulein (n)
8 -
Fig 4 The effect of ingestion of 60 ml corn oil on plasma chole­
cystokinin concentrations in 6 normal subjects Open cir- 
cles indicate antibody T204 and filled circles antibody 
1703 Asterisks indicate significant differences from basal 
value (p <  0 05)
-i------- - ---- 1_____ i_____________i_____ I____________ i_____ 1___
1 5  10 50  100 500  1000
c [pmol/l]
Fig 3 Standard curvcs of antibody T204 using Bolton-Hunter la­
belled cholecystokinin 1-33 The antibody binds to 
cholecystokinin-gastnn peptides containing the sulphated 
tyrosinc region cholccystokinm 1 -39 (A), cholecystokin­
in 1-33 ( • ) , trypsinized cholecystokinin 1-33 (■), sul­
phated cholecystokinin 26-33 (x), caerulein (□) and sul­
phatcd gastnn (▲) Binding to cholccystokinm-gastrin 
peptides lacking the sulphated tyrosine region is absent 
unsulphated cholecystokinin 26—33 (O), and unsulphated 
gastnn (V)
Basal plasma cholecystokinin concentrations were 
very low, 2.7 ± 0.5 pmol/l as measured with anti­
body T204, and 1.0 ± 0.3 pmol/l as measured with 
antibody 1703. Ingestion of corn oil induced signifi­
cant increases in plasma cholecystokinin (p <  0.05). 
The peak plasma cholecystokinin concentrations 
were found 20 minutes after ingestion of the corn oil. 
The increases in plasma cholecystokinin were similar 
for both antibodies (fig. 4).
Discussion
This study shows that cholecystokinin 1-33 is an ex­
cellent immunogen when Bolton-Hunter labelled 
cholecystokinin 1-33 is employed as the radioactive 
peptide in radioimmunoassays Immunization of 
rabbits with albumin-coupled cholecystokinin 1-33 
produced high titer antibodies in 5 of 10 animals, 
while immunization of 9 rabbits with uncoupled 
cholecystokinin 1 —33 produced high titer antibodies 
in one animal Four of these antibodies had high 
binding energies with affinity constants of more than
5 x 10'1 1/mol. No antibodies were obtained in gui- 
nea pigs immunized with uncoupled or albumin- 
coupled cholecystokinin 1-33 or in rabbits immun­
ized with albumin-coupled cholecystokinin frag- 
ments. Therefore, immunization of rabbits with al­
bumin-coupled cholecystokinin 1 — 33 seems to be 
the most suitable method to produce antibodies for 
the radioimmunoassay of cholecystokinin. In con­
trast to a previous report (9), our results confirm 
Rehfeld's finding that cholecystokinin 1 — 33 has 
good immunogenic properties (12). It has been 
claimed by Rehfeld that cholecystokinin 1-33 is a 
good immunogen provided cholecystokinin is not ex- 
posed to oxidation during the labelhng procedure 
(12). However, high titer cholecystokinin antibodies 
have been desenbed in radioimmunoassays using 
cholecystokinin 1-39 or nonsulphated cholecysto­
kinin 26-33 labelled with 125I by the chloramine T 
method (15, 17, 18). On the other hand, it seems to 
be extremely difficult to raise high titer antibodies 
against cholecystokinin 1 — 33 when an oxidizing la- 
belling method is used. Thompson's group has pro­
duced an antibody against cholecystokinin 1-33
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which binds 25 to 35% of cholecystokmin 1-39, la­
belled with 12,I by the chloramine T method, at a 
final dilution of 1 100000(17) In most radioimmu- 
noassays using cholecystokmin 1-33 or cholecysto- 
kinin 1-39, labelled by the chloramine T method, 
the titers of the antibodies are extremely low (8, 10,
19, 20, 21) From the present study ït cannot be con- 
cluded whether the excellent immunogenicity of 
cholecystokmin 1-33 in our hands is attnbutable to 
the immunization schedule employed or to the use of 
a non-oxidizing labelling method Using Bolton- 
Hunler labelled cholecystokmin 1-33, Rehfeld re- 
ported cholecystokmin antibodies with a titer be- 
tween 1 10000 and 1 30000 m 3 of 10 rabbits ïm- 
munized with albumin-coupled cholecystokmin
1 — 33 (12) Howevcr, none of these antibodies had 
affimty constants above 5 x 10“ 1/mol Byrnes et al 
(22) immunized 16 rabbits with albumin-coupled 
cholecystokmin 1-33 and only one of the ammals 
produced an antibody with a titer of 1 10000 When 
Bolton-Hunter labelled cholecystokmin 1-33 was 
uscd in the assay the affimty constant was 5 5 x 10" 
l/mol (22) Rehfeld suggested that cholecystokmin 
1-33 is particularly ïmmunogenic in guinea pigs 
(12) Twelve of 30 ammals produced antibodies with 
titers between 1 10000 and 1 50000 Ihree of these 
antibodies had affimty constants of more than 5 x 
10" 1/mol While Rehfeld (12) and Byrnes et al (22) 
did not fmd antibody titers higher than 50000, we 
found this level of titers in 4 rabbits Some authors 
advocate an immunization schedule in which crude 
cholecystokmin 1-33 is used for the mitial ïmmum- 
zations followed by 99% pure cholecystokmin 1 -33 
for the final immunization (17) In our study excel­
lent antibodies wcre obtained after immunization 
with 30% pure cholccystokinin 1-33 99% pure 
cholecystokmin 1 — 33 is difficult to obtain and our 
data do not support the need for highly punfied 
cholecystokmin 1 — 33 as immunogen
The high binding energy of 4 antibodies (K >  5 x 
10" 1/mol) in the present study was reflccted in the 
high sensitivity of the radioimmunoassays The dose 
of cholecystokmin 1-33 at which the binding be­
tween label and antibody was inhibited by 50% 
(IDso) ranged from 2 8 to 5 0 pmol/1 The detection 
limit of these assays was between 0 5 and 3 pmol/1 
sample These assays were extremely sensitive and 
they were able to measure the very low concentra- 
tions of cholecystokmin present in the circulation 
(fig 4)
Five antibodies bound to cholecystokmin 1-33 and 
cholecystokmin 1 — 39, but not to synthetic cholccys- 
tokinin fragments (sulphated and non-sulphated 
cholecystokmin 26 — 33, cholecystokmin 30-33. 
cholecystokmin 10-20) or cholecystokmin frag­
ments prepared by trypsmization of cholecystokmin 
1-33 (cholecystokmin 1-6, cholecystokmin 7-11, 
cholecystokmin 12-21, cholecystokmin 22-25. sul­
phated cholecystokmin 26-33) Co et al (10) and 
Straus & Yalow (11) produced antibodies to chole­
cystokmin 1-33 which reacted only with porcine 
cholecystokmin. but not with cholecystokmin from 
othcr species They suggested that there might be 
species differences in the structure of cholecystokin- 
m 1 — 33 at the NH;-terminus Our antibodies not 
only bound to porcine cholecystokmin but also to 
human cholecystokmin Since the antibodies do not 
cross-react with gastrin or with structurallv unrclatcd 
peptides, these antibodies are extremely suitable for 
quantifying large forms of cholecystokmin in blood 
and tissue One antibody (T204) seems to be direct- 
ed to the sulphated tyrosine region of the molecule 
It binds to large cholecystokmin and cholecystokmin 
fragments contaming the sulphated tyrosine region 
(cholecystokmin 1-39, cholecystokmin 1-33, cae- 
rulein, sulphated cholecystokmin 26-33, trypsinized 
cholecystokmin 33) but not to unsulphated cholccys- 
tokinin fragments (non-sulphated cholecvstokinin 
26-33, cholecystokmin 10-20, cholecystokmin 
30-33) Since the binding to sulphated gastrin 1-17 
and sulphated gastnn 1-34 is low and the binding to 
non-sulphated gastrin 1-17 and gastrin 1-34 and 
structurally unrelated peptides is absent, this anti­
body is suitable for quantifying the sulphated forms 
of cholecystokmin in blood and tissue Since only 
sulphated molecular forms of cholecystokmin pos- 
sess biological activity, this assay will quantify only 
the biological activc forms of cholecystokmin
In conclusion, immunization of rabbits with chole­
cystokmin 1 -33 resulted in antibodies which can be 
used in sensitive and specific radioimmunoassays for 
cholecystokmin
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LOW BINDING OF BOLTON-HUNTER-LABELLED 
CHOLECYSTOKININ-33 TO CARBOXYL-TERMINAL 
CCK-ANTIBODIES
J.B .M .J. JANSEN 1 and C.B H.W. LAM ERS 2
Gastrointestinal Hormone Laboratory, Division o f  Gastroenterology, St. Radboud Hospi­
tal, University o f  Nijmegen, Nijmegen, The Netherlands
(Received 27 Ju ly 1981, accepted 3 December 1981)
Labelling of cholecystokinin-33 (CCK33) with [125I]hydroxyphenylpropionic acid- 
succinimide ester (Bolton-Hunter reagent) results in labels with excellent immunoreactiv- 
ity when tested with non-carboxyl-terminal CCK-antibodies but extremely low binding to 
carboxyl-terminal CCK-antibodies This finding might explain some of the difficulties 
experienced with production o f immunoreactive CCK33 labels prepared by the Bolton- 
Hunter method.
Key words: cholecystokinin assay — Bolton-Hunter-labellmg reagent — hormone assay
INTRODU CTION
Cholecystokinin (CCK) is one of the classical gut hormones (Rayford et 
al., 1976). In intestinal extracts of man CCK is present in different molecular 
forms including CCK33 and CCK8 (Rehfeld, 1978b). This peptide hormone 
is a potent stimulant of pancreatic protein secretion and gall bladder contrac- 
tion. Despite its important physiological role few reliable radioimmunoassays 
for CCK have been published. One of the major problems in developing a 
radioimmunoassay for CCK is the production of immunoreactive CCK-labels. 
Preparation of [lJ5I]CCK33 by conventional oxidizing methods presents dif­
ficulties, because the single tyrosine residue in CCK33 is sulphated (Mutt and 
Jorpes, 1971). In addition, it has been shown that both the chloramine T 
and the lactoperoxidase methods result in great loss in immunoreactivity of 
CCK (Rehfeld, 1978a). This has been overcome by labelling CCK33 by a 
non-oxidizing method (Rehfeld, 1978a). With [155I]hydroxyphenylpro-
1 Supported by the Foundation for Medical Research FU N G O  (Grant No. 13-37-32).
2 Correspondence to: C. Lamers, M .D ., Ph.D., Division o f Gastroenterology, St. Radboud 
Hospital, 6500 HB Nijmegen, The Netherlands.
0022-1759/82/0000—0000/$02.75 ©  1982 Elsevier Biomedical Press
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pionic acid-succinimide ester (Bolton-Hunter reagent) CCK33 labels of good 
quality could be obtained (Rehfeld, 1978a; Sankaran et al., 1979; Beinfeld 
et al., 1981; Byrnes et al., 1981).
In the present study we report that such [12SI]Bolton-Hunter-CCK33 
labels may show extremely low binding to carboxyl-terminal CCK-anti- 
bodies.
M ATERIALS A N D  METHODS
Radioiodination procedures
[nsI]Bolton-Hunter reagent ([125I]hydroxyphenylpropionic acid-succini­
mide ester, New England Nuclear, Boston, MA, U.S.A.) was conjugated to 
99% pure porcine CCK33 (V. Mutt, Karolinska Institutet, Stockholm, 
Sweden) as described by Sankaran et al. (1979). The label was subsequently 
purified on Sephadex G-50 SF columns, 100.0—1.0 cm (Pharmacia, Uppsala, 
Sweden) using 0.5 M acetic acid and 0.2% gelatin as eluant. Peak II in Fig. 1 
represents labelled CCK33. This Bolton-Hunter-labelled CCK33 eluted as a 
single peak after refiltration on SP-Sephadex G-25 (Pharmacia, Uppsala, 
Sweden) with a 0.5 M—1.5 M sodium acetate pH 4.0 gradiënt as eluting buf­
fer. The label retained its immunoreactivity when tested with non-carboxyl- 
terminal CCK-antibodies for at least 3 months. Label damage in the absence
Fig. 1. E lution profile o f 125I-radioactivity after application o f reaction mixture o f 
CCK33 with [125I]hydroxyphenyl propionic acid-succinimide ester (Bolton-Hunter 
reagent) to a Sephadex G-50 superfine column. Peak I I  represents labelled CCK33. For 
details see text.
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Fig. 2. E lution profile o f 125I-radioactivity after application o f reaction mixture of 
CCK8I w ith [125I]Na to DE52 cellulose. The first peak represents unreacted 1JSI and the 
second peak [12SI]CCK8I. For details see text.
of antibody was 2—7%. The specific activity of the label ranged from 219 to 
398 iiCi/jug (n = 3).
Non-sulphated CCK8 (CCK8I, Squibb Institute, Princeton, NJ, U.S.A.) 
was labelled with 12SI (Behringwerke A.G., Marburg, F.R.G.) by the chlo- 
ramine T method (Dockray, 1980). The labelled peptide was purified on 
DE52 cellulose columns, 1 cm X 10 cm (Whatman, Maidstone, England) 
with a 0.05 M to 0.5 M ammonium carbonate gradiënt as eluant (Fig. 2). 
This [125I]CCK8I label retained its immunoreactivity when tested with 
carboxyl-terminal antibodies for at least 2 months. Label damage in the 
absence of antibody was less than 2%.
Antisera
The following non-carboxyl-terminal CCK-antibodies were tested: anti­
body T104 was raised against CCK33 coupled to bovine serum albumin 
(Behringwerke A.G., Marburg, F.R.G.) using l-ethyl-3-(3-dimethylaminopro- 
pyl)-carbodiimide (I.C.N., Plainview, NJ, U.S.A.), and antibody 1703 was 
raised against uncoupled CCK33 (Fig. 3). When Bolton-Hunter-labelled 
CCK33 was used, these antibodies reacted with CCK33 and CCK39, but not 
with CCK8II, CCK8I, caerulein (Farmitalia, Milan, Italy), gastrin 17, gastrin 
14-17, CCK 10-20 (U.C.B., Brussels, Belgium) or CCK33 fragments prepared 
by trypsinization.
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Fig. 3. Standard curve o f a non-carboxyl-terminal CCK*antibody (1703), showing no 
cross-reactivity with CCK8 or gastrin. [ 12SI]Bolton-Huntcr-CCK33 used as label.
The following carboxyl-terminal CCK-antibodies were tested: antibody 
L48, raised against sulphated CCK8 (CCK8II) coupled to bovine serum albu- 
min using the carbodiimide method (Dockray, 1980), was purchased from 
Merseyside Laboratories, Woolston, U.K.; antibody 5135, raised against 
CCK8I coupled to bovine serum albumin by the carbodiimide method 
(Rosenquist and Walsh, 1980), was a gift from Drs. Rosenquist and Walsh 
(Fig. 4); antibody LAL was raised against non-sulphated gastrin (gastrin 171) 
coupled to bovine serum albumin using the carbodiimide method. When 
[125I]CCK8I was used as label, all these antibodies reacted with CCK39, 
CCK33, CCK8II, CCK8I, gastrin 17 and gastrin 14-17. All antibodies were 
raised in rabbits.
Radioimmunoassay procedure
Radioimmunoassays were performed in plastic tubes in an ice-bath using 
0.02 M sodium barbital buffer pH 8.4 containing 30 ^mol/1 human serum 
albumin (Behringwerke A.G., Marburg, F.R.G.) and 0.6 mmol/1 thiomersal
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Fig. 4. Standard curve o f a carboxyl-terminal CCK-antibody (5135), showing cross- 
reactivity with CCK8 and gastrin. [125I]CCK8I used as label.
(Aldrich, Beerse, Belgium). The 2.2 ml incubation mixture contained 1.0 ml 
of approximately 2000 cpm label, 0.2 ml Standard solution, and 1.0 ml 
diluted antiserum. The tubes were incubated for 96 h at 4°C. Antibody- 
bound radioactivity was separated from unbound label using a suspension 
containing 25 mg activated charcoal (Merck, Darmstad, F.R.G.), 2.5 mg dex- 
tran T70 (Sigma, St. Louis, MO, U.S.A.), and 16 mg bovine serum albumin 
(Sigma, St. Louis, MO, U.S.A.). The tubes were vortexed and immediately 
centrifuged (3000 X#, 10 min). Both the supematant and the pellet were 
counted in an automatic gamma scintillation counter (Philips PW4800; 
Philips, The Netherlands).
RESULTS
[12SI]Bolton-Hunter-CCK33 showed excellent binding to non-car- 
boxyl-terminal CCK-antibodies. The antisera could be used in final dilutions 
of 1 : 22,500 and 1 : 100,000 (Table 1). The antibodies did not show sig­
nificant binding to [12SI]CCK8I. Using [lïsI]Bolton-Hunter-CCK33, the 
concentration of Standard CCK33 that produced 50% inhibition of binding
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T A B L E 1
Binding of Bolton-Hunter-labelled CCK33 ([12SI]BH-CCK33) and [n s I]CCK8I to non- 
carboxyl-terminal and to carboxyl-terminal specific CCK-antibodies.
Non-carboxyl terminal 
CCK-antibodies 
T l 04 
1703
Titer a ID ,0 b
(pmol/1)
[ 125I ]BH-CCK33 [1 JSI)C CK 8I CCK33 CCK8II
1 : 22 500 
1 : 100 000
<500
<500
15.5
5.9
>10 000 
>10 000
Carboxyl-terminal CCK  
antibodies 
L48 
5135 
LAL
<500
<500
<500
1 : 100 000 
1 ■ 2 000 000 
1 • 1 000 000
9.1
7.7
16 0
3.1
3.1 
3.6
a Final dilution of antiserum giving 50% binding between antibody and label 
b Inhibition doseso: concentration of peptide giving 50 % inhibition o f the binding 
between label and antibody (pmol/1 incubation mixture).
between label and antibody (ID50) ranged from 5.9 to 15.5 pmol/1, while 
there was no binding to CCK8I or CCK8II (Table 1).
[12SI]CCK8I showed excellent binding to carboxyl-terminal CCK-anti­
bodies (Table 1). These carboxyl-terminal CCK-antibodies could be used in 
final dilutions of 1 : 100,000—1 : 2,000,000. The IDS0 for CCK8II ranged 
from 3.1 to 3.6 pmol/1, and for CCK33 from 7.7 to 16.0 pmol/1. Although 
unlabelled CCK33 displaced [125I]CCK8I from these antibodies, there was 
negligible binding of [12SI]Bolton-Hunter-CCK33 to the carboxyl-terminal 
CCK-antibodies. Even when the carboxyl-terminal CCK-antibodies were used 
in excess (1 : 500) binding to [12SI]Bolton-Hunter-CCK33 was less than 50%. 
These findings were consistently obtained using 3 different [12SI]Bolton- 
Hunter-CCK33 preparations. The binding of [12SI]Bolton-Hunter-CCK33 to 
excess antibody (1 : 500) ranged for antibody L48 from 17.2 to 17.8%, 
for antibody 5135 from 1.3 to 10.5%, and for antibody LAL from 13.6 
to 16.2%.
DISCUSSION
Comparable values for IDS0 for CCK33 could be obtained with 2 differ­
ent types of radioimmunoassays: (1) with [12,T]Bolton-Hunter-CCK33 and 
non-carboxyl-terminal CCK-antibodies, and (2) with [125I]CCK8I and car­
boxyl-terminal CCK-antibodies. Although CCK33 displaced [125I]CCK8I 
from carboxyl-terminal CCK-antibodies, [125I]Bolton-Hunter-CCK33 did not
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show significant binding to carboxyl-terminal antibodies, even when these 
antibodies were used in excess. Therefore, labelling of CCK33 with Bolton- 
Hunter reagent as described in this study may interfere with binding to car- 
boxyl-terminal antibodies. Bolton-Hunter reagent is known to bind to basic 
amino acid residues (Bolton and Hunter, 1973). However, the carboxyl-ter­
minal portion of CCK33 is deprived of basic amino acid residues (Mutt and 
Jorpes, 1971). Therefore, the decrease in immunoreactivity of CCK33 is not 
simply due to binding of the Bolton-Hunter reagent to amino acid residues 
in the carboxyl-terminal portion of the molecule. Further we found that 
another CCK-antibody (T204), specific for the region containing the sul­
phated tyrosine residue but not for the carboxyl-terminus (binding to 
CCK39, CCK33, CCK8II and caerulein, but not to CCK8I, gastrin 17 or 
gastrin 14-17), showed excellent binding to [125I]Bolton-Hunter-CCK33 
(data not shown). In contrast to our findings, Rehfeld (1978a) and Beinfeld 
et al. (1981) reported good binding of [125I]Bolton-Hunter-CCK33 to anti­
bodies against gastrin 17 and against CCK8II. In our study, carboxyl-ter­
minal CCK-antibodies raised against gastrin 17, CCK8I and CCK8II did not 
show significant binding to [12SI]Bolton-Hunter-CCK33. The reason for this 
discrepancy is not apparent. It is possible that carboxyl-terminal CCK-anti- 
bodies differ in their sensitivity to alterations in the conformation of the 
CCK33 molecule. Jacobson et al. (1972) have shown that blocking lysine 
residues by succinylation alters the tertiary structure and immunochemical 
reactivity of albumin. By analogy, conformational changes of CCK33 
induced by Bolton-Hunter labelling might interfere with binding to some 
carboxyl-terminal CCK-antibodies.
Previously, we and other workers have experienced considerable diffi­
culties in producing immunoreactive [125I]Bolton-Hunter-CCK33 when 
tested with carboxyl-terminal CCK-antibodies (Rosenquist, Walsh, personal 
Communications). This might be related to the present finding that [ 12SI]- 
Bolton-Hunter-CCK33 showed excellent binding to non-carboxyl-terminal 
CCK-antibodies and negligible binding to some carboxyl-terminal antibodies.
Another interesting finding in the present study is that [125I]CCK8I labels 
with excellent immunoreactivity can be obtained with the chloramine-T 
method. This is in agreement with other studies (Dockray, 1980; Lamers 
et al., 1980), but contrasts with Rerifeld’s finding of large losses in immuno­
reactivity by this oxidizing method (Rehfeld, 1978a). Since immunoreactive 
[125I]CCK39 labels have also been produced by the chloramine T or lacto- 
peroxidase methods (Schlegel et al., 1977; Bernard et al., 1981; Lonovics 
et al., 1981), the effect of the use of oxidizing methods on the immuno­
reactivity of CCK labels needs further investigation.
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IV CHARACTERIZATION OF ANTISERA TO CHOLECYSTOKININ EMPLOYING 
DIFFERENT CHOLECYSTOKININ LABELS
Abstract
Antisera raised against synthetic sulphated CCK 26-33 (n=4)
and against 30% pure porcine CCK (n=ll) were characterized emplo-
ying different CCK-labels. CCK 39 and CCK 26-33 were coupled to 
125 I using the chloramine-T method, while CCK 33 was conjugated 
125to I-hydroxyphenylpropionic acid-succinimide ester (Bolton-
Hunter reag e n t ) • Antisera raised against CCK 26-33 bound to 
12 5
( I )CCK 26-33 only. Of the antisera raised against 30% pure 
CCK, 2 bound to all 3 labels, 4 to (125I)BH-CCK 33 and (125I)CCK 
26-33, 3 to (125I)CCK 39 and (125I)BH-CCK 33, one to (125I)CCK 
26-33 only, and one to (^2 ^I)BH-CCK 33 only. The antibodies re- 
acting with (12^I)CCK 26-33 also bound to (12^I)Gastrin 1-17. 
Different CCK-labels bound to different binding sites in the 
same antiserum (antibody heterogeneity). The pattern of reacti- 
vity of the antiserum to CCK-peptides was dependent of the type 
of label used. Using these different labels, antibodies specific 
for CCK 39, for CCK 33 and CCK 39, for sulphated forms of CCK, 
and for all CCK-peptides and gastrin could be detected.
It is concluded that antisera raised against CCK should be 
characterized employing different CCK-labels.
Introduction
Cholecystokinin (CCK) together with secretin and gastrin 
constitute the classical triad of gut-hormones (Rayford et al, 
1976). CCK stimulates gallbladder contraction (Ivy & Oldberg,
1928) and pancreatic enzyme secretion (Harper & Raper, 1943). 
Originally, CCK was isolated from acid extracts of hog small 
intestine as a molecule containing 33 amino acid residues (CCK 33) 
(Mutt & Jorpes, 1967). A molecular form extended at the amino- 
terminus by a further 6 amino acid residues (CCK 39) was descri- 
bed some years later (Mutt, 1976). In intestinal extracts of man, 
CCK is present in different molecular forms, including CCK 33 and 
CCK 26-33 (Rehfeld, 1978b), While the roles of secretin and gas­
trin, in the meantime, have been well established, the physiolo-
48
gical and pathophysiological significance of CCK have remained 
speculative, mainly due to the lack of sensitive and specific 
radioimmunoassays. One of the major problems in developing spe­
cific radioimmunoassays for CCK is the production of immunorÊac-
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tive CCK-labels. Preparation of ( I)CCK 33 by conventional oxi- 
dizing methods presents difficulties because the single tyrosyl 
residue in CCK 33 is sulphated (Mutt, 1976). In addition, it has 
been shown that treatment of CCK with chloramine-T or lactoper- 
oxidase strongly diminishes the bioactivity of the peptide, pro- 
bably due to the deleterious effects of oxidation on the methio- 
nyl residues in CCK (Mutt, 1964; Rehfeld, 1978a). Recently, Reh­
feld (1978a) reported that oxidative radioiodination techniques 
also abolished CCK-immunoreactivity, while labelling by a non- 
oxidizing conjugation method (Bolton-Hunter reagent)(Bolton &
Hunter, 1973) resulted in CCK-labels with excellent immunoreac- 
tivity. However, in other studies CCK-labels prepared by oxida­
tive radioiodination techniques were successfully employed in the 
radioimmunoassay of CCK (Dockray, 1980; t«alsh et al, 1982; Lilja 
et al, 1982; Chang & Chey, 1983). Furthermore, it has recently 
been reported that Bolton-Hunter labelled CCK 33 often shows low 
binding to carboxyl-terminal CCK-antibodies (Jansen & Lamers, 1982).
In the present study we have tested antisera raised against 
30% purified porcine CCK and synthetic CCK 26-33 employing labels 
prepared by both oxidative and conjugative labelling techniques 
using different CCK-peptides.
Materials
99% pure porcine CCK 33, 99% pure porcine CCK 39 and 30%
pure porcine CCK were obtained from prof. V. Mutt, Karolinska
Institute, Stockholm, Sweden; synthetic sulphated and unsulpha-
ted CCK 26-33 from the Squibb Institute, Princetown, N.J., USA;
synthetic unsulphated human gastrin 1-17 from Imperial Chemical
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Industries, Cheshire, England; ( I)hydroxyphenylpropionic
acid-succinimide ester (Bolton-Hunter reagent) from New England
125
Nuclear, Boston, Ma, USA; ( I)Na from Behringwerke AG, Marburg/ 
Lahn, FRG; sodiumethylmercurithiosalycilate from Aldrich-Europe,
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Beerse, Belgium; Sephadex G 50 SF and CM-Sephadex C 25 from 
Pharmacia, Uppsala, Sweden; AE 41 and DE 52 cellulose from What- 
man, Maidstone, England; dextran T 70 and bovine serum albumin 
(RIA-grade), from Sigma St. Louis, Mo, USA; human and bovine se­
rum albumin from Behringwerke AG, Marburg/Lahn, FRG; all other 
reagents from E. Merck, Darmstadt, FRG.
Antisera
Among 29 rabbits and 5 guinea pigs immunized with partly 
purified porcine CCK or synthetic CCK fragments (Jansen & Lamers, 
1983), 15 rabbits produced antisera binding to at least one of 
the CCK-labels studied in a dilution of more than 1:500 (table I).
T A B L E  I
T i t e r s  of C C K - a n t i s e r a  e m p l o y i n g  d i f f e r e n t  l a b e l s
A n t i -  I mm- A n t i s e r u m  t i t e r 3
' no . gen 12 5 I C C K 3 9 1 2 5 I B H C C K 3 3 b
1 25
I C C K 2 6 - 3 3
1 2 5
Igas t r i n l - 17
7 BSA - <50 0 <500 660 <500
8 EC D - <500 <500 2 0 , 0 0 0 1 2 , 0 0 0
9 CCK <500 <500 9 ,900 1 0 , 0 0 0
1 0 26-33° <500 <500 1 7 , 5 0 0 2 0 , 0 0 0
1 1 BS A - <500 2 , 7 5 0 19 , 0 0 0 2 5 , 0 0 0
1 2 EC D - <500 2 7 , 0 0 0 3 , 5 0 0 5 ,000
1 3 CCK 6 5 , 0 0 0 7 5 , 0 0 0 3 8 , 0 0 0 39 ,000
1 4 ( 30% ) ° <500 5 0 , 0 0 0 7 0 , 0 0 0 4 0 , 0 0 0
Tl 4 5 , 0 0 0 2 2 , 5 0 0 <500 <500
T 2 15 , 0 0 0 80 ,000 <500 <500
1 5 CC K <500 <500 2 8 , 0 0 0 3 0 , 0 0 0
1 6 (30%) 600 1 ,500 <500 <500
1 7 <500 5 2 , 0 0 0 5 , 0 0 0 2 , 500
1 8 32 , 000 2 ,500 8 ,500 2 ,500
T 3 <500 2 ,600 <500 <500
a. F i n a l  d i l u t i o n  of a n t i s e r u m  g i v i n g  50% b i n d i n g  b e t w e e n  a n t i ­
b o d y  and label.
12 5 . .
b. C C K - 3 3  c o u p l e d  to I - h y d r o x y p h e n y l p r o p  i o n i c  a c i d - s u c c i n i m i d e -
e s t e r  ( B o l t o n - H u n t e r  r e a g e n t ) .
c. C C K - p e p t i d e s  c o u p l e d  to b o v i n e  s e r u m  a l b u m i n  u s i n g  l - e t h y l - 3 -  
( 3 - d i m e t y l a m i n o p r o p y l ) - c a r b o d i i m i d e .
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Four animals were immunized with synthetic CCK 26-33 coupled to 
bovine serum albumin using the carbodiimide method (120 nmol at 
the initial- and 60 nmol at booster injections), 6 with 30% pure 
porcine CCK (20 nmol at the initial- and 10 nmol at booster in­
jections) . The antisera tested in the present study were obtai- 
ned after the fourth immunization. Binding of the antisera to 
(12sI)CCK 39, (125I)BH-CCK 33, (125I)CCK 26-33 and (125I )gastrin 
1-17 was determined. When the titer, defined as the dilution of 
the antiserum giving 50% binding of the labelled peptide, was 
higher than 1:15,000, displacement studies with CCK-peptides and 
gastrin were performed.
Radioiodination
Non-sulphated CCK 26-33 was labelled with (^2^I) by the 
chloramine-T method as described previously (Jansen & L a m e r s ,
1982). The labelled peptide was purified on DE 52 cellulose 
columns (1 cm x 10 cm) using a 0.05 M to 0.5 M  ammoniumcarbo- 
nate pH 5.0 gradiënt as eluant. The labelled peptide retained 
its immunoreactivity for at least 2 months. Label damage in the 
absence of antibody was less than 2%. The specific radioactivi­
ty of the label ranged from 260-500 yCi/yg (n=5).
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Non-sulphated gastrin 1-17 was labelled with ( I) by the 
chloramine-T method (Stadil & Rehfeld, 1972) . The labelled pep­
tide was purified on AE 41 cellulose columns (1 cm x 10 cm) with 
a 0.05 M to 0.2 M  ammoniumbicarbonate pH 8.4 gradiënt as eluant. 
The labelled peptide retained its immunoreactivity for at least
2 months. Label damage in the absence of antibody ranged between 
1-5% and the specific radioactivity from 275-525 yCi/yg (n=10).
Conjugation of CCK 33 with Bolton-Hunter reagent was per-
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formed as described before (Jansen & Lamers, 1982). I-hydroxy- 
phenylpropionic acid-succinimide ester was dried under a gentle 
stream of nitrogen according to the instructions of the manufac- 
turer. 5 yg 99% pure CCK 33, dissolved in 5 yl 0.05 M  acetic acid 
was added to the bottom of the vial. After addition of 15 yl 0.05 
M  sodiumborate pH 10, the vial was gently agitated in an ice bath. 
After one hour 0.2 M glycine in 500 yl 0.05 M  sodiumborate pH 8.5
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was added to the mixture and the vial was agitated for another
5 m i n u t e s . The reaction mixture was then chromatographed at 4
°C on a Sephadex G 50 SF column (100 cm x 1 cm) using 0.5 M
acetic acid containing 1 g/1 gelatin as eluant. Every hour 5
fractions of 1 ml were collected. The fraction with the highest
radioactivity of the immunoreactive peak was diluted in 0.05 M
acetic acid and stored at -20 °C. This ( ^ ^ I ) B H - C C K  33 label
retained its immunoreactivity for at least 2 months. Label dama-
ge in the absence of antibody ranged between 2-7%. The specific
radioactivity of the label ranged from 260-485 yCi/yg (n=8).
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99% pure porcine CCK 39 was labelled with I by the chlor-
125amine-T method. 0.25 mCi I dissolved in 5 yl 0.25 M  sodium
phosphate buffer pH 7.5 was mixed vigorously with 5 yg 99% pure
CCK 39, dissolved in 5 yl 0.05 M  sodium phosphate buffer pH 7.5
and 10 yg chloramine-T dissolved in 10 yl sodium phosphate buffer
pH 7.5 in a glass tube. After 20 seconds the reaction was termi-
nated by addition of 20 yg sodiummetabisulphite dissolved in 10
yl sodium phosphate buffer pH 7.5. The labelled peptide was puri-
fied on CM-Sephadex C 25 columns (1 cm x 10 cm) with a 0.05 M to
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0.5 M ammoniumacetate gradiënt as eluant (fig 1). This ( I)CCK 
39 label retained its immunoreactivity for at least 2 months.
Label damage in the absence of antibody was less than 5%. The 
specific activity of the label ranged from 250-410 yCi/yg (n=3).
Incubation conditions
Radioimmunoassays were performed in plastic tubes in an ice 
bath. 0.05 M sodium phosphate buffer pH 7.4 containing 0.08 mmol/1 
human serum albumin and 0.06 mmol/1 sodiumethylmercurithiosali- 
cylate was used as assay buffer. The incubation mixture contained
0.2 ml of approximately 33 dps labelled peptide, 0.2 ml Standard 
solution and 0.1 ml diluted antiserum. The tubes were incubated 
for 9 6 hours at 4 °C to determine antibody titers, while a pre- 
equilibrium assay was used to set up Standard curves with CCK- 
peptides or gastrin. In this pre-equilibrium assay, addition of 
labelled peptide was delayed until 20 hours before separation of 
free from antibody bound peptide was performed. Separation of
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free and antibody bound peptide was performed by addition of a
1.5 ml charcoal suspension, containing 25 mg activated charcoal,
2.5 mg dextran T 70 and 16 mg bovine serum albumin (RIA-grade) 
in the assay buffer. The tubes were vortexed and centrifuged 
(3000 g, 10 m i n u t e s ) . Both supernatant and pellet were counted 
in an automatic y-scintillation counter.
Fraction number
F i g u r e  1
E l u t i o n  p r o f i l e  of 1 2 5 I - r a d i o a c t i v i ty a f t e r  a p p l i c a t i o n  of the 
r e a c t i o n  m i x t u r e  of C C K  39 w i t h  1 2 5 I N a  to a C M - S e p h a d e x  C 25 
c o l u m n  (1 c m  x 10 cm) u s i n g  a 0.05 M to 0.5 M  a m m o n i u m a c e t a t e  
b u f f e r  pH 5.0 g r a d i ë n t .  The f i r s t  p e a k  r e p r e s e n t s  u n r e a c t e d  
1251 and the s e c o n d  p e a k  ( 1 2 5 I ) C C K  39. For d e t a i l s  see text.
Results
I O C
Antisera raised against CCK 26-33 bound to ( I)CCK 26-33, 
but not to ( 3I)CCK 39 or ( DI)BH-CCK 33 (table X). However, 
when (1^ I ) C C K  26-33 was used as label, both CCK 39 and CCK 33 
were able to displace the label from the antisera (table I I ) .
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TABLE I I
D I S P L A C E M E N T  OF D I F F E R E N T  L A B E L S  F R O M  C C K - A N T I S E R A  BY C C K - P E P T I D E S
A N D  G A S T R I N
R e l a t i v e  b i n d i n g 3
C C K 3 9  C C K 3 3  C C K 2 6 - 3 3  C C K 2 6 - 3 3  G a s t r i n l - 1 7  
s u l p h a t e d  u n s u l p h a ­
ted.
8 1 2 5 I - C C K 8 b 1 . 00 0 ,.81 3 ., 53 4 .,51 5 ., 56
1 0 1 2 5 i - c c k 8 1 .00 1.,00 9.,38 8. 3 I 8 .69
1 1 1 2 5 i - c c k 8 1 . 00 1., 08 4 ., 1 6 5 ., 1 0 5 .,56
1 2 12 5 i - b h - C C K 33 1.00 1,,25 <0 .,01 N .,T.C N .,T.°
1 3 1 2 5 i - c c k 8 1 . 00 1., 14 1 ., 20 1 , 14 1 .,08
12 5 i - c c k 39 1 . 00 1., 1 9 <0.,01 <0,,01 <0 ,01
1 2 5 i - b h - C C K 33 1 . 00 2 ,. 1 4 <0,,01 <0,.01 <0,,01
1 4 1 2 5 i - c c k 8 1 . 00 1,. 1 I 2 ., 90 2 , 60 2 , 1 0
1 2 5 i - b h - C C K 33 1 . 00 1,,25 <0., 0 1 N , T . N , T .
T 1 1 2 5 i - b h - C C K 33 1.00 2 ,. 00 <0 ,01 N ., T . N . T .
1 2 5 i - c c k 39 1 . 00 1,.43 <0,,01 N,. T . N..T.
T 2 12 5 i - b h - C C K 33 1 . 00 0,.89 0 ,.83 <0 ,.01 <0,.01
12 5 i - c c k 39 1 .00 0 . 90 0 ,.79 <0,.01 <0,.01
1 5 12 5 i - c c k 8 1 . 00 1 . 1 2 0,,84 0,.75 0,.70
1 7 12 5 i - b h - C C K 33 1 . 00 1 . 14 <0 .01 <0,.01 <0,.01
1 8 12 5 i - c c k 39 1 . 00 <0,.01 <0,.01 <0 ,.01 <0..01
a. The relative binding of CCK-peptides and gastrin to antisera 
was calculated from the ID-50 for each peptide (Inhibition 
dose 50 (ID-50) is the dose of the peptide that reduces bin­
ding between label and antibody by 50%).
1 2 5
b. ( I)CCK 26-33.
c. N.T.: not tested.
Of the antisera raised against 30% pure porcine CCK, 2 bound to
all 3 CCK-labels, 4 to (125I )BH-CCK 33 and (125I)CCK 26-33, 3 to
(125I)CCK 39 and (125I)BH-CCK 33, one to (125I)CCK 26-33 only,
125
and one to ( I)BH-CCK 33 only (table I). The 2 antisera binding 
to all 3 CCK-labels showed different displacements curves for
A n t  i- L a b e l  l ed 
s e r u m  p e p t i d e
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CCK-peptides when tested with different CCK-labels (table I I ) .
12 5
Vvhen tested with ( I)CCK 26-33, antiserum 13 bound to all CCK-
peptides and gastrin 1-17, whereas this antiserum bound to CCK 33
and CCK 39 only when tested with (125 i )CCK 39 or (125I)BH-CCK 33
(table II; fig 2). When antiserum 18 was tested with (125I)CCK 39,
it was found to be specific for CCK 39 (fig 3). Of the a anti-
1 ?  S 1 ?  ■ï
bodies reacting with both ( I)BH-CCK 33 and ( I)CCK 26-33
one bound to all CCK-peptides and gastrin, 2 bound to CCK 39 and
CCK 33 only, while antiserum 14 bound to all CCK-peptides and
1 TC
gastrin when tested with ( I)CCK 26-33, and with CCK 39 and 
CCK 33 only, when tested with (125I)BH-CCK 33 (table II).
F i g u r e  2 
D i f f e r e n t  p a t t e r n s  of 
d i s p l a c e m e n t  of d i f f e r e n t  
C C K - l a b e l s  f r o m  the same 
a n t i s e r u m  (no. 13) by 
C C K - p e p t i d e s .
p M
Of the antisera reacting with both (125I)CCK 39 and (125I)BH-CCK
33, antiserum Tl bound to CCK 39 and CCK 33 only, while antiserum
T2 bound to CCK 39, CCK 33 and sulphated CCK 26-33, but not to
non-sulphated CCK 26-33 and gastrin (table II). Antiserum 15,
. 1 2 5
reacting to ( I)CCK 26-33 bound to all CCK peptides and gastrin. 
All antisera reacting to (125I)CCK 26-33 bound also to (125I) 
gastrin 1-17. Except for antiserum T2, all antisera reacting to
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sulphated CCK 26-33 bound a l s o ,unsulphated CCK 26-33 and gastrin.
B / F  ( % )
T----- 1----------- 1----- 1--
5 10 50 100
p M
F i g u r e  3
I 2 5
S t a n d a r d  c u r v e  of a n t i b o d y  18 u s i n g  ( I ) C C K  39 as label. The 
a s s a y  is s p e c i f i c  for C C K  39.
Discussion
This study shows that antisera raised against CCK may bind 
to CCK-labels prepared by both oxidative and non-oxidative radio- 
iodination methods. It can therefore be concluded that, in con­
trast to a previous report (Rehfeld, 197 8 a ) , CCK-labels prepared 
by oxidative techniques do not necessarily lose their immunore- 
active properties. This is in agreement with previous reports on 
radioimmunoassays for CCK employing CCK-labels prepared by the 
chloramine-T method (Dockray, 1980; Walsh et al, 1982; Lilja et 
al, 1982; Chang & C h e y , 1983); The data presented in the present
study confirms our previous observation that antibodies binding 
125
to ( I)CCK 26-33 and therefore directed towards the carboxyl- 
terminal region of CCK often possess low affinity to Bolton- 
Hunter labelled CCK 33 (Jansen & Lamers, 1982). Two antisera
125
(no. 13 and no. 14), however, bound in high titers to both ( I) 
1 2R
CCK 26-33 and ( I)BH-CCK 33 (table I). These antibodies showed
different displacement profiles for CCK-peptides and gastrin when
studied with (125I)BH-CCK 33 or (125I)CCK 26-33 (table II). When 
125
tested with ( I)CCK 26-33, the antisera bound to all CCK-pepti- 
des and gastrin, while they bound to CCK 39 and CCK 33 only when 
tested with (^2^I)BH-CCK 33. It is therefore likely that (*2^I)
56
1 ? R
CCK 26-33 and ( 3 I)BH-CCK 33 bind to different antibody popula-
tions in the 2 antisera. One antibody population can be detected
by both ( ^ ^ I ) C C K  26-33 and (*2^I) gastrin 1-17, whereas the other
125
antibody population in these antisera can be detected by ( I) 
BH-CCK 33. The first antibody population is not specific for CCK 
because of cross-reactivity with gastrin, while the latter anti»- 
body is specific for the larger forms of CCK (table II, fig 2).
Five antisera bound to ( * ^ I ) C C K  39 (table I). Antisera Tl 
and T2 showed similar displacement profiles for CCK-peptides 
when tested with (125I)BH-CCK 33 and (125I)CCK 39 (table II), 
however, the binding sites for CCK of both antibodies differ, 
since antiserum Tl does not bind to CCK 26-33, while antiserum 
T2 binds to sulphated CCK 26-33 but not to unsulphated CCK 26-33 
and gastrin. It is therefore likely that antiserum T2 is
directed towards the sulphated tyrosyl region of CCK.
From the displacement profiles it can be derived that antiserum 
Tl is directed towards either the amino-terminus or the midregion 
of CCK. It is, however, unlikely that antiserum Tl is directed 
towards the amino-terminus of CCK, since the antiserum shows si­
milar binding properties to CCK 39 and CCK 33 which differ from 
each other in the amino-terminal region (Mutt, 1976). When anti­
serum 18 was tested with (12^I)CCK 39, CCK 39 was the only pepti­
de that displaces the label from the antiserum. It is therefore 
likely that this antiserum is directed to a region in CCK 39 that
IOC
CCK 39 and CCK 33 have not in common. Employing ( I)CCK 39 as
label and 99% pure porcine CCK 39 as Standard, antiserum 18 can
be used in a radioimmunoassay specific for CCK 39 (Jansen & La-
mers, 1983b). Antisera binding to (12^I)CCK 39 do not necessarily 
125
bind to ( I)BH-CCK 33. An explanation for this phenomenon is 
not apparent. It might, however, be possible that structural or 
conformational changes in the CCK-molecule, introduced by diffe­
rent labelling techniques, are responsible for different binding 
of antisera to the 2 labels.
125
All antisera reacting with ( I)CCK 26-33 bound also to 
gastrin. The cross-reactivity of carboxyl-terminal CCK-antisera 
with gastrin is probably related to structural similarities in 
the carboxyl-terminal regions of CCK and gastrin (Mutt & Jorpes,
57
1967). Therefore, carboxyl-terminal CCK-antisera are not suitable 
for specific measurements of CCK-concentrations.
In conclusion, this study demonstrates the importance of tes- 
ting antisera raised against CCK with labels prepared by different 
labelling techniques using different CCK-pe p t i d e s .
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Summary
Using a sensitive and specific radioimmunoassay for cholecysto- 
kinin-39 (CCK-39), CCK-39 was demonstrated in aqueous-acid 
extracts of procine brain. The highest concentration of CCK-39 
was found in the cortex (6.1±1.5 pmol/g). In the cortex CCK-39 
comprised 21% of total CCK-inmunoreactivity and 51% of large 
CCK-imnunoreactivity
Cholecystokinin (CCK) has been isolated from porcine intestines by Mutt and 
Jorpes (1). These workers found that intestinal CCK consisted of 33 amino 
acid residues (CCK-33). In addition, they characterized a CCK-peptide of 39 
amino acid residues corresponding to the form of 33 residues extended at 
the NH2-terminus by 6 residues (CCK-39) (2). Furthermore, a small mole­
cular form CCK-peptide, suggested to contain 8 amino acid residues, was ex- 
tracted from small intestine of several marmialians (3,4). Recently, CCK- 
like peptides were discovered in brain extracts (5). It is suggested that 
these CCK-like peptides in the brain play a role as neuromodulator or neuro­
transmitter. A small molecular form of CCK was demonstrated in cerebral ex­
tracts from different species (3,4,6,7,8,9). This small molecular form CCK 
from sheep brain was chemically characterized and it was found to be identi- 
cal to the 8 C-terminal amino acid residues of porcine CCK (10). Using inrnu- 
no-chemical methods some workers have demonstrated larger forms of CCK in 
cerebral extracts (4,7,8), whereas other workers using similar techniques 
were unable to demonstrate these large molecular forms of CCK (3,9).
Although CCK-39 was isolated and chemically characterized already in 1976 
(2) almost no attention has been paid to this molecular form of CCK. The 
lack of data on CCK-39 is due to the absence of specific radioimnunoassays 
for CCK-39 and to the fact that CCK-39 cannot be separated from CCK-33 by 
conventional separation techniques, such as Sephadex G50 column chromatography. 
We have developed a specific and sensitive radioimmunoassay for CCK-39. This 
assay enabled us to demonstrate the presence of CCK-39 in porcine brain. Fur- 
thermore, the concentrations of CCK-39 in different regions of the brain were 
compared with CCK-concentrations obtained with 3 other radioimmunoassays 
using antibodies with different specificities.
Methods
Fresh porcine brains were obtained from the local abattoir. Specimens from 
different regions of the brain were extracted in boiling water (1 g/1Oml)
0024-3205/83/080911-03$03.00/0 
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for 10 minutes. After homogenïzation and centrifugation the supernatant was 
decanted and the pellet was re-extracted in 0.5 M boiling acetic acid (1 g/ 
10 ml) for another 10 minutes. After centrifugation the supernatant was ad­
ded to the supernatant of the aqueous extraction, rapidly frozen, lyophi- 
lized and redissolved in assay buffer prior to the assay.
The concentrations of CCK in tissue extracts were measured by 4 radioimmuno- 
assays with different specificities.
TABLE 1
Ab.1804 Ab.1703 Ab.T204 Ab.5135
CCK39 1.00 1.00 1.00 1.00
CCK33 <0.001 1.12 0.89 1.09
CCK8 sulfated <0.001 <0.001 0.83 1.20
CCK8 non-sulfated <0.001 <0.001 <0.001 1.20
Binding of antibodies 1804, 1703, T204 and 5135 
to different molecular forms of cholecystokinin 
Antibody 1804 is specific for CCK 39, antibody 
1703 for large molecular forms of CCK, antibody 
T204 for sulphated forms of CCK, while antibody 
5135 binds to all molecular forms of CCK
All antibodies were raised in rabbits; Ab 1703 against 30% pure porcine CCK, 
Ab 1804 and Ab T204 against 30% pure porcine CCK coupled to bovine serum al- 
burnin, and Ab 5135 against synthetic non-sulfated CCK-8 coupled to bovine 
serum albumin. In the assay using Ab 1804 the label was prepared by coupling 
99% pure CCK-39 to 125i by the chloramine T method (11), for Ab 1703 and 
Ab T204 by coupling 99% pure CCK-33 to 125i-hydroxyphenylpropiomc acid- 
succinimide ester (12), and for Ab 5135 by coupling synthetic non-sulfated 
CCK-8 to 125i by the chloramine T method (8,11).99% pure CCK-39 was used as 
Standard in all assays. 0.05 M sodium phosphate buffer pH 7.4 containing 80 
ymol/1 human serum albumin and 60 umol/1 sodiumethylmercurithiosalicylate was 
used as assay buffer. Separation of free and bound label was performed by ad­
dition of an activated charcoal suspension. The 50% inhibition dose for CCK- 
39 (ID50) was 4.5 fmol/ml for Ab 1804, 2.8 fmol/ml for Ab 1703, 3.3 fmol/ml 
for Ab T204, and 4.0 fmol/ml for Ab 5135. Intra-assay variations were less 
than 10%
Results 
TABLE 2
Ab.1804 Ab.1703 Ab.T204 Ab.5135
Brain(n=5)
Cortex 6.1±1.5 11.8±0.5 24.1+3.0 28.4+5.1
Thalamus 0.2±0.1 2.0±0.6 2.4±0.8 3.3±0.5
Hypothalamus 0.4±0.1 2.6±0.6 3.0±0.7 3.5±0.5
Pons 0.1±0.1 1.8+0.6 2.1±0.7 2.U0.5
Cerebellum <0.1 <0.1 <0.1 <0.1
Concentrations of Cholecystokimn-like ïmnuno- 
reactivity (pmol/g) in aqueous-acid extracts of 
porcine brain as measured by radioimmunoassays 
using antibodies with different specificities. 
Dilution curves of all tissue extracts were paral­
lel to the Standard curves
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Discussion
By using a sensitive and specific radioimmunoassay for CCK-39 we have shown 
for the first time that CCK-39 is present in porcine brain. It was further 
shown that the highest concentrations of CCK-39 are found in the cortex. Thus, 
the distribution of CCK-39 is not different from other molecular forms of 
CCK. In the cortex CCK-39 comprised 20-25% of total CCK-irminoreactivity as 
measured by assays specific for the C-terminus (Ab 5135) and for the sulfated 
tyrosine region (Ab T204) and 507» of large CCK-iimunoreactivity as measured 
by radioimmunoassay using Ab 1703. From this study it cannot be derived 
whether CCK-39 plays a physiological role in the brain or that it merely re­
presents a precursor of smaller biologically active forms of CCK. Since the 
concentration of CCK in the cortex as measured by Ab 1703 is about twice 
that measured by the CCK-39 specific antibody (Ab 1804), it is likely that 
in addition to CCK-39 other large molecular forms of CCK are present in the 
brain.
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Sumniary
A highly sensitive radioimmunoassay for cholecystokinin (CCK) without any 
cross-reactivity with gastrin is described. The antibody was raised in a rabbit by 
immunisation with 30% CCK and bound to all COOH-terminal CCK-peptides 
containing at least 14 amino acid residues. The affinity constant of the antibody was
59.4 X  10'° 1 /m ol.
CCK 33 conjugated to [l25I]hydroxyphenylpropionic acid-succinimide ester was 
used as label. The binding between label and antibody was inhibited by 50% (ID50) 
at a concentration of 2.8 pmol/1 cholecystokinin 33. The detection limit of the assay 
was between 0.5 and 1.0 pmol/1 plasma. Concentrations of CCK in aqueous acid 
extracts of human upper small intestine were 36.5 ±  9.8 pm ol/g and of human 
cerebral cortex 28.2 + 2.5 pm ol/g tissue. Plasma samples were extracted in 96% 
ethanol prior to assay. No advantage was obtained by adding aprotinin to the tubes. 
When frozen at — 20°C plasma CCK was stable for at least 6 months. Basal plasma 
CCK concentrations in 30 normal subjects were very low, 0.9 ± 0.1 pmol/1, range 
0.5 to 3.1 pmol/1. Intraduodenal administration of fat induced significant increases 
in plasma CCK from 1.1 ± 0.1 to 8.2 ±  1.3 pmol/1 ( p  = 0.01). Infusion of exogenous 
CCK, resulting in plasma CCK levels slightly lower than those measured during 
administration of fat, induced pancreatic enzyme secretion and gallbladder contrac- 
tion. The reliability of this radioimmunoassay for measurements of CCK in human 
plasma was extensively evaluated.
Introduction
Even though the first radioimmunoassay of cholecystokinin (CCK) was reported 
as long ago as 1969 [1], no specific radioimmunoassays sufficiently sensitive to
* Correspondence lo Dr. C. Lamers, Division of Gastroenterology, St. Radboud Hospital, 6500 HB 
Nijmegen, The Netherlands.
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measure CCK concentrations in human plasma have been published. All published 
assays either show some cross-reactivity with gastrin or the cross-reactivity especially 
with sulphated gastrins was not adequately tested [1 — 10]. Furthermore, some radio­
immunoassays of CCK are extremely sensitive to non-specific interference by 
plasma factors [5,8]. In fact, basal plasma CCK concentrations varied from less than 
0.8 pmol/1 to 1 200 pmol/1 and postprandial plasma CCK levels from 2.0 to 2 275 
pmol/1, as measured by the different radioimmunoassays.
We report on a highly sensitive radioimmunoassay for CCK without any cross-re- 
activity with gastrin. The reliability of this assay for measurements of CCK in 
human tissue and plasma has been extensively evaluated.
Materials and methods
Peptides
99% pure porcine CCK 39 and CCK 33 and 30% pure porcine CCK were 
purchased from Prof. V Mutt, Karolinska Institute, Stockholm, Sweden; synthetic 
CCK-peptides were obtained from Prof. N. Yanaihara, Shizuoka College of 
Pharmacy, Oshika, Japan; the Squibb Institute, Princetown, NJ, USA; UCB, Brus­
sels, Belgium; Bachem, Torrance, CA, USA; and Sigma, St. Louis, MO, USA. 
Gastrin-peptides were obtained from Prof. M Grossman, Los Angeles, CA, USA 
and Imperial Chemical Industries, Cheshire, UK.
Reagents and other materials
[125I]Hydroxyphenylpropionic acid-succinimide ester (Bolton Hunter reagent) 
was purchased from New England Nuclear, Boston, MA, USA; Sephadex G50 
Superfine from Pharmacia, Uppsala, Sweden; human serum albumin from Be- 
hringwerke AG, Marburg am Lahn, FRG; sodium ethylmercurithiosalicylate from 
Aldrich-Europe, Beerse, Belgium; dextran T70 and bovine serum albumin (RIA- 
grade) from Sigma, St. Louis, MO, USA; double antibody solid phase (DASP) from 
Organon, Oss, The Netherlands; aprotinin (Trasylol®) from Bayer, Leverkusen, 
FRG; Intralipid from Vitrum AB, Stockholm, Sweden; all other reagents from E. 
Merck, Darmstadt, FRG.
Apparatus
Automatic gamma scintillation counter Philips PW 4800, Philips, Eindhoven, The 
Netherlands.
Standard
99% pure natural pojcine CCK 33 dissolved in assay buffer was used as Standard. 
Labelled peptide
CCK 33 was coupled to [12SI]hydroxyphenylpropionic acid-succinimide ester 
(Bolton-Hunter reagent) as described before [11].
Antibodies
Ten rabbits and three guinea pigs were immunised with 30% pure porcine CCK
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coupled to bovine serum albumin, nine rabbits and two guinea pigs with uncoupled 
30% CCK, five rabbits with synthetic CCK 10-20 coupled to bovine serum albumin 
and four rabbits with sulphated CCK 26-33 coupled to bovine serum albumin. In the 
initial immunisations the dose of antigen was 10-20 nmol for CCK and 120 nmol 
for CCK-fragments, while at booster injections half of the initial dose was adminis- 
tered. After the fourth immunisation five rabbits immunised with albumin-coupled 
CCK had antibody titres between 1 :22 500 and 1 :80000, while one rabbit im­
munised with uncoupled CCK had a titre of 1 :52000. The affinity constants of 
these six antibodies ranged from 2.0 X 10'° to 72.3 X 1010 1/mol. In the guinea pigs 
immunised with CCK and in the rabbits immunised with CCK-fragments antibody 
titres were less than 1 :500. In the present study antibody 1703, obtained from a 
rabbit after the third immunisation with uncoupled CCK, was used. This antibody 
was used in a dilution of 1: 100000. The affinity constant of the antibody was
59.4 X l O 10 1/mol and the ID50 was 2.8 pmol/1. Antibody 1703 bound to all 
COOH-terminal CCK-peptides containing at least 14 amino acid residues and did 
not show any binding to gastrins (Table I). The lack of cross-reactivity with gastrin 
was validated by measurements of samples with very high concentrations of endoge- 
nous human gastrin (extracts of antral and gastrinoma tissue and plasma from 
gastrectomised Zollinger-Ellison patients). Results obtained with antibody 1703 were 
compared with those obtained with antibody T204. Antibody T204 was harvested 
from a rabbit after the fourth immunisation with albumin-coupled CCK and was 
used in a dilution of 1 : 80000. The affinity constant of this antibody was 52.2 X 1010 
1/mol and the ID50 was 3.3 pmol/1. The antibody was specific for the sulphated
T A B L E I
Relative potencies of CCK-peptides and gastnns to antibodies 1703 and T204
Antibody
1703
Antibody
T204
CC K  39 0.91 1.09
CC K  33 1.00 1.00
CCK 20-33 0 62 1 69
CCK 22-33 <0.01 1.71
CCK 24-33 <0.01 0.78
CCK 26-33 sulphated <0.01 0.65
CCK 26-33 unsulphated <0.01 <0.01
CCK 30-33 < 0 0 1 <0.01
CCK 1-21 < 0 0 1 <0.01
CCK 1-15 <0.01 <0.01
CCK 10-20 <0.01 <0.01
C C K  16-27 0.01 0.01
CCK 20-27 0.01 0.02
gastrin 34 sulphated <0.01 0.02
gaslnn 34 unsulphated <0.01 <0.01
gastrin 17 sulphated <0.01 0.02
gastnn 17 unsulphated <0.01 <0.01
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tyrosine region in the CCK molecule (Table I). Antibody T204 showed low binding 
to sulphated gastrins but did not react with unsulphated gastrins (Table I). The 
antibodies were further characterised by measurement of the eluates from a Sep- 
hadex G-50 column to which an aqueous-acid extract of human small intestine was 
applied. No binding with structurally unrelated polypeptide hormones was found.
Conditions for incubation
The optimum incubation time was determined. Equilibrium and non-equilibrium 
systems with delayed addition of labelled peptide were lested. Furthermore, the 
optimum pH was determined and interference by different concentrations of sodium 
chloride, albumin and urea was assessed.
Separation procedure
Two separation techniques were compared: (1) adsorption of free peptide to 
charcoal, and (2) binding of antibody-bound peptide to a second antibody. Different 
amounts of charcoal (1 to 128 mg per tube) in a solution containing fixed amounts 
of bovine serum albumin and dextran T70 were added to the incubation tubes. 
Furthermore, the effect of delaying separation after the addition of the charcoal 
suspension for periods of 5 to 60 min were tested. In the double-anlibody separation 
technique 1 ml of 1 :20 diluted sheep anti-rabbit immunoglobulin (DASP) was 
added to the tube and incubated for 4 to 8 h at 4°C before centrifugation.
Tissue extraction
Gastrinoma and antral tissues were extracted in boiling water, whereas brain and 
small intestinal tissues were first extracted in water followed by extraction in acid. 
The aqueous-acid extracts were prepared as follows. The tissue was extracted in 
boiling water (1 g/10 ml) for 10 min. After homogenisation and centrifugation the 
supernatant was decanted and the pellet was re-extracted in 0.5 mol/1 acetic acid (1 
g /10 ml) for 10 min. After centrifugation the supernatant was added to the 
supernatant of the aqueous extraction, rapidly frezen, lyophilised, dissolved in 0.05 
mol/1 sodium phosphate buffer, pH 7.4, and applied to a 100 X  1 cm Sephadex 
G-50 Superfine column eluted with 0.05 mol/1 sodium phosphate buffer, pH 7.4, 
containing 0.06 mmol/1 sodium ethylmercurithiosalicylate.
Treatment o f blood samples
In order to evaluate the stability of CCK, blood samples were collected in both 
glass tubes at room temperature and in ice-chilled glass tubes containing 2 g/1 
ethylenediaminetetraacetate (EDTA) and 1000 K U /m l aprotinin (Trasylol®). The 
blood samples were either allowed to clot at room temperature or were kept on ice 
until centrifugation within 2 h after collecting the samples. Both serum and plasma 
samples were frozen at — 20°C. Plasma samples without added aprotinin containing 
endogenous CCK in concentrations from 1.0 to 19.0 pm ol/l were re-assayed after 
storage for 6 months at — 20° C.
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Extractwn o f samples
Since initial experiments showed that hormone-free plasma induced non-specific 
interference in the assay, CCK was extracted from plasma by addition of ethanol, 
methanol or acetone. The extracts were centrifuged at room temperature at 3000 X g 
for 15 min. The supernatant was decanted and dried under nitrogen at 37°C. The 
dried product was stored at -  20°C and reconstituted to the original volume in assay 
buffer. In order to determine whether ethanol-extracted plasma interfered with the 
antigen-antibody binding, Standard curves of CCK 33 were run in assay buffer or in 
ethanol-extracted hormone-free plasma. Hormone-free plasma was prepared by the 
addition of charcoal to the plasma (20 g/1). Subsequently, the plasma was vigorously 
stirred, centrifuged and filtered until no charcoal was visible in the filtrate.
Reliabihty o f the assay
Accuracy. The recovery of known amounts of CCK 33 and sulphated CCK 8 
added to hormone-free plasma was determined. In addition, recovery of CCK 33 
coupled to [ l25I]hydroxyphenylpropionic acid-succinimide ester added to hormone- 
free plasma was studied. Standard CCK 33 solutions added to hormone-free plasma 
bef ore and after ethanol extraction were chromatographed on a 100 X 1 cm Sep­
hadex G-50 Superfine column to exclude conversion of CCK 33 to smaller molecular 
forms. Serial dilutions of aqueous-acid extracts of human brain and gut, and of 
plasma containing a high concentration of endogenous CCK were measured and 
compared with the dilution curve of CCK 33 Standard.
Precision. Intra-assay and inter-assay variations were determined by 12-fold 
measurements of samples containing between 0.4 to 25 pmol/1 CCK.
Detection limit. The detection limit was defined as the smallest amount of CCK 
which could be differentiated from zero hormone concentration with 95% confi- 
dence.
Human studies
Endogenous CCK. Fasting concentrations of CCK were measured in 30 normal 
subjects (20 male, 10 female; age 42 + 3 yr, range 21-69 yr). In four normal subjects 
(all male, 23 ±  1 yr) the effect of intraduodenal administration of fat (250 ml 20% 
Intralipid® over 1 h) on plasma CCK concentrations was studied.
Exogenous CCK. To evaluate whether plasma CCK concentrations comparable 
to those measured during administration of fat were able to stimulate pancreatic 
enzyme secretion and gallbladder contraction, plasma CCK concentrations and 
bilirubin and amylase output into the duodenum were measured during infusion of
12.5 pmol • kg- 1 • h ~ 1 CCK.
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Statistical analysis
Results were expressed as the mean + 1 SEM, unless otherwise stated. Statistical 
analysis was done by Student’s /-test.
Results
Antibody characterisation with endogenous human peptides
Radioimmunoassay using antibody 1703 showed CCK-like immunoreactivity in 
brain (28.2 ± 2.5 pm ol/g, n =  3) and upper small intestine (36.5 ± 9.8 pm ol/g, 
n = 3). In five of six gastrectomised patients with gastrin-producing tumours (Zol- 
linger-Ellison syndrome) and very high plasma gastrin concentrations (262-50000 
pmol/1) plasma CCK concentrations were less than 1 pmol/1, while one such patiënt 
had a basal plasma CCK concentration of 1.4 pmol/1. No CCK was demonstrable 
in aqueous extracts of two gastrin-producing tumours and five antral extracts with 
gastrin concentrations ranging from 10310 to 130475 pmol/1.
Fig. 1 shows the elution profile of an aqueous-acid extract of human small 
intestine applied to a Sephadex G-50 column as measured by radioimmunoassay 
using antibody 1703 and antibody T204. Radioimmunoassay with antibody 1703 
revealed four and with antibody T204 five distinct peaks of CCK-like immunoreac­
tivity. The peak co-eluting with the CCK 33 Standard and the peak intermediate 
between Standard CCK 33 and Standard CCK 8 com prised the majority of the
Fig. 1. Elution profile of an aqueous-acid extract of hum an small intestine applied to a Sephadex G-50 
column as measured by radioimmunoassay using antibody 1703 (upper panel) and antibody T204 (lower 
panel).
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CCK-like im m unoreactivity The peak co-eluting with the CCK 8 Standard was only 
detectable by radioim m unoassay usmg antibody T204
Incubation conditions
Equilibrium between antibody-bound and free labelled peptide was achieved after 
incubation for 96 h However, the most sensitive radioimmunoassay was obtained 
when a non-equilibnum system with 72 h pre-incubation followed by 20 h incuba­
tion with labelled peptide was used The optimum pH of the assay buffer was 
between 6 and 8 Sodium chloride interfered with the binding between peptide and 
antibody when present in concentrations above 220 mmol/1, while interference by 
albumin was found when the concentration exceeded 0 33 mmol/1 However, when 
albumin was present in concentrations of less than 0 04 mmol/1, a marked decrease 
in binding between peptide and antibody was observed Urea concentrations exceed- 
ing 800 mmol/1 also produced non-specific interference in the assay For routine 
measurements of CCK 200 ftl of sample or Standard were incubated with 100 jul 
diluted antiserum for 72 h at 4°C After addition of 200 fi\ labelled CCK 33 
containing approximately 2000 dpm and incubation for another 20 h at 4°C, free 
and antibody-bound peptide were separated 0 05 m o l/l sodium phosphate buffer, 
pH 7 4, containing 0 08 mmol/1 human serum albumin and 0 06 mmol/1 sodium 
ethylmercunthiosalicylate was used as assay buffer
Separation procedure
Optimal separation between free and antibody-bound peptide was obtained when 
between 10 and 32 mg charcoal was added to each tube Delay of centrifugation 
after imxing for penods of up to 60 min did not change the equilibrium between free 
and bound peptide However, when the mixture was centrifuged within 5 min after 
addition of the charcoal suspension, marked differences in the ratio between free 
and bound peptide were found Delay of decantation of the supernatant after 
centrifugation for penods of up to 60 min did not mterfere with the equilibrium In 
Ihe absence of antibody between 2 and 1% of the radioactive label was not absorbed 
to the charcoal pellet and thus measured as aspecifically bound radioactivity 
Separation by the double antibody solid phase (DASP) techmque was as effective as 
the charcoal separation method
In routine assays separation was performed by the addition of 16 mg charcoal, 2 5 
mg dextran T70 and 15 mg bovine serum alburrun, dissolved in 1 5 ml 0 05 m o l/l 
sodium phosphate buffer, pH 7 4, to each test tube in an ïce-bath The mixture was 
centnfuged for aboul 10 mm (3000 X g for 15 min), the supernatant was subse- 
quently decanted, and both the supernatant and the pellet were counted in a gamma 
spectrometer
Treatment o f blood samples
Concentrations of CCK were not influenced by the treatment of the blood 
samples Sinular results were obtained when blood was collected in ïce-chilled tubes 
containing ethylenediaminetetraacetate and aprotimn, or in tubes without additions 
at room temperature ( y  =  1 06x — 0 12, r  = 0 983, n =  19) Storage of plasma sam-
7 0
pies containing 1.0 to 19.0 pmol/1 CCK for 6 months at -2 0 °C  did not affect the 
CCK concentration measured (_y = 1.1 lx  -  0.14; r = 0.977; n = 13).
For routine purpocp? blood samples were collecled in ice-chilled tubes containing
2 g/1 ethylenediaminetetraacetate. All samples were measured in duplicate.
Extraction procedure
No advantage was obtained by using methanol or acetone over ethanol. For 
routine extractions 2 vols. of 96.% ethanol were added to 1 vol. of plasma or serum. 
After mixing and centrifugation (3000 X g for 15 min) the supernatant was evaporated 
to dryness under nitrogen al 37°C. The dried supernatant was reconstituted in assay 
buffer to the original sample volume immediately before the assay. Standard curves 
in assay buffer and hormone-free plasma were identical, indicating that extracted 
hormone-free plasma did not interfere in the binding between peptide and antibody.
Reliabihty o f the assay
Accuracy. Recovery of CCK 33 added to hormone-free plasma in concentrations 
from 1.2 to 20.0 pmol/1 was 85.4 ± 2.0% (mean +SD ; n = 11). When 0.8 to 43.0 
pmol/1 sulphated CCK 8 was added to hormone-free plasma, recovery was 89.8 ± 
1.7% as measured with antibody T204 (n = 7). Recovery of different amounts of 
labelled CCK 33 (1000 to20000dpm ) added to hormone-free plasma was 83.0 ±  1.3% 
( n =  12). CCK 33 was not converted to smaller molecular forms as shown by
Fig. 2. Senal dilulions of Standard CCK 33 ( • --------- • ) ,  of an aqueous-acid extract of hum an small
intestine (□ --------- □), of an aqueous-acid extract of human brain ( O ----------O ), and of plasma contain-
ing a high concentration of endogenous CCK ( a --------- a).
Fig. 3. Intra-assay ( O --------- O ) and inter-assay ( • ---------- • )  vanations of CCK measurements.
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measurement of immunoreactivity in the eluates of a Sephadex G-50 column to 
which CCK 33 in hormone-free plasma before and after ethanol extraction was 
applied (data not shown). Senal dilutions of an aqueous-acid extract of human bram 
and upper small ïntestme and of plasma containing high concentrations of endoge- 
nous CCK were superimposable on the Standard curve (Fig 2)
Precision Intra-assay and inter-assay precision are presented in Fig 3
Detection limit The delection limit of the assay was approximately 0 5 pmol 
CCK per 1 plasma when a freshly prepared CCK label was used and about 1.0 
pm o l/l when a CCK label, prepared more than 8 weeks before the assay, was used. 
This reduction in sensitivity was due to a change in the slope of the dose-response 
curvc.
Human studies
Fasting plasma CCK concentrations in 30 normal subjects were 0 9 ± 0 1 pm ol/l 
with a range of 0.5 to 3 1 p m ol/l (Fig 4). In the majonty of subjects basal plasma 
CCK concentrations were less than 1 pm ol/l. Sirrular results were obtained when the 
samples were measured with antibody T204 after correction for the slight cross-reac- 
tivity of thjs antibody with sulphated gastnn. There was no significant difference in 
plasma CCK concentrations between men and women Furthermore, no relation 
between basal plasma CCK concentration and age was observed Intraduodenal 
instillation of fat induced significant increases in plasma CCK from 1 1 ± 0 1 to 
8.2 ±  1.3 pm ol/l ( p  =  0 01, Fig 5) The increase in plasma CCK as measured with 
antibody T204 was similar to that measured using antibody 1703 (Fig. 5). Infusion 
of exogenous CCK in a dose of 12 5 pmol kg - 1 • h " 1 resulted in increases in plasma 
CCK to levels of about 6 p m ol/l (Fig. 6). This increase in plasma CCK was 
accompanied by an increase in pancreatic amylase secretion from 9 to 32 K U /15 
min and an increase in duodenal bilirubin to 18 m m ol/15 min indicating gallbladder 
contraction (Fig. 6).
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Fig 4 Fasting plasma CCK concentrations in 30 normal subjects
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Fig. 5 The effect of intraduodenal admirustration of fat on plasma CCK concentrations m 4 normal 
subjects as measured by radioimmunoassay using antibody 1703 (upper panel) and antibody T204 (lower 
panel). Astensks indicate significant ( p  < 0 05) differenceS from basal value
Fig 6 The effect of infusion of exogenous CCK on plasma CCK concentrations, and on amylase and 
bihrubin outputs into the duodenum.
Discussion
The present study describes a highly sensitive radioimmunoassay for CCK in 
human plasma without any cross-reactivity with gastrin. The absence of cross-reac- 
tivity with gastrin was substantiated by measurements of extracts of human antral 
and gastrinoma tissues and of plasma from gastrectomised patients with 
Zollinger-Ellison syndrome, all containing very large amounts of gastrin. By column 
chromatography of an aqueous-acid extract of human small intestine it was shown 
that the antibody bound to all molecular forms of CCK larger than CCK 8. Since all 
four molecular forms of CCK measured by the assay also reacted with an antibody 
specific for the sulphated tyrosine region in CCK (T204), it can be concluded that all 
these components contain the sulphated tyrosine region and consequently possess 
biological activity. Using this assay it was found that basal plasma CCK concentra-
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tions are very low. It is interesting to note that secretin, another hormone rcleased 
from the upper small intestine with stimulatory actions on the pancreas, circulales in 
similarly low concentrations [12]. Basal plasma concentrations of other gastrointesti- 
nal hormones, e.g. gastrin, pancreatic polypeptide, glucagon, insulin, and gastric 
inhibitory polypeptide, are much higher than those of CCK and secretin. The 
finding ihat plasma CCK concentrations are very low compared to those in most 
previous reports is probably attributable to the absence of cross-reactivity with 
gastrin and to the lack of non-specific interference in the present assay. The low 
concentrations of CCK are not due to the absence of cross-reactivity with CCK 8, 
since similar results were obtained by radioimmunoassay using an antibody (T204) 
binding to all molecular forms of CCK containing the sulphated tyrosine region. In 
two recent studies in which CCK was partly separated from gastrin by column 
chromatography prior to measurement by a CCK-assay highly cross-reacting with 
gastrin, it was found that both CCK 8 and larger molecular forms of CCK were 
undetectable in basal plasma [9,10]. In another recent study it was found that the 
mean basal plasma concentration of CCK in man was 12 pmol/1 [8]. However, 
chromatography and charcoal treatment showed that this apparent CCK-like im- 
munoreactivity was almost exclusively due to non-specific interference in that assay 
[8]. The finding that plasma CCK concentrations in man are so low compared to 
those of gastrin makes the application of radioimmunoassays for CCK cross-reacting 
with gastrin undesirable. Several methods have been employed in an attempt to 
separate CCK from gastrin in order to overcome the problem of interference of 
gastrin in the CCK assay, such as column chromatography [9,10], saturation of the 
antibodies with gastrin [6] or extraction of the sample in ethanol [6]. However, none 
of these methods have been proven to be successful in separating larger forms of 
CCK from gastrin. Furthermore, the suggestion that gastrin is poorly extracted in 
96% ethanol could not be confirmed in our laboratory. The cross-reactivity of 
antibodies with sulphated gastrin 17 and non-sulphated and sulphated gastrin 34 has 
been reported in only a few studies [9,10]. This is the more troublesome because 
antibodies specific for the sulphated tyrosine region in CCK usually do not cross-re- 
act with unsulphated gastrins but often do with sulphated gastrins and because 
gastrin 34 is the predominant molecular form of gastrin in fasting plasma [13].
It was further shown that intraduodenal administration of fat, a potent stimulus 
of pancreatic enzyme secretion and gallbladder contraction, resulted in significant 
increases in plasma CCK concentrations. Since the assay measures all molecular 
forms of CCK larger than CCK 8, it is evident that the increase in plasma CCK has 
to be atlributed to larger or intermediate forms of CCK. Increases in CCK measured 
by an antibody specific for the sulphated tyrosin region in CCK and therefore 
cross-reacting with CCK 8 (T204) were identical, indicating that the majority of 
CCK in the circulation is larger than CCK 8. This finding, although contrasting with 
some previous studies [8-10], is not unexpected since smaller gastrin-CCK like 
peptides are degradated by passage through the liver [14]. It has previously been 
suggested that CCK 4 is a major molecular form of CCK in tissue and possibly in 
blood [15]. Since our assays do not cross-react with CCK 4, we are unable to confirm 
or to reject this suggestion. However, CCK 4 is very unlikely to play a hormonal role
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in the stimulation of pancreatic enzyme secretion and gallbladder contraction, since 
CCK 4 is effectively inactivated by the liver [14].
The finding that infusion of exogenous CCK, resulting in slightly lower plasma 
CCK concentrations as during administration of fat, induces pancreatic enzyme 
secretion and gallbladder contraction indicates that CCK may play a physiological 
role in the regulation of pancreatic secretion and gallbladder contraction in man.
In conclusion, using a highly sensitive and specific radioimmunoassay for CCK it 
was shown that basal plasma CCK concentrations are very low, that ïntraduodenal 
administration of fat induces increases in plasma CCK and that CCK may play a 
physiological role in the regulation of pancreatic enzyme secretion and gallbladder 
contraction in man.
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VII EFFECT OF INSULIN-HYPOGLYCAEMIA ON PLASMA CHOLECYSTOKININ
AND PANCREATIC POLYPEPTIDE
Introduction
Pancreatic enzyme secretion during a meal is at least partly 
mediated by vagal-cholinergic mechanisms (1). This vagal-choliner- 
gic stimulation of pancreatic enzyme secretion may be either di­
rect or indirect through the release of cholecystokinin (CCK) 
from the upper small intestinal mucosa. The latter mechanism is 
supported by the recent finding that cholecystokinin release d u ­
ring feeding is inhibited by atropine (2). The present study was 
undertaken to determine whether activation of vagal-cholinergic 
mechanisms by insulin-hypoglycaemia induces the release of CCK 
into the circulation of man.
Subjects and methods
After an overnight fast an intravenous bolus of 0.1 U/kg
Insulin Actrapid was administered to 5 healthy volunteers (3M,
2 F ; age 29-61 y r ) . Plasma CCK, pancreatic polypeptide (PP) and
glucose were measured at -10, 0, 10, 20, 30, 40, 50, 60, 70, 80
and 90 min. Plasma CCK was measured by radioimmunoassay using
two antibodies with different specificities. Cross-reactivity
studies with purified porcine CCK preparations, CCK fragments,
and intestinal and cerebral extracts showed that antibody 1703
binds to component I-CCK, CCK-39, CCK-33 and intermediate CCK,
while antibody T 204 , directed to the sulphated tyrosvl region,
binds also to sulphated CCK-8 (fig 1). In the assay 99% pure
1 25
porcine CCK-33 conjugated to 1-hydroxyphenylpropionic acid 
succinimide ester was used as label and 99% pure porcine CCK-33 
as Standard. Intra-assay precision was less than 8% and inter- 
assay precision less than 15%. The detection limit of the assay 
was about 0.5 pmol/1 plasma. The assays for CCK were further va- 
lidated by the demonstration of increases in plasma CCK after 
oral ingestion of fat or a mixed meal, during intraduodenal ad- 
ministration of fat, and during infusion of bombesin (3). Plas­
ma PP was measured by radioimmunoassays as described previously (4).
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pmol /1
Fig 1 C ross-reactiv ity  o f an tib o d y  T204 and 1703 w ith p u n ficd  porcine C C K  p rep a ra tio n s , C C K -fragm ents and 
gastn n .
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Results
As shown in fig 2 injection of 0.1 U/kg insulin induced a 
significant decrease in plasma glucose and a significant rise in 
plasma PP. However, plasma CCK concentrations did not change du- 
ring insulin-hypoglycaemia.
Discussion
The present study shows that plasma CCK concentrations in 
man are very low. This is in agreement with a recent study sho- 
wing that the apparent CCK-like immunoreactivity in basal human 
plasma of 12 pmol/l was almost exclusively due to non-specific 
interference in that assay (5). The slightly higher concentra­
tions measured with antibocjy ^ 2 0 4  coinPared with the levels ob- 
tained with antibody 1 703 are probably a t t n b u t a b l e  to a higher 
sensitivity to non-specific factors of antibody ^ 2 0 4  anc  ^ not to 
the presence of sulphated CCK-8 in plasma. Recent studies have 
shown that the amount of CCK-8 m  basal plasma is negligible 
(6,7). Insulin-hypoglycaemia did not induce increases in plasma 
CCK. On the other hand, plasma PP concentrations were s i g m f i -  
cantly increased during insulin-hypoglycaemia. This increase in 
plasma PP in the absence of a rise in plasma CCK is noteworthy, 
since PP is suggested to counteract the effects of CCK on pan­
creas and gallbladder, while CCK is probably involved m  the 
postprandial PP release.
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VIII EFFECT OF BOMBESIN ON PLASMA CHOLECYSTOKININ IN 
NORMAL SUBJECTS AND GASTRECTOMIZED PATIENTS 
MEASURED BY SEQUENCE SPECIFIC RADIOIMMUNOASSAYS
Abstract
Since bombesin is known to stimulate pancreatic enzyme se­
cretion and gallbladder contraction, we have measured plasma 
cholecystokinin (CCK) concentrations during bombesin infusion 
using sequence-specific radioimmunoassays. Antibody 1703 binds 
to COOH-terminal CCK-peptides containing at least 14 amino acid 
residues, while antibody ^ 2 0 4  •'■s specific for the sulphated ty­
rosyl region of CCK. In 9 normal subjects infusion of increasing 
doses of bombesin (2.4 pmol/kg.20 min; 6 pmol/kg.20 min; 18 pmol/ 
kg.20min and 60 pmol/kg.20 min) induced dose-related integrated 
plasma CCK-responses (58.5 + 9.7; 70.5 + 12.2; 79.5 + 11.1 and
101.4 + 15.4 pmol/1.20 min (antibody 1703) and 50.4 + 11.9; 62.0 
+ 13.4; 74.7 + 9.2 and 116.1 + 11.3 p mol/1.20 min (antibody T 2 0 4 ^ - 
Infusion of 60 pmol/kg.20 min bombesin in 8 patients with partial 
gastrectomy resulted in similar increases in plasma CCK (8.1 +
1.8 pmol/1, antibody 1703; 9.5 + 2.0 pmol/1, antibody T 2 0 4 ) as in 
8 normal control subjects (6.5 + 0.9 pmol/1, antibody 1703, 8.8 
+ 1.0 Dmol/1, antibody T 2 0 4 ^ • Durin9 infusion of bombesin plasma 
gastrin increased from 16.7 + 1.4 to 49.6 + 8.1 pmol/1 (p<0.005) 
in normal subjects, while there was no significant change in plas­
ma gastrin in gastrectomized patients. In the 3 patients with 
partial gastrectomy studied, bombesin did not significantly in- 
fluence gastric acid secretion.
It is concluded that infusion of bombesin releases CCK in 
man by a gastrin-independent mechanism.
Introduction
Bombesin, a tetradecapeptide originally isolated from amphi- 
bian skin, possesses powerfull stimulatory actions on several 
gastrointestinal functions (1). Recently, a mammalian 27 amino 
acid polypeptide sharing structural and functional similarities 
with bombesin (gastrin releasing Deptide) has been isolated from 
the gastrointestinal tract (18). Bombesin-like immunoreactivity
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has been demonstrated in the gastrointestinal tract of man and it 
has been suggested that bombesin-like peptides may be implicated 
in the physiological regulation of gastrointestinal functions (4, 
21). Since bombesin-like peptides appear to be confined to nerves 
(7) , it is likely that these substances may have a neurotransmit­
ter rather than an endocrine function. Several studies suggest 
that bombesin-like peptides are implicated in the physiological 
regulation of gastrin secretion from the antrum (10,23,25). One of 
the most striking properties of bombesin is its ability to stimu- 
late pancreatic enzyme secretion and gallbladder contraction in man 
(2). Based on experiments using antrectomy and enterectomy in dogs 
it was suggested that bombesin stimulates pancreatic emzyme secre­
tion by releasing CCK from the upper small intestine (14). However, 
the presence of specific receptors for bombesin on the acinar cells 
suggests a direct action of bombesin on the pancreas (6). Further- 
more, the localization of bombesin in nerves may be suggestive of 
a role for bombesin in activating an enteropancreatic reflex (16). 
Using sensitive sequence-specific radioiirununoassays for CCK, we 
were able to demonstrate that bombesin releases CCK in man. To ex- 
clude the possibility that the increase in plasma CCK was second- 
ary to gastrin-stimulated gastric acid secretion in response to 
bombesin, both plasma CCK and plasma gastrin were measured during 
infusion of bombesin in patients with partial gastrectomy.
Subjects and methods
After an overnight fast increasing doses of bombesin (2.4;
6; 18; 60 pmol/kg) were administered to 9 normal subjects (8M,
1F, age 22-54 y e a r s ) . The doses of bombesin were infused during 
20 minute periods separated from each other by infusion of saline 
for 4 5 minutes. Blood samples for measurement of CCK were obtained 
at -5, 0, 5, 10, 15 and 20 minutes during each dose of bombesin. 
Furthermore, the plasma CCK and gastrin responses to 60 pmol/kg.
20 min bombesin in 8 patients with partial gastrectomy (6M, 2F, 
age 35-68 years) were compared to those obtained in 8 normal sub­
jects (5M, 2F, age 36-69 years). Five patients had Billroth-II 
anastomosis and 3 Billroth-I anastomosis. Blood samples for m easu­
rement of CCK and gastrin were obtained at -5, 0, 5, 10, 15 and 20
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minutes. In 3 patients with partial gastrectomy and Roux-Y ana- 
stomosis (3M, age 47-54 years) gastric acid secretion was measu­
red during infusion of saline for 1 hour followed by infusion of 
180 pmol/kg bombesin for another hour.
Plasma CCK concentrations were measured by 2 sequence-spe- 
cific radioimmunoassays employing antibody 1703 and antibody 
^204 • Antibody 1703 binds to all COOH-terminal CCK-peptides
containing at least 14 amino acid residues and does not show any 
cross-reactivity with gastrin (table 1). Antibody ^204 bin|3s to 
all CCK-peptides containing the sulphated tyrosyl region. This 
antibody shows low binding to sulphated gastrins but it does not 
bind to unsulphated gastrins (table 1). The antibodies do not 
bind to structurally unrelated regulatory peptides, including 
insulin, glucagon, pancreatic polypeptide, somatostatin, secretin, 
gastric inhibitory polypeptide, vasoactive intestinal polypeptide, 
neurotensin or bombesin. Measurement of the eluate of a Sephadex 
G50 SF column to which an aqueous-acid extract of human upper small 
intestine was applied showed that both antibodies bind to compo­
nent I-CCK, CCK 33, CCK 39, and intermediate forms of CCK, while 
antibody T 2q^ binds also to CCK 8 (12) . CCK 33 coupled to 125I- 
hydroxyphenylpropionic acid-succinimide ester (Bolton-Hunter rea­
gent) was used as label (11). 99% pure porcine CCK 33 was used as 
* Standard. 0.05 mol/1 sodium phosphate buffer pH 7.4 containing
0.08 mmol/1 human serum albumin and 0.06 mmol/1 sodiumethylmercu- 
rithiosalicylate was used as assay buffer. A non-equilibrium sys- 
tem was used with 72 hour preincubation followed by 24 hours incu­
bation after addition of the labelled peptide. Separation between 
free and antibody bound hormone was performed by adsorption of the 
free peptide to plasma-coated charcoal. The 50% inhibition dose 
(ID^q) was 2.8 pmol/1 for antibody 1703 and 3.3 pmol/1 for anti­
body ^204' p lasma samples were extracted in 96% ethanol, dried un- 
der nitrogen at 37 °C and reconstituted in assay buffer to the or- 
iginal volume before the assay. Recovery of CCK 33 and sulphated 
CCK 8 added to hormone free plasma was 85.4 + 2.0% (n=ll) and 89.8 
+ 1.7% (n=7), respectively. The detection limit of both assays was 
about 0.5 pmol/1 plasma. The intra-assay variation was between 4.6
8 6
and 11.5%, and the inter-assay variation ranged from 11.3 to 26.1%. 
Dilution curves of plasma samples containing a high concentration 
of endogenous CCK were parallel to the Standard curve. Plasma 
gastrin concentrations were measured by radioimmunoassay as pre- 
viously described (15). Synthetic bombesin-14 was purchased from 
Boehringer Mannheim Biochemicals, Indianapolis, Indiana.
Results were expressed as the mean + SEM. The integrated plas­
ma CCK secretion during infusion of bombesin was determined by 
calculating the area under the curve after subtraction of basal 
value. Statistical analysis was done by Student's t-test for pai- 
red and unpaired results. Informed .consent was obtained from all 
subjects studied.
Table 1
R e l a t i v e  b i n d i n g  of C C K - p e p t i d e s  and g a s t n n s  
to a n t i b o d y  1703 a n d  a n t i b o d y  T 2 0 4
a n t i b o d y  1703 a n t i b o d y  T 2Q4
C C K 39 0 . 9 1 1 .09
CCK 33 1 ,.00 1 .00
CCK 2 0 - 3 3 0 ,.62 1 .69
CCK 2 2 - 3 3 <0 . 0 1 1 . 7 1
CCK 2 4 - 3 3 <0 ,. 0 1 0 . 78
CCK 2 6 - 3 3 s u l p h a t e d <0 ,. 0 1 0 ,.65
CCK 2 6 - 3 3 u n s u l p h a t e d <0..01 <0 . 0 1
CCK 3 0 - 3 3 <0 .01 <0 ,. 0 1
CCK 1-2 1 <0 .01 <0 ,. 0 1
CCK 1 - 1 5 <0 . 0 1 <0 .01
C C K 1 0 - 2 0 <0 . 0 1 <0 . 0 1
C CK 1 6 - 2 7 0 ,. 0 1 0 . 0 1
C CK 2 0 - 2 7 0 . 0 1 0 .02
G a s t r i n 3 4 s u l p h a t e d <0 . 0 1 0 ., 02
G a s t n n 3 4 u n s u l p h a t e d <0 . 0 1 <0 .01
G a s t r i n  1 7 s u l p h a t e d <0 ., 0 1 0 .,02
G a s t r i n  1 7 un s u l p h a t e d <0 ., 0 1 <0 .,01
Results
Infusion of increasing doses of bombesin into 9 normal sub­
jects induced dose-related increases of plasma CCK (fig 1). The 
integrated plasma CCK response to infusion of 18 pmol/kg.20 min 
and 60 pmol/kg.20 min bombesin was significantly greater than 
the response to 2.4 pmol/kg.20 min bombesin (p<0.05 and p<0.01,
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respectively), whereas the CCK secretion induced by 6 pmol/kg.
20 min bombesin was not significantly different from the CCK-re- 
lease during infusion of 2.4 pmol/kg.20 min bombesin (fig 1).
Basal plasma CCK concentrations in 8 patients with partial 
gastrectomy (1.4 + 0.4 pmol/1, antibody 1703; 1.8 + 0.4 pmol/1, 
antibody T 2 q4  ^ were not significantly different from those m e a ­
sured in 8 normal control subjects (1.2 + 0.3 pmol/1, antibody 
1703; 1.6 + 0.3 pmol/1, antibody T 2Q4). Infusion of 60 pmol/kg. 
20 min bombesin induced significant increases in plasma CCK both 
in patients with partial gastrectomy and in normal subjects 
(fig 2 and 3).
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F i g u r e  2 
The e f f e c t  of i n f u s i o n  of 60 
p m o l / k g . 2 0  m i n  b o m b e s i n  on 
p l a s m a  C C K  c o n c e n t r a t i o n s  in 
8 n o r m a l  s u b j e c t s .  T h e  u p p e r  
p a n e l  r e p r e s e n t s  the r e s u l t s  
o b t a i n e d  w i t h  a n t i b o d y  1703 
and the l o w e r  p a n e l  t h o s e  
o b t a i n e d  w i t h  a n t i b o d y  T204.
* p < 0 . 0 5 ,  ** p < 0 . 0 1 ,  *** 
p < 0  . 005.
F i g u r e  3 
Th e  e f f e c t  of i n f u s i o n  of 60 
p m o l / k g . 2 0  m i n  b o m b e s i n  on 
p l a s m a  C C K  c o n c e n t r a t i o n s  in
8 p a t i e n t s  w i t h  p a r t i a l  g a s -  
t r e c t o m y .  T h e  u p p e r  p a n e l  r e ­
p r e s e n t s  the r e s u l t s  o b t a i n e d  
w i t h  a n t i b o d y  1703 a n d  the  l o ­
w e r  p a n e l  t h o s e  o b t a i n e d  w i t h  
a n t i b o d y  T20 4 .  * p < 0 . 0 5 ,  ** 
p < 0 . 0 1 ,  *** p < 0 . 0 0 5 .
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The increments in plasma CCK during infusion of bombesin in the 
gastrectomized patients (8.1 + 1.8 pmol/l, antibody 1703; 9.5 +
2.0 pmol/l, antibody Tjg^) were not significantly different from 
those in normal subjects (6.5 + 0.9 pmol/l, antibody 1703; 8.8 +
1.0 pmol/l, antibody T 2Q4). Similarly, the integrated plasma CCK 
secretion during bombesin in the gastrectomized patients (81.5 +
18.5 pmol/l.20 min, antibody 1703; 121.5 + 25.5 pmol/l.20 min, 
antibody T 2Q4) did not significantly differ from that in the nor­
mal subjects (89.0 + 27.0 pmol/l.20 min, antibody 1703; 122.8 +
28.0 pmol/l.20 min, antibody T j q ^). Infusion of bombesin into nor­
mal subjects induced significant increases in plasma gastrin from 
16.7 + 1.4 to 49.6 + 8.1 pmol/l (fig 4). On the other hand, in the 
gastrectomized patients plasma gastrin concentrations were not 
significantly affected by bombesin (fig 4).
Plasma gastnn 
( p m o l /  I )
5 10 15 20
Tim e (m in)
F i g u r e  4
P l a s m a  g a s t r i n  c o n c e n t r a t i o n s  d u r i n g  i n f u s i o n  of 60 p m o l / k g . 2 0  
m i n  b o m b e s i n  in 8 n o r m a l  s u b j e c t s  ( u p p e r  p a n e l )  and in 8 p a t i e n t s  
w i t h  p a r t i a l  g a s t r e c t o m y  ( l o w e r  p a n e l ) .  * p < 0 . 0 5 ;  ** p<
0.01; *** p < 0 . 0 0 5 .
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Infusion of 180 pmol/kg bombesin over 1 hour in 3 patients with 
partial gastrectomy and Roux-Y anastomosis did not significantly 
influence gastric acid secretion. In 2 of the patients gastric 
acid was unchanged, while in the third patiënt gastric acid se­
cretion increased slightly from 0.1 to 0.4 mmol/h. This patiënt, 
however, showed an increase in serum gastrin from 10 to 24 pg/ml. 
Infusion of bombesin was w e l l -tolerated.
Discussion
The present study showed that infusion of bombesin into hu- 
mans induced significant increases in plasma CCK as measured by 
sequence-specific radioimmunoassays. Since CCK is a potent sti­
mulus of pancreatic enzyme secretion and gallbladder contraction 
(2), it is possible that the effects of bombesin on pancreas and 
gallbladder are mediated by CCK. In fact, bombesin is the first 
described and only known peptide capable to release CCK in man. 
Since it has been reported that instillation of hydrochloric 
acid into the duodenum releases CCK (5,19), it might be possible 
that the bombesin-induced increase in plasma CCK is mediated by 
stimulation of gastrin and subsequently of gastric acid during 
infusion of bombesin. However, antrectomy abolishing the plasma 
gastrin response to bombesin did not affect the bombesin-stimula- 
ted increase in plasma CCK. It has been reported that in patients 
with partial gastrectomy infusion of bombesin does not result in 
increases in plasma gastrin and gastric acid secretion (3). Since 
infusion of bombesin provokes gallbladder contraction, it might 
be possible that the absence of stimulation of gastric acid by 
bombesin is due to neutralization because of an increased reflux 
of bile to the stomach. Therefore, we have studied the effect of 
bombesin on gastric acid secretion in patients with partial gas­
trectomy and Roux-Y anastomosis, preventing the reflux of bile. 
Also in these patients infusion of bombesin did not influence 
gastric acid secretion. Thus, the increase in plasma CCK during 
infusion of bombesin is not secondary to a gastrin-induced increa­
se in gastric acid secretion.
It has been shown that CCK in tissue extracts is present in 
several molecular forms (12,22). At present it is not known which
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molecular forms of CCK are released into the circulation during 
infusion of bombesin. In this study we found that bombesin indu- 
ced increases in plasma CCK, as measured by radioimmunoassays 
using 2 antibodies with different specificities. Antibody ^ 2 0 4  
is specific for the sulphated tyrosyl region of CCK. Since sul- 
phation of the tyrosyl residue in position 27 of the CCK molecule 
is required for biological activity, it is likely that the mo l e ­
cular forms of CCK released during infusion of bombesin possess 
biological activity. Antibody 1703 binds to all COOH-terminal 
CCK-peptides containing at least 14 amino acid residues, sugges- 
ting that large or intermediate forms of CCK are present in the 
circulation during infusion of bombesin. This finding is in a- 
greement with a previous study in dogs showing that infusion of 
bombesin increases plasma CCK levels as measured with an antibody 
specific for large molecular forms of CCK (20). Ghatei and co- 
workers reported increases in plasma CCK during infusion of bom­
besin into humans by a radioimmunoassay system using an antibody 
fully cross-reacting with gastrin (8). However, the release of 
large amounts of gastrin during bombesin infusion makes the in- 
terpretation of the results of that study very difficult (8).
The finding that bombesin releases CCK in man may have phy- 
siological significance. The localization of bombesin in nerves 
of the gut suggests that the peptide is involved in the nervous 
control of the gastrointestinal tract (7,23). Recent studies have 
pointed to an important role for bombesin-like peptides in the 
release of gastrin from the antrum (10,23,25). Similarly, it is 
possible that bombesin-like peptides in small intestinal nerves 
are involved in the release of CCK from the gut.
Furthermore, the finding that bombesin releases CCK in man 
suggests that the CCK response to bombesin can be used as a sim- 
ple and safe test to study the function of CCK-cells in disorders 
with suggested or suspected abnormalities of CCK release, such as 
coeliac disease, extensive small bowel resection, gallbladder and 
pancreatic diseases (9,13,17,24).
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Summary
Bombesin is a tetradecapeptide with stimulatory actions on several 
gastrointestinal functions. Infusion of bombesin (60 pmol/kg. 20 min) 
into 7 normal subjects induced significant increases in plasma chole­
cystokinin (CCK) as measured with 2 sequence-specific radioinmunoassays. 
Employing antibody 1703, specific for carboxyl-terminal CCK-peptides 
containing at least 14 amino acid residues, plasma CCK concentrations 
rose from D.8±0.2 pmol/1 to 9.9 ± 1.7 pmol/1 (p<0.005), while using anti­
body T204, specific for the sulfated tyrosine region of CCK, plasma CCK 
levels increased from 2.9±0.5 pmol/1 to 12.4±1.3 pmol/1 (p<0.005). Plasma 
samples obtained from 3 subjects during bombesin infusion were 
fractionated by Sephadex column chromatography. Fractionation revealed 
4 molecular forms of CCK: peak I eluted in the void volume and comprised 
0-7% of CCK-like inmunoreacti vity, peak II eluted at 35% and comprised 
8-41% of CCK-like immunoreactivity, peak III eluted at 50% and comprised 
44-61% of CCK-like iinnunoreactivity, and peak IV eluted at 75% and com­
prised 15-27% of CCK-like immunoreactivity. Radioinmunoassay with a 
carboxyl-terminal CCK-antibody fully cross-reacting with gastrin did not 
reveal additional molecular forms of CCK. Since both the carboxyl-terminus 
and the sulfated tyrosine region are required for biological activity of 
CCK, it is likely that al 1 these molecular forms of CCK possessbiological 
activity.
Cholecystokinin (CCK) is a 33 amino acid polypeptide hormone isolated 
from hog small intestine (1). The hormone is suggested to play an important 
role in postprandial gal 1 bladder contraction and enzyme secretion from the 
pancreas (1,2). In addition, a polypeptide of 39 amino acid residues corres- 
ponding to the form of 33 residues extended at the amino-terminus by 6 resi­
dues (CCK39) has been characterized (3). Column chromatography of human small 
intestinal extracts has revealed additional CCK-peptides, both larger and 
smaller than those chemically characterized (4).
Previous studies have suggested that bombesin, a tetradecapeptide iso­
lated from amphibian skin with powerful actions on the gastrointestinal tract, 
releases CCK from the small intestine (5). This suggestion was based upon the 
finding that infusion of bombesin induced gallbladder contraction and pan­
creatic enzyme secretion (5,6). In the absence of reliable radioinmunoassays 
for CCK other mechanisms for the action of bombesin on gallbladder contraction 
and pancreatic enzyme secretion have been proposed. A direct action of bombesin 
on the pancreas was supported by the finding of receptors for bombesin on the
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pancreatic acinar cells and on the gallbladder (7,8), while the localization 
of bombesin in small intestinal nerves suggested a role in the activation of 
a duodenopancreatic reflex-mechanism (9).
We have developed sequence-specific radioimmunoassays sufficiently sensi- 
tive to measure the low CCK concentrations in human plasma. Using these assays 
we showed that infusion of bombesin into healthy humans releases large amounts 
of CCK into the circulation. Furthermore, we characterized the molecular forms 
of CCK in human plasma during infusion of bombesin by column chromatography 
and sequence-specific radioinmunoassays.
Subjects and methods
Seven healthy subjects (6 male, 1 female, mean age 46 years, range 33-56 
years) were studied. After an overnight fast 60 pmol/kg bombesin (Boehringer 
Mannheim Biochemicals, Indianapolis, Indiana, USA) was infused over 20 minutes 
and plasma samples for CCK were obtained a t -5,0,5,10,15 and 20 minutes. Plas­
ma CCK concentrations were measured by radioimmunoassay using 2 sequence- 
specific antibodies 1703 and T204 (10). In addition, plasma samples (4-5 ml) 
from 3 subjects during infusion of bombesin were fractionated by Sephadex G50 
column chromatography. These plasma samples were extracted in 96% ethanol, 
evaporated to dryness under a stream of nitrogen at 37°C, dissolved in 1 ml of 
the elution buffer and applied to the column. Furthermore, 1 ml of a 1:10 
diluted aqueous-acid extract of human upper small intestine was fractionated 
by Sephadex G50 column chromatography. A freshly obtained biopsy of upper small 
intestine from a normal subject was extracted in boiling water (1g/ 10 ml) for 
10 minutes. After centrifugation the supernatant was decanted and the pellet 
was re-extracted in 0.5 M boiling acetic acid (Ig/IOml) for another 10 minutes. 
After centrifugation the supernatant was added to the supernatant of the aqueous 
extraction, rapidly frozen, lyophilized, and redissolved in the elution buffer. 
The columns (100 x 1 cm) were eluted with 0.05 mol/1 sodium phosphate buffer pH
7.4 containing 0.06 mmol/1 sodiumethylmercurithiosalicylate. To prevent adherence 
of peptides to the glass wall of the column, the column was previously coated 
with dichlordimethylsilane. The fractions eluting from the column were measured 
by radioimmunoassay using antibodies 1703, T204 and 5135. Antibody 1703 binds 
to carboxyl-terminal CCK-peptides containing at least 14 amino acid residues 
and the antibody does not show any cross-reactivity with gastrins. Antibody 
T204 binds to all CCK-peptides containing the sulfated tyrosine region of CCK 
and the antibody shows low binding to sulfated gastrins but it does not cross- 
react with unsulfated gastrins. Antibody 5135 binds to carboxyl-terminal CCK- 
peptides and shows full cross-reactivity with both sulfated and unsulfated 
gastrins. The binding of the 3 antibodies to highly purified porcine CCK pre- 
parations, to synthetic CCK fragments and to gastrin is reported in table 1.
None of the antibodies showed cross-reactivity with structurally unrelated 
regulatory peptides. Bombesin, studied in concentrations of up to 3000 pmol/1, 
did not bind to the antibodies. In the assays using antibodies 1703 and T204 
99% pure CCK33 coupled to l25i_hydroxyphenylpropionic acid-succinimide ester 
(Bolton-Hunter reagent) was used as label, whereas in the assay using anti­
body 5135 unsulfated CCK8 coupled to 125i was employed (11). 0.05 mol/1 sodium 
phosphate buffer pH 7.4 containing 0.08 mmol/1 human serum albumin and 0.06 
mmol/1 sodiumethylmercurithiosalicylate was used as assay buffer. A non- 
equilibrium system was used with 72 hours preincubation followed by 24 hours 
incubation after addition of the labeled peptide. Separation between free 
and antibody bound hormone was performed by adsorption of the free peptide 
to plasma-coated charcoal for antibodies 1703 and T204 and to amberlite IRP-67 
for antibody 5135. The 50% inhibition dose (ID50) was 2.8 pmol/1 for antibody 
1703, 3.3 pmol/1 for antibody T204 and 4.0 pmol/1 for antibody 5135. Plasma 
samples were extracted in 96% ethanol, dried under nitrogen at 37°C and
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Table 1
antibody antibody antibody
1703 T204 5135
CCK 39 0.91 1.09 1.06
CCK 33 1.00 1.00 1.00
CCK 20-33 0.62 1.69 2.89
CCK 22-33 <0.01 1.71 2.01
CCK 24-33 <0.01 0.78 1.92
CCK 26-33 sulfated <0.01 0.65 2.49
CCK 26-33 unsulfated <0.01 <0.01 2.59
CCK 30-33 <0.01 <0.01 <0.01
CCK 1-21 <0.01 <0.01 <0.01
CCK 1-15 <0.01 <0.01 <0.01
CCK 10-20 <0.01 <0.01 <0.01
CCK 16-27 0.01 0.01 0.09
CCK 20-27 0.01 0.02 0.06
gastrin 34 sulfated <0.01 0.02 2.21
gastrin 34 unsulfated <0.01 <0.01 2.29
gastrin 17 sulfated <0.01 0 .02 2.38
gastrin 17 unsulfated <0.01 <0.01 2.32
Relative binding of cholecystokinin- 
peptides and gastrins to antibodies 1703, 
T 204 and 5135
reconstituted in assay buffer to the original volume before the assay. Recovery of 
CCK33 and sulfated CCK8 added to hormone-free plasma was 85.4 ± 2.0% (n=11) 
and 89.8 ± 1.7% (n=7), respectively. The detection limit of the assay employing 
antibody 1703 and antibody T204 was about 0.5 pmol/1 sample and for antibody 
5135 about 1 pmol/1 sample. The intra-assay variation was between 4.6 and 11.5% 
and the inter-assay variation ranged from 6.8 to 26.1%. Dilution curves of plasma 
samples containing a high concentration of endogenous CCK were parallel to the 
Standard curve.
Results were expressed as the mean ± 1 SEM. The integrated CCK secretion 
during infusion of bombesin was determined by calculating the area under the 
curve after subtraction of the basal values. Statistical analysis was done by 
Student 's t-test. Informed consent was obtained from all subjects studied.
Resul ts
Basal plasma CCK concentrations in 7 normal subjects were very low (0.8 
± 0.2 pmol/1, antibody 1703; 2.9 ± 0.5 pmol/1, antibody T204). Infusion of 60 
pmol/kg bombesin over 20 minutes induced significant (p<0.005) increases in 
plasma CCK to peak levels of 9.9 ± 1.7 (antibody 1703) and 12.4 ± 1.3 pmol/1 
(antibody T204) (fig.1). The peak increments in plasma CCK were not signifi- 
cantly different when measured with antibody 1703 (8.7 ± 1.6 pmol/1) or with 
antibody T204 (9.5 ± 1.2 pmol/1). Similarly, the integrated plasma CCK secre­
tion measured with antibody 1703 (117.5 ± 19.0 pmol/1.20 min) did not signi- 
ficantly differ from that determined with antibody T204 (114.3 ± 10.7 pmol/1.
20 min.). Infusion of saline did not significantly change plasma CCK concen­
trations. Basal plasma CCK concentrations were 0.9 ± 0.2 pmol/1 (antibody 1703) 
and 2.2 ± 0.3 pmol/1 (antibody T204), while peak concentrations were 1.0 ± 0.2 
pmol/1 (antibody 1703) and 2.3 ± 0.3 pmol/1 (antibody T204).
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FIG. 1
The effect of infusion of 60 pmol/kg.20 min 
bombesin into 7 normal subjects on plasma 
cholecystokinin as measured with antibody 
1703 (left panel) and antibody T204 (right 
panel). Asterisks denote significant 
(p<0.005) differences from basal value
TABLE II
antibody antibody
1703 T204
peak I 5( 0- 7) 3( 0- 5)
peak II 23( 8-41) 17( 8-21)
peak III 51(44-61) 59(58-61)
peak IV 21(15-25) 21(16-27)
Percentage distribution (mean and range) 
of molecular forms of cholecystokinin in 
plasma form 3 normal subjects during in­
fusion of bombesin
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F ra c tio n  n u m b e r
FIG. 2
Elution profile of cholecystokinin in human plasma during bombesin 
stimulation fractionated by Sephadex G50 column chromatography. The 
upper panel represents the results obtained with antibody 1703, the 
middle panel with antibody T204, and the lower panel with antibody 
5135. The column was previously calibrated with albumin (V ), ’“I 
(Vt), pure porcine cholecystokinin 33 (50%) and synthetic Sulfated 
cholecystokinin 8 (112%). Recovery of cholecystokinin-1ike inmuno- 
reactivity was between 73 and 94%.
1 0 0
Fraction num ber 
FIG. 3
Elution profile of an aqueous-acid extract of human upper small intestine 
fractionated by Sephadex G50 column chromatography. The upper panel represents 
the results obtained with antibody 1703, the middle panel with antibody T204, 
and the lower panel with antibody 5135. The column was previously calibrated 
with albumin (V0 ). (Vt), pure porcine cholecystokinin 33 (50%) and syn- 
thetic sulfated cholecystokinin 8 (112%). Recovery of cholecystokinin-1ike 
iimunoreactivity was between 76 and 81%.
1 0 1
Fractionation of basal plasma by Sephadex column chromatography did not 
reveal any peaks when measured with antibodies 1703 and T204. Fractionation of 
plasma during bombesin infusion revealed 4 seperate peaks demonstrable with 
antibodies 1703 and T204 (fig. 2, table 2). Peak I eluted in the void volume 
and comprised 0-7% of CCK-like immunoreactivity, peak II eluted at 35% and com- 
prised 8-41% of CCK-like immunoreactivity, peak III eluted at 50% and comprised 
44-61% of CCK-like immunoreactivity, and peak IV eluted at 75% and comprised 
15-27% of CCK-like immunoreactivity. Interpretation of the results obtained 
with antibody 5135 was hampered by the cross-reactivity of the antibody to 
gastrins (table 1). The elution positions of gastrin 34 and gastrin 17 over- 
lapped with those of the CCK-peptides. However, no additional peaks were ob- 
served employing antibody 5135. Comparison of the molecular forms of CCK in 
plasma with those demonstrated in an aqueous-acid extract of human upper small 
intestine revealed an additional peak of CCK-like immunoreactivity in the 
intestinal extract eluting at 112% of the elution volume (fig. 2 and 3). This 
peak was observed with antibodies T204 and 5135, but not with antibody 1703.
Discussion
The present study showed that infusion of bombesin into humans stimulates 
plasma CCK secretion as measured by sequence-specific radioimmunoassays. One 
previous study on the effects of bombesin on plasma CCK in man has been reported 
(12). However, the antibody used in that study showed full cross-reactivity 
with gastrin (12). Since plasma gastrin concentrations are several times higher 
than those of CCK and large amounts of gastrin are released during infusion of 
bombesin (5,13), cross-reactivity of the antibody with gastrin makes interpre­
tation of the results of that study very difficult. Bombesin has been demon­
strated in the human gastrointestinal tract (14,15). Since bombesin in the 
gastrointestinal tract is localized in nerves (16), it is suggested that bom­
besin acts as a neurotransmitter (2,16). Recent studies have pointed to an 
important role for bombesin in the stimulation of gastrin release from the 
antrum (5,13,17). Similarly, it might be possible that bombesin plays a role in 
the physiological regulation of CCK secretion from the upper small intestine. 
Infusion of bombesin is known to stimulate pancreatic enzyme secretion and 
gaïlbladder contraction in man (6). Since CCK is a potent stimulus for pan­
creatic enzyme secretion and gaTlbladder contraction (1,2), it is possible 
that the effects of bombesin on pancreas and gaTlbladder are mediated by CCK. 
Furthermore, it might be possible that other effects of bombesin, such as in- 
hibition of gastric emptying (18) and induction of satiety (19), are similarly 
mediated by the release of CCK. However, a direct action of bombesin on the 
pancreas and gaTlbladder cannot be excluded.
The present study showed that CCK in human plasma during infusion of bom­
besin is heterogenous. Four sepera'te peaks of CCK-like immunoreactivity were 
found. All 4 peaks were demonstrated by antibodies 1703 and T204. Because anti­
body 1703 binds to carboxyl-terminal CCK-peptides containing at least 14 amino 
acid residues and antibody T204 is specific for the sulfated tyrosine region 
of CCK, it can be concluded that these molecular forms consist of at least the 
14 carboxyl-terminal amino acid residues and contain the sulfated tyrosine 
region of CCK. Since the presence of both the carboxyl-terminus and the sulfated 
tyrosine region are required for biological activity (1,2), it is likely that 
all these 4 molecular forms of CCK demonstrated in plasma possess biological 
activity. The majority of CCK eluted in peaks II, III and IV. Peak II corres- 
ponds to so-called component I CCK found in the present and other studies in 
small intestinal extracts (4,10,20). In a recent study the partial structure 
of this large form of CCK, extracted from canine small intestine, was 
elucidated and was found to consist of 58 amino acid residues (20). Based on 
the elution position it is likely that peak III corresponds to CCK 33 and
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CCK 39, which CCK-peptides are not separated from each other by Sephadex G50 
column chromatography. The CCK-peptide eluting at 75% of the elution volume 
(peak IV) corresponds to intermediate CCK in intestinal extracts (4,10). The 
chemical structure of intermediate CCK has not been elucidated, but the pre­
sent study suggests that it consists of at least 14 amino acid residues. Com- 
parison of the molecular forms of CCK in plasma during bombesin infusion and 
in an extract of human small intestine showed that all 4 molecular forms found 
in plasma were also present in the small intestine. In addition, a small mole­
cular form eluting after the salt peak was demonstrated in the intestinal ex­
tract. Since this peptide bound to antibodies T204 and 5135 and not to anti­
body 1703, it can be derived that it must contain the carboxyl-terminus and 
the sulfated tyrosine region of CCK and that it consists of less than 14 amino 
acid residues. Although the chemical structure of this CCK-peptide has not been 
characterized, it is generally accepted that it represents the 8 carboxyl- 
terminal amino acid residues of CCK (CCK8 ) (2,4). Several reports suggest that 
CCK 8 is the predominant molecular form of CCK in postprandial plasma (21,22, 
23), while these studies were unable to demonstrate large forms of CCK in 
plasma after feeding. These findings suggest that the molecular forms of CCK 
in plasma during infusion of bombesin differ from those found in postprandial 
plasma. However, in most reports the small form of CCK in postprandial plasma 
eluted earlier farm the column than synthetic CCK 8 or the small form of CCK 
present in intestinal extracts (21,23). This finding suggests that either 
small CCK in postprandial plasma is larger than CCK 8 or that the elution 
position of CCK 8 is altered by plasma factors. The failure to demonstrate 
large forms of CCK in postprandial plasma can be attributed to several 
factors, such as low binding of many carboxyl-terminal antibodies to large 
forms of CCK (24,25), overlap in elution position between large forms of CCK 
and gastrins when samples are fractionated by Sephadex chromatography, and 
low recovery of large forms of CCK from columns due to adherence of large CCK- 
peptides to plastic or glass. In a recent study, in which large CCK was sepa­
rated from gastrins by high pressure liquid chromatography and the concen- 
tration of large CCK was corrected for the lower binding of CCK 33 to the car- 
boxyl-terminal antibody used, it was found that concentrations of large and 
small forms of CCK in postprandial plasma were about equal (26). However, 
from that study no conclusions could be drawn about the presence of other 
molecular forms of CCK in postprandial plasma (26).
It is concluded that infusion of bombesin into humans stimulates secre- 
tion of CCK into the circulation and that CCK in plasma during infusion of 
bombesin is heterogenous.
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X PLASMA CHOLECYSTOKININ CONCENTRATIONS IN PATIENTS WITH 
PANCREATIC INSUFFICIENCY
Abstract
It has been claimed that plasma cholecystokinin (CCK) con­
centrations are raised in patients with nancreatic ïnsufficien- 
cy. Wc have measured plasma CCK concentrations m  32 patients 
with pancreatic insuffïciency ( 2 2 alcoholic patients and 1 0 
cystic fibrosis) and in 30 normal subjects by radioimmunoassay 
u s m g  antibodies with different specif ï c ities. Antibody 1703 
binds to COOH-terminal forms of CCK containing at least 14 ami- 
no acid residues and does not cross-react with gastrins. Anti­
body T 2 q 4 binds to all CCK-peptides containing the sulphated 
tyrosyl region and shows low cross-reactivity with sulphated 
gastrins but no binding to non-sulphated gastrins. Antibody 
5135 binds to all COOH-terminal CCK-peptides and shows full 
cross-reactivity with gastrins. In oatients with pancreatic ïn- 
sufficiency plasma CCK concentrations (1.2 ± 0.1 pmol/1, anti­
body 1703; 2.0 ± 0.2 pmol/1, antibody T 2 0 4 ' 12.5 ± 1.4 pmol/1, 
antibody 5135) were not signifïcantly different from those in 
normal subjects (1.1 + 0.1 pmol/1, antibody 1703; 2.2 ± 0.3 
pmol/1, antibody T 2 0 4 ' 10.5 ± 0*9 pmol/1, antibody 5135). Fur- 
thermore, plasma CCK concentrations in patients with pancreatic 
insuffïciency due to alcoholic pancreatitis (1 . 2  ± 0 . 1  o mol/ 1 , 
antibody 1703; 1.9 + 0.2 pmol/1, antibody T 2 Q 4 ; 14.0 ± 0.1 pmol/1, 
antibody 5135) were not signifïcantly different from those in 
patients with cystic fibrosis (1.2 ± 0.2 pmol/1, antibody 1703;
2.4 ± 0.4 pmol/1, antibody ~  ^‘ ^  Pm°l/lf antibody 5135).
Cross-reactivity with gastrin accounted for almost all CCK-like 
immunoreactivity measured with antibody 5135. Oral ingestion of 
250 ml 20% intralipid induced similar increases in plasma CCK in
6 patients with pancreatic insuffïciency (4.3 ± 1.5 pmol/1, an­
tibody 1703; 2.9 ± 0.6 pmol/1, antibody T 2 Q 4 ) as in 7 normal 
subjects (5.0 ± 0.9 pmol/1, antibody 1703; 4.3 ± 0.9 pmol/1, an ­
tibody t 2 Q 4 ) .
1 0 6
It is concluded that CCK concentrations m  fasting plasma 
are very low, that oral fat induces significant increases in 
plasma CCK, and that m  patients with pancreatic insufficiency 
plasma CCK levels are not increased.
Introduction
It has been claimed that plasma cholecystokinin (CCK) con­
centrations are elevated in patients with pancreatic insuffici­
ency (1-5). It was suggested that these high CCK levels result- 
ed from an impaired inhibition of CCK secretion by pancreatic 
enzymes. However, c n t i c i s m  on the radioimmunoassay method em- 
ployed has been raised (6,7). Confirmation of the increased 
plasma CCK concentrations in patients with pancreatic insuffi­
ciency by reliable radioimmunoassays for CCK would support the 
possibility to diagnose pancreatic insufficiency by measurement 
of CCK m  a single blood sample.
We have developed radioimmunoassays for CCK using antibo­
dies with different specifïcities. The assays were sufficicntly 
sensitive to enable measurement of low CCK concentrations in 
plasma. In the present study we have measured basal plasma CCK 
concentrations in patients with pancreatic insufficiency due to 
alcoholic pancreatitis or cystic fibrosis and in normal subjects. 
Furthermore, the plasma CCK responses to oral ingestion of fat 
were determined in patients with pancreatic insufficiency and 
normal subjects.
Subjects and methods
Basal plasma CCK concentrations were measured m  32 pa ­
tients with pancreatic insufficiency and 30 normal subjects. 22 
patients (16M, 6F; mean age 45 years, range 26-75 years) had 
pancreatic insufficiency due to alcoholic pancreatitis. 8 of 
these patients had diabetes mellitus and all were treated with 
pancreatic enzyme supplements. 10 patients (7M, 3F; mean age 22 
years, range 17-37 years) had cystic fibrosis. All these pa ­
tients were treated with pancreatic enzyme supplements, but 
none of them had diabetes mellitus. In addition, 30 normal
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subjects (25M, 5F; mean age 41 years, range 19-69 years) wit h ­
out known gastrointestinal or metabolic diseases were studied.
In 6 patients with pancreatic insufficiency (5M, 1F; mean age 
43 years, range 25-52 years) and in 7 normal subjects (6M, 1F; 
mean age 41 years, range 24-60 years) plasma CCK concentrations 
were measured by radioimmunoassay using antibodies 1703 and 
T 2 Q 4 after oral ingestion of 250 ml 20% intralipid (Vitrum AB, 
Stockholm, S w eden). All subjects were studied after an overnight 
fast. Pancreatic enzyme therapy was discontinued for at least 
18 hours.
Plasma CCK concentrations were measured by radioimmunoassay 
using 3 antibodies with different specificities (8,9). Antibody 
1703 binds to all COOH-terminal CCK-peptides containing at least 
14 amino acid residues and the antibody does not show any cross 
reactivity with g a s t n n s .  Antibody ^204 t,ln<3s to all CCK pepti­
des containing the sulphated tyrosyl region of CCK and the an­
tibody shows low binding to sulphated forms of gastrin but it 
does not react with unsulphated g a s t n n s .  Antibody 5135 binds 
to COOH-terminal CCK-peptides and shows full cross-reactivity 
with both sulphated and unsulphated g a s t n n s .  None of the anti­
bodies showed significant binding to C C K - 4 . The binding of the 
3 antibodies to porcine CCK preparations, to synthetic CCK 
fragments and to g a s t n n s  is presented m  fig 1 and table 1 .
None of the antibodies showed cross-reactivity with structural- 
ly unrelated peptides. Measurement of the eluate on a Sephadex 
G 50 SF column to which an aqueous-acid extract of human upper 
small intestine was applied showed that all 3 antibodies bound 
to component-I CCK, CCK-33/CCK-39 and intermediate CCK(s),
while antibodies T_„. and 5135 bound also to CCK- 8 . In the as- 
204
says using antibodies 1703 and T„n . 99% pure porcine CCK-33 
125
coupled to I-hydroxyphenylpropionic acid-succinimide ester
(Bolton-Hunter reagent) was used as label, whereas m  the assay
1 25
using antibody 5135 unsulphated CCK - 8  coupled to I was em- 
ployed (9). 0.05 mol/l sodium phosphate buffer pH 7.4 contain­
ing 0.08 mm o l / 1  human serum albumin and 0.06 mm o l / 1  sodium- 
ethylmercurithiosalycilate was used as assay buffer. A  non-equi-
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Plasma ( pmol/1)
1000 10 0 0 0  
Plasma ( p m o l/ l )
F i g u r e  1
S t a n d a r d  c u r v e s  of a n t i b o d y  1703 (left p a n e l ) , a n t i b o d y  T 2 0 4  ( m i d d l e  p a n e l )  
a n d  a n t i b o d y  5 1 3 5  ( n g h t  pa n e l )  .
1
0
9
R E L A T I V E  P O T E N C I E S  OF C C K - P E P T I D E S  T O  A N T I B O D I E S  1703, T 2 0 4  A N D  5135 D E T E R M I N E D  BY C O M P A -  
R I N G  T H E  I N H I B I T I O N  D O S E - 5 0  (ID-50) F O R  T H E  D I F F E R E N T  P E P T I D E S  AS P R E S E N T E D  B E T W E E N
B R A C K E T S  ( P M O L / L ) .
A N T I B O D Y  1703 T 2 0 4  5 1 35
C C K 39 0 .91 ( 3 . 1) 1 .09 ( 3 .0) 1 . 06 ( 12 0)
C C K 33 1 . 00 ( 2 .8) 1 . 00 ( 3 .3) 1 . 00 ( 12 0)
C C K 20- 33 0 .62 ( 4 .7 ) 1 .69 ( 2 .0) 2 .89 ( 3 5)
C C K 22- 33 <0 . 0 1 ( 933 ) 1 . 7 1 ( 2 .0) 2 . 0 1 ( 5 0)
C C K 24- 33 <0 . 0 1 ( > 1 0 0 0 ) 0 .78 ( 5 .5) 1 .92 ( 5 1 )
C C K 26- 33 s u l p h a t e d <0 . 0 1 ( >10 0 0 ) 0 .65 ( 6 .6) 2 .49 ( 4 0)
C C K 26 - 33 n o n s u l p h a t e d <0 . 0 1 (>1000 ) <0 .01 (>1000 ) 2 .59 ( 3 8)
C C K 30- 33 <0 . 0 1 (>1000 ) <0 .01 (>1000 ) <0 . 0 1 (>1000 )
C C K 1- 21 <0 . 0 1 (>1000 ) <0 . 0 1 (>1000 ) <0 . 0 1 ( > 1000 )
CC K 1- 15 <0 .01 (>1000 ) <0 .01 (>1000 ) <0 . 0 1 ( > 1000 )
CC K 10- 20 <0 .01 (>10 00 ) <0 .01 (>1000 ) <0 . 0 1 (>1000 )
C C K 16- 27 0 .01 ( 280 ) 0 . 0 1 ( 330 ) 0 .09 ( 111 )
Gas trin 34 s u l p h a t e d <0 . 0 1 (>1000 ) 0 .02 ( 165 ) 2 . 2 1 ( 4 5)
G a s t r i n 34 n o n s u l p h a t e d <0 .01 (>10 00 ) <0 .01 (>1000 ) 2 .29 ( 4 3)
G a s t r i n 1 7 s u l p h a  te d <0 . 0 1 (>1000 ) 0 .02 ( 165 ) 2 .38 ( 4 2)
Ga s t rin 17 n o n s u l p h a t e d <0 .01 (>1000 ) <0 . 0 1 (>1000 ) 2 . 32 ( 4 3 )
T A B L E  1
librium system was used with 72 hours preincubation followed by 24 
hours incubation after addition of the labelled peptide. Separa­
tion between free and antibody bound hormone was performed by ad- 
sorption of the free peptide to charcoal for antibodies 1703 and 
^204 anc  ^ to amberlite IRP-67 for antibody 5135. The 50% inhibition 
dose for CCK-33 was 2.8 pmol/l for antibody 1703, 3.3 pmol/l for 
antibody ^204 ant  ^ 12 •0 pmol/l for antibody 5135 (table 1). Plasma 
samples were extracted in 96% ethanol, d n e d  under nitrogen at 37 
°C and reconstituted in assay buffer to the o n g i n a l  volume be f o ­
re the assay. Recovery of CCK-33 and sulphated CCK - 8  added to 
hormone-free plasma was 85.4 ± 2.0% {n =11) and 89.8 ± 1.7% (n = 7) 
respcctively. The detection limit of the assays employing antibody 
1703 and antibody T 2 Q4 was a*3°ut 0.5 pmol/l plasma and for anti­
body 5135 about 1 pmol/l plasma. The intra-assay v a n a t i o n  was 
11.5% at 1.2 pmol/l, 8.4% at 2.5 pmol/l and 4.6% at 8.0 pmol/l 
(n=5) . The inter-assay v a n a t i o n  was 26.1% at 1.3 pmol/l, 11.3% 
at 2.6 pmol/l and 15.4% at 8 . 8  pmol/l (n=5). Dilution curves of 
plasma samples containing a high conccntration of endogenous CCK 
were parallel to the Standard curve.
Results were expressed as the mean ± 1 SEM. The integrated 
CCK secretion after ingestion of fat was determined by calculating 
the area under the curve after subtraction of basal values. 
Statistical analysis was done by Student's t-test for paired and 
unpaired results. Informed consent was obtained from all subjects 
studied.
Results
Fasting plasma CCK concentrations in 30 normal subjects were
1.1 ± 0.1 pmol/l when measured with antibody 1703 and 2.2 ± 0.3 
pmol/l when measured with antibody T 2 0 4’ p lasma CCK levels m  32 
patients with pancreatic insuffïcicncy (1 . 2  ± 0 . 1  pmol/l, anti­
body 1703 and 2.0 ± 0.2 pmol/l, antibody ^ 2 0 4  ^ were not s i g m f i -  
cantly different from those in normal subjects. Furthermore, 
there were no significant differences between plasma CCK concen­
trations in 2 2 patients with pancreatic insuffïciency due to al- 
coholic pancreatitis (1.2 ± 0.1 pmol/l, antibody 1703; 1.9 ± 0.2
111
pmol/1, antibody T 2Q4 ) and those in 10 patients with pancreatic 
insufficiency due to cystic fibrosis'(1.2 ± 0.2 pmol/1, antibody 
1703; 2.4 ± 0.4 pmol/1, antibody Plasma CCK-like immuno­
reactivity measured with antibody 5135 was markedly higher in 
all subjects, but was not significantly different between the 
groups of subjects studied {10.5 ± 2.9 pmol/1 in normal subjects, 
14.0 ± 1.9 pmol/1 in patients with alcoholic pancreatitis and
9.1 ± 1.0 pmol/1 in patients with cystic fibrosis). However, mea- 
surement of the samples with antibody 2604, specific for gastrin 
without cross-reactivity with CCK (10), showed that almost all 
immunoreactivity measured with antibody 5135 could be attributed
to gastrin. The distribution of plasma CCK concentrations as 
measured with the 3 antibodies is depicted in figure 2.
C ys tic  
f ib ro sis  
(n  =10)
2 0  2 5  30 
pm o l/l
D i s t r i b u t i o n  of b a s a l  p l a s m a  C C K  c o n c e n t r a t i o n s  in 30 n o r m a 1 sub — 
je c t s ,  in 22 p a t i e n t s  w i t h  p a n c r e a t i c  i n s u f f i c i e n c y  d u e  to a l c o ­
h o l i c  p a n c r e a t i t i s ,  a n d  in 10 p a t i e n t s  w i t h  p a n c r e a t i c  i n s u f f i c i -  
e n c y  d u e  to c y s t i c  f i b r o s i s ,  as m e a s u r e d  w i t h  a n t i b o d y  1703 (left
p a n e  1) , 
p a n e l )  .
a n t i b o d y  T
204 (middle panel) a n d  a n t i b o d y  5135 (right
11 2
Ingestion of 250 ml 20% intralipid induced significant in­
creases in plasma CCK m  both normal subjects and patients with 
pancreatic insuffïciency (figure 3).
P la sm a  CCK 
( pm ol/1)
Tim e  (m in) T im e  (m in)
F i g u r e  3
T he e f f e c t  of i n g e s t i o n  of 250 ml 20% I n t r a l i p i d  on p l a s m a  C C K
in 7 n o r m a l  s u b j e c t s  (•----•) and  6 p a t i e n t s  w i t h  p a n c r e a t i c  ïn-
s u f f ï c i e n c y  (o----o) as m e a s u r e d  w i t h  a n t i b o d y  1703 (le ft p a n e l )
a n d  a n t i b o d y  T 2Q4 (right panel)
Postprandial plasma CCK concentrations in normal subjects were 
signifïcantly higher than basal values at 1 0 , 2 0 , 30, 40, 50, 60, 
75 and 105 minutes (p<0.05 - p<0.005) when measured with anti­
body 1703 and at 10, 20, 30, 40, 50, 60 and 90 minutes (p<0.05 - 
p < 0 .005) when measured with antibody ^ 20 4’ In P atlents with pan­
creatic insuffïciency plasma CCK levels at 10, 20, 30 and 40 
minutes (p<0.05; antibodies 1703 and l^g^) were signifïcantly 
higher than basal concentrations. There were no significant dif- 
ferences between the two groups m  fat-stimulated plasma CCK 
concentrations. The peak increments in plasma CCK in normal sub­
jects (5.0 ± 0.9 pmol/1, antibody 1703 and 4.3 ± 0.9 omol/1, an-
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tibody T 2 o 4 > were not sic?n;i-f icantly different from those in pa- 
tients with pancreatic insufficiency (4.3 ± 1.5 pmol/1, antibody 
1703 and 2.9 + 0.6 pmol/1 antibody T 2Q4). Similarly, there were 
no significant differences in the integrated plasma CCK secre- 
tions after ingestion of fat between the normal subjects (264 ± 
58 pmol/1.120 min., antibody 1703 and 175 ± 25 pmol/1.120 min., 
antibody T 2Q4) and the patients with pancreatic insufficiency 
(217 ± 99 pmol/1.120 min, antibody 1703 and 125 ± 38 pmol/1.120 
min., antibody T2Q4) (figure 4).
Integrated 
plasma CCK 200 - 
pmol/1.120 _
minutes.
100 -
300 -
200  -  
100 -
normal pancreatic
subjects insufficiency
F i g u r e  4
I n t e g r a t e d  p l a s m a  C C K  s e c r e t i o n  a f t e r  oral i n g e s t i o n  of 250 ml 
20% I n t r a l i p i d  in 7 n o r m a l  s u b j e c t s  a n d  6 p a t i e n t s  w i t h  p a n c r e ­
a t i c  i n s u f f i c i e n c y  as m e a s u r e d  w i t h  a n t i b o d y  T 2 0 4  (upper p a n e l )  
a n d  a n t i b o d y  1703 (lo w e r  panel)
Discussion
In the present study plasma CCK concentrations were measured 
in normal subjects and in patients with pancreatic insufficiency 
by radioimmunoassay using antibodies with different specificities. 
The development of a radioimmunoassay for CCK in plasma has proven 
to be very difficult. Several factors contribute to the difficul­
ties in developing reliable radioimmunoassays for CCK, such as
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diffïculties in producing antibodies (1 1 ), cross-reactivity of 
the antibodies with gastrin due to s i m i l a n t i e s  in structure be- 
tween gastrin and CCK, suspected species differences between hu ­
man and porcine CCK (12,13), lack of p u n f i e d  or synthetic human 
CCK and availability of only limited amounts of pure porcine CCK 
and difficulties in preparing immunoreactive CCK-labels (9,14).
In the present study it was further shown that CCK concentrations 
in plasma measured with specific antibodies were so low that they 
can only be detected by very sensitive radioimmunoassays. Since 
plasma gastrin concentrations are many times higher than those 
of CCK (15), radioimmunoassays signifïcantly cross-reacting with 
gastrin are not suitable for measurement of CCK in plasma. For 
example, cross-reactivity with gastrin accounted for almost all 
immunoreactivity measured in plasma with antibody 5135. Unfor-
tunately, in some previous reports antibodies showed full cross- 
reactivity with gastrin, while in other studies the cross-reac- 
tivity of the antibodies was not tested for sulphated gastrins 
or g a s t r m - 3 4  (16-20). Failure to determine the cross-reactivity 
of CCK antibodies with sulphated gastrins or gastrin-34 is the 
more disturbing, first, because antibodies specific for the sul­
phated tyrosyl region of CCK usually do not cross-react with u n ­
sulphated gastrins but often do with sulphated gastrins (19,20), 
second, because gastrin-34 is the predominant molecular form of 
gastrin in plasma of fasting humans (15).
In radioimmunoassays for CCK in plasma either gastrin-anti- 
bodies with different degrees of cross-reactivity with CCK (21—
24) or more or less specific CCK-antisera have been employed
(19.25.26). Three studies using radioimmunoassays with gastrin- 
CCK-antibodies in combination with chromatographic separation 
techniques showed that basal plasma CCK concentrations were be- 
low the detection limit of the assay (21-23), while one study 
reported very high basal plasma CCK levels of more than 100 pmol/1 
(24). In assays using more or less specific CCK antibodies basal 
CCK concentrations in human plasma ranged from 5 to 12 pmol/1
(19.25.26). However, m  none of these studies the presence of 
significant amounts of CCK in basal plasma could be confirmed by
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chromatography. In the present study, using specific radioimmu- 
noassays for CCK basal plasma CCK levels were much lower. It is 
generally accepted, that hormone concentrations are lower when 
measured by radioimmunoassays employing highly immunoreactive 
labels and high affinity antibodies (8 ). The high quality of la­
bel and antibodies used in the present study is reflected in the 
very low inhibition dose 50 ( I D ^ )  and detection limit of the 
assay (fig 1, table 1). The higher concentrations of CCK in basal 
plasma measured by the other assays (19,25,26) may be due to 
cross-reactivity with gastrins, but may also result from a higher 
sensitivity of the assays for non-specific factors. In fact, in 
one of the studies it was shown by column chromatography and char­
coal treatment that the apparent CCK-like immunoreactivity of 12 
pmol / 1  in basal plasma was almost exclusively due to non-specific 
interference in that assay (25). It is interesting to note that 
secretin, an other polypeptide hormone released from the upper 
small intestine with stimulatory action on the pancreas circula- 
tes in similar low concentrations as CCK (27). Basal plasma con­
centrations of most other gastrointestinal hormones are many ti- 
mes higher than those of CCK and secretin.
There is considerable controversy related to the molecular 
forms of CCK in postprandial plasma. In the present study oral 
ingestion of intralipid induced significant increases in plasma 
CCK as measured with two specific CCK-antibodies. Since antibody 
1703 binds to COOH-terminal CCK-peptides containing at least 14 
amino acid residues, it can be concluded that large or interme- 
diate forms of CCK are present in plasma after ingestion of fat. 
Measurement with antibody T^g^ indicates that sulphated forms of 
CCK are released during stimulation. We have recently shown by 
column chromatography that several molecular forms of CCK, both 
larger and smaller than CCK-33, are released during infusion of 
bombesin in man (9). Studies using radioimmunoassay techniques 
employing gastrin-antibodies with different degrees of cross- 
reactivity with CCK have suggested that a small molecular form 
of CCK, possibly CCK-8 , predominates in postprandial plasma (21, 
22,24). However, radioimmunoassays using more specific CCK-anti-
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bodies or other separation techniques indicate that considerable 
amounts of larger forms of CCK are released after feeding (19, 
23,26). The failure to demonstrate large molecular forms of CCK 
in the circulation by radioimmunoassays employing gastrin/CCK- 
antibodies and column chromatography can be attnbuted to several 
factors, such as a relative low binding of COOH-terminal anti­
bodies to large forms of CCK (18), overlap between large forms 
of CCK and gastrins in elution position from Sephadex columns 
(22) and low recovery of large forms of CCK from columns due to 
adherence of the peptide to plastic or glass. It has recently 
been shown by high pressure liquid chromatography and radioimmu­
noassay using a g a s t n n / C C K - a n t i b o d y  that after correction for 
the lower binding of the antibody to CCK-33 the molar concentra­
tions of CCK-33- and CCK-8 -like ïmmunoreactivity in postprandial 
plasma were similar (23). In this respect it is interesting to 
note that after feeding in dogs small forms of CCK predominate 
in portal blood, while large forms of CCK predominate in peri- 
pheral plasma (28). In another study by the same group it was 
shown that the different ratios between large and small forms of
CCK in portal and peripheral plasma resulted from preferential 
elimination of small forms of CCK by passage through the liver 
(29) . In analogy, it is very unlikely that CCK-4 c o n t n b u t e s  to 
CCK in postprandial plasma, as suggested in some studies (24,30), 
since CCK-4 is effectively inactivated by passage through the 
liver (31). In any case, CCK-4 does not contribute to CCK ïmmuno­
reactivity measured in the present study since none of the anti­
bodies showed significant cross-reactivity with this peptide.
The presence of large forms of CCK in the circulation is of phy- 
siological significance, because recent studies have shown that 
small and large forms of CCK have similar potencies in contract- 
ïng the gallbladder and s t i m u l a t m g  pancreatic enzyme secretion 
(32,33). In the absence of agreement on the molecular forms of 
CCK in postprandial plasma, it is essential to measure plasma 
CCK-concentrations by several assays using sequence-specifie an­
tibodies as done in the present study.
In contrast to orevious reports (1-5), this study showed that
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plasma CCK-concentrations were not increased in patients with 
pancreatic insuffïciency. Both patients with alcoholic pancrea- 
titis and those with cystic fibrosis had similar plasma CCK- 
concentrations as normal subjects. Since the 3 antibodies used 
in the assays showcd binding to different regions of the CCK 
molecule, it is unlikely that the failure to find elevated plas­
ma CCK levels in patients with pancreatic insufficiency is re- 
lated to the specificity of the antibodies. The increased plasma 
CCK concentrations reported previously were suggested to result 
from impaired inhibition of CCK release by the lack of sufficiënt 
amounts of pancreatic enzymes in the upper small intestine in p a ­
tients with pancreatic insufficiency. However, a feedback control 
mechanism between pancreatic enzymes in the upper small intestine 
and pancreatic secretion seems to exist in the rat, but not in 
the dog or in man (34). Furthermore, it was shown in the present 
study that ingestion of fat induced significant increases in pla s ­
ma CCK in both normal subjects and in patients with pancreatic 
insufficiency. The n s e s  in plasma CCK in the patients with p a n ­
creatic insufficiency were similar to those in normal subjects.
It is therefore concluded that in patients with pancreatic ïn- 
sufficiency neither basal nor fat-stimulated plasma CCK-concen­
trations are increased m  c o m p a n s o n  with normal subjects.
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Chapter XI PLASMA CHOLECYSTOKININ AND GALLBLADDER RESPONSES TO 
INTRADUODENAL FAT IN PATIENTS WITH COELIAC DISEASE.
Abstract
Plasma cholecystokinin (CCK) responses to intraduodenal m -  
stillation of 60 ml corn oil were studied in 9 patients with a 
flat ]e]unal mucosa due to coeliac disease, in 5 coeliac patients 
with a normal mucosa on a gluten-free diet and in 7 normal sub­
jects. Basal plasma CCK concentrations were similar in the 3 
groups studies (2.4 ± 0.5 pmol/1 in untreated patients, 2.2 ± 0.4 
pmol/1 m  treated patients and 2.1 ± 0.3 pmol/1 in normal sub­
jects). Intraduodenal administration of fat failed to increase 
plasma CCK in untreated patients, whereas significant (p<0.31) 
increases were observed in treated patients (3.4 + 0.9 pmol/1) 
and in normal subjects (3.3 ± 1.1 pmol/1). In the 3 untreated 
patients studied by ultrasonography gallbladder volume was un- 
affected by administration of fat, whereas gallbladder volume 
decreased by 70 ± 7% in 4 treated patients and by 83 + 5% in 7 
normal subjects.
It is concluded that m  patients with untreated coeliac dis­
ease intraduodenal instillation of fat does not increase plasma 
CCK concentrations and does not induce gallbladder contraction, 
whereas coeliac patients on a gluten-free diet show normal in­
creases in plasma CCK accompanied by contraction of the gallblad­
der. These studies point to an important role for CCK in the re- 
gulation of gallbladder contraction in response to intraduodenal 
f a t.
Introduction
Coeliac disease is characterized by a gluten-induced hyper- 
regenerative villous atrophy of the small intestinal mucosa re- 
sulting in m a l a b s o m t i o n  and nutritional deficiency (1). Most 
coeliac patients show a favourable clinical and histological res­
ponse to withdrawal of gluten from their diet (1). It has previ- 
ously been reported that coeliac patients often show a reduced 
pancreatic enzyme secretion and an impaired gallbladder contrac-
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tion in response to intestinal stimuli (2,3). The mechanism for 
this impaired pancreatic secretion and gallbladder contraction 
has not been elucidated. Based on high circulating cholecystoki­
nin (CCK) concentrations and a reduced pancreatic response to 
stimulation with exogenous hormones, it was suggested that the 
gallbladder and pancreas in coeliac patients were less sensitive 
to hormonal stimulation (3). Another study, however, showed that 
in coeliac patieijts gallbladder and pancreatic responses to exo­
genous hormones were normal (2). It was therefore concluded that 
the impaired gallbladder and pancreatic responses to intestinal 
nutrients were secondary to a reduced secretion of CCK from the 
upper small intestine (2). In the absence of reliable radioimmu­
noassays for CCK this controversy could not be settled. We have 
recently developed a sensitive and specific radioimmunoassay for 
CCK (4). Using this assay we have studied plasma CCK responses to 
intraduodenal fat in patients with a flat jejunal mucosa due to 
coeliac disease, in coeliac patients with a normal mucosa on a 
gluten-free diet and in normal subjects. In addition, m  some of 
the subjects aallbladder volume before and at regular intervals 
after intraduodenal instillation of fat was measured by ultra- 
sonography.
Patients and methods
Plasma CCK concentrations were measured in 9 coeliac patients 
with a flat jejunal mucosa before gluten-withdrawal (3M, 6F, age 
27 - 70 years) , in 5 coeliac patients with a normal mucosa d u n n g  
gluten-free diet (1M, 4F, age 21 - 51 years) and in 7 normal sub­
jects (5M, 2F, age 21 - 28 years). Two of the patients were stu­
died before gluten-withdrawal and d u n n g  complete normalisation 
of small bowel mucosa and laboratory parameters on a gluten-free 
diet. In 3 of the untreated patients, in 4 of the treated patients 
and in 7 normal subjects gallbladder volumes were studied by ul- 
trasonography.
After an overnight fast the tip of a duodenal tube was posi- 
tioned in the third part of the duodenum under fluoroscopic con- 
t r o l . 60 ml corn oil was subsequently administered intraduodenally
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within 5 minutes. Blood samples for CCK were drawn from an ïn- 
dwelling venous catheter at -10, 0, 10, 20, 30, 40, 50, 60, 75 
and 90 minutes. Blood was collected in ïce-chilled glass tubes 
containing 2 g/1 e t h y l e n e d i a m m e t e t r a a c e t a t e . Samples were cen- 
t n f u g e d  and the plasma was stored at -20 °C within 2 hours a f ­
ter collection. Plasma CCK concentrations were measured by a sen­
sitive and specific radioimmunoassay (4). Antibody ^ 204' ralsed 
m  a rabbit after the fourth immunization with albumin-counled 
CCK (5), was used in a dilution of 1:80,000. The antibody binds 
to all carboxyl-terminal CCK-peptides containing the sulphated 
tyrosyl region (fig 1). The antibody shows very small cross- 
reactivity with sulphated gastrins (about 2 %), but does not show 
any binding to unsulphated gastrins or structurally unrelated 
regulatory peptides (4).
Figure 1 
B i n d i n g  of h i g h l y  p u r i f i e d  
p o r c i n e  a n d  s y n t h e t i c  C C K  
p e p t i d e s  to a n t i b o d y  T204. 
99% p u r e  p o r c i n e  C C K - 3 3  
c o u p l e d  to 1 2 5 I - h y d r o x y -  
p h e n y l p r o p i o m c  a c i d s u c -  
c i n i m i d e  e s t e r  ( B o lton- 
H u n t e r  r e a g e n t )  w a s  u s e d  
as l a b e l .
10 1 0 0 1000 
(p m o l / 1)
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99% pure porcine CCK 33 was used as Standard. The detection li­
mit of the assay was between 0.5 and 1.0 pmol/l plasma. The in- 
tra-assay precision was 11.5% at 1.2 pmol/l, 8.4% at 2.5 pmol/l 
and 4.6% at 8.0 pmol/l (n=5), while the inter-assay orecision was 
26.1% at 1.3 pmol/l, 11.3% at 2.6 pmol/l and 15.4% at 8 . 8  pmol/l. 
Plasma samples were measured in duplicate.
Gallbladder volumes were measured before and during the 
first hour of the study by ultrasonography using the sum of cy- 
linders method as described by Everson (6 ). The mean of 3 mea- 
surements was used for calculation. The variation of this method 
for the volumes measured ranged from 10.0 to 17.5%.
Results were expressed as mean ± 1 SEM. The integrated plas­
ma CCK concentrations were determined by calculating the area un ­
der the curve after subtraction of the basal value. Statistical 
analysis was done by Student's t-test for paired and unpaired 
results. Informed consent was obtained from all subjects studied.
Results
Basal plasma CCK concentrations were similar in all 3 groups 
studied (2.4 ± 0.5 pmol/l in untreated patients, 2.2 ± 0.4 pmol/l 
in treated patients and 2.1 ± 0.3 pmol/l in normal subjects). 
Intraduodenal instillation of corn oil in normal subjects induced 
significant increases in plasma CCK at 20, 30, 40, 50, 60 and 75 
minutes ( p<0.05 - p<0.001). In untreated coeliac patients intra­
duodenal instillation of corn oil failed to increase plasma CCK 
concentrations (fig 2). In contrast, coeliac patients on a gluten 
free diet showed plasma CCK responses to corn oil similar to tho- 
se found in normal subjects (fig 3). In these patients plasma CCK 
levels were significantly elevated over basal value at 30, 40, 50, 
60 and 75 minutes (p<0.05 - p<0.005). The peak increments in plas­
ma CCK in untreated patients (0.1 ± 0.5 pmol/l) were significant­
ly lower (p<0.01) than those found in normal subjects (3.3 ± 1.1 
pmol/l) and in treated patients (3.4 ± 0.9 pmol/l). Similarly, 
the integrated plasma CCK concentrations in response to corn oil 
in the untreated patients (11.8 ± 8.3 pmol/l.hr) was significantly 
(p<0.001) lower than in normal subjects (110.2 ± 29.1 pmol/l.hr)
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and in the treated coeliac patients (137.2 ± 39.8 pmol/1.hr).
The integrated CCK secretion in the treated patients was not 
significantly different from the normal subjects (fig 4). In the 
normal subjects the increase in plasma CCK after intraduodenal 
corn oil was accompanied by significant decreases in gallbladder 
volume (fig 5). The gallbladder volumes at 30, 40, 50 and 60 
minutes were significantly lower (p<0.05 - p<0.001) than basal 
volume. There was a highly significant inverse correlation b e ­
tween plasma CCK concentrations and gallbladder volumes (r= 
0.931, p < 0 . 0 1 ) .
Time (min)
F i g u r e  2
P l a s m a  C C K  r e s p o n s e s  to i n t r a d u o d e n a l  i n s t i l l a t i o n  of
oil in 9 c o e l i a c  p a t i e n t s  w i t h  a flat m u c o s a  (o p e n  ci 
7 n o r m a l  s u b j e c t s  ( c l o s e d  c i r c l e s ) .  A s t e r i s k s  d e n o t e  
d i f f e r e n c e s  b e t w e e n  the two g r o u p s .
60 ml c orn 
rc l e s )  and 
s i g n i f i c a n t
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The 3 untreated coeliac patients tested showed, in addition to 
the absence in increases in plasma CCK, a failure of gallbladder 
contraction in response to intraduodenal corn oil (fig 5). In 
contrast, in the 4 treated coeliac patients studied, the increa­
ses in plasma CCK were accompanied by decreases in gallbladder 
volumes not significantly different from those found in normal 
subjects (fig 6 ) .
Time (min)
F i g u r e  3
P l a s m a  C C K  r e s p o n s e s  to i n t r a d u o d e n a l  i n s t i l l a t i o n  of 60 ml c o r n  
oil in 5 c o e l i a c  p a t i e n t s  w i t h  a n o r m a l  m u c o s a  on a g l u t e n - f r e e  
diet (open c i r c l e s )  and 7 n o r m a l  s u b j e c t s  ( c l o s e d  c i r c l e s ) .
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Integrated gallbladder volumes in the untreated coeliac patients 
3
(-1.1 ± 0.5 cm .hr) were significantly (p<0.001) lower than those
3
in normal subjects (161.0 ± 29.5 cm .hr) and in the treated pa-
3
tients (132.9 ± 16.9 cm .hr). None of the subjects experienced 
adverse reactions during the study.
Integrated CCK response 
( pm ol / l . hr)
normal celiacs celiacs 
subjects flat normal
m ucosa m ucosa
(n =7 ) (n=9) (n=5)
F i g u r e  4
Integrated plasma CCK secretion in response to intraduodenal 
instillation of 60 ml corn oil in 7 normal subjects, 9 coeliac 
patients with a flat mucosa and 5 coeliac patients with a nor­
mal mucosa on a gluten-free diet.
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T m *  (min)
F i g u r e  5
G a l l b l a d d e r  v o l u m e  r e s p o n s e s  to i n t r a d u o d e n a l  i n s t i l l a t i o n  of 
co r n  oil in 3 c o e l i a c  p a t i e n t s  w i t h  a f l a t  m u c o s a  a n d  in 7 n or-
m a 1 s u b ) e c  t s .
G a l l b l a d d e r  v o l u m e  r e s p o n s e s  to i n t r a d u o d e n a l  i n s t i l l a t i o n  of 
co r n  oil in 3 u n t r e a t e d  c o e l i a c  p a t i e n t s  a n d  4 t r e a t e d  c o e l i a c  
p a t i e n t s .  A s t e . n s k s  d e n o t e  s i g n i f i c a n t  d i f f e r e n c e s  b e t w e e n
the 2 g r o u p s .
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Discussion
The present study showed that in patients with a flat mucosa 
due to coeliac disease intraduodenal instillation of fat failed 
to induce increases in plasma CCK. 2 previous studies on the e f ­
fect of nutrients on plasma CCK in coeliac patients have been 
reported (3,7). Low-Beer et al (3) found that basal plasma CCK 
concentrations in patients with coeliac disease were about 15 
times higher than those in normal subjects, while the peak plas­
ma CCK concentrations after an oral fat meal were not signifi- 
cantly different. The reliability of the radioimmunoassay for 
CCK used in that study has repeatedly been questioned (8,9). On 
the other hand, Calam et al (7) found that C C K - 8  was undetecta- 
ble in basal plasma from both coeliac patients and normal sub­
jects. After ingestion of a mixed meal CCK - 8  was detectable in 
plasma from all 5 normal subjects, but in plasma from only one 
of 6 coeliac patients studied (7). In the latter study CCK was 
measured by radioimmunoassay using a CCK-antibody fully cross- 
reacting with gastrin in combination with column chromatography. 
By this assay only CCK - 8  like immunoreactivity could be detected 
in plasma (7). Several recent studies, however, have indicated 
that molecular forms larger than CCK - 8  are present in human and 
canine plasma (10-13). The antibody used in the present study 
binds to both CCK - 8  and to larger molecular forms of CCK (6,13) .
The finding of impaired CCK secretion in response to intes- 
tinal nutrients in coeliac patients is not unexpected, since a 
reduced secretion of 2 other polypeptide hormones produced in 
the upper small intestinal mucosa has previously been reported 
(14). Intraduodenal instillation of acid resulted in a reduced 
secretin production, while ingestion of a mixed meal induced a 
subnormal release of gastric inhibitory polypeptide (GIP).
Since CCK is known to stimulate gallbladder contraction (15), 
the failure of coeliac patients to contract their gallbladder af ­
ter intraduodenal fat is not unexpected. Using isotope cholecys- 
tography, Low-Beer et al (3) showed that ingestion of a fatty 
meal induced subnormal but significant gallbladder contraction 
in coeliac patients, while DiMagno et al (2) found that bilirubin
130
output into the duodenum did not respond to duodenal perfusion 
with essential amino acids. In the present study the absence of 
gallbladder contraction was demonstrated by u l t r a s o nography, a 
sensitive t e c h m q u e  obviating the need for intubation or the use 
of isotopes (6 ). Impaired gallbladder contraction has been sug­
gested to play a possible role in the pathogenesis of gallstones 
(16). However, to our knowledge no increased prevalence of chole- 
lithiasis in coeliac patients has been reported. It has been spe- 
culated that undersaturation of gallbladder bile as a result of 
the intestinal lesion prevents the formation of gallstones m  
such patients (17).
Coeliac patients with normal ^ejunal mucosa on a gluten-free 
diet showed normal plasma CCK responses to m t r a d u o d e n a l  m s t i l -  
lation of fat. In these patients fat-induced increases in plasma 
CCK were accompanied by effective gallbladder contraction. These 
findings suggest that the impairment of plasma CCK and gallblad­
der responses to fat in coeliac patients is reversible. This sug- 
gestion was substantiated in the 2 patients who could be studied 
before and after gluten withdrawal.
Recently, the existence of an enterocholecystic reflex mecha- 
nism for the stimulation of gallbladder contraction in response 
to intestinal stimuli has been suggested (18). The present study, 
however, points to an important role for CCK in the stimulation 
of gallbladder contraction after m t r a d u o d e n a l  fat. This finding 
is in agreement with a previous study showing that infusion of 
CCK to plasma concentrations similar to those found after a meal 
induces gallbladder contraction as measured by ultrasonography (19).
In conclusion, the present study shows that in coeliac p a ­
tients with a flat je;junal mucosa, plasma CCK and gallbladder res­
ponses to m t r a d u o d e n a l  fat are greatly impaired, whereas such 
functions are normal in coeliac patients on a gluten-free diet.
These findings point to an important role for CCK m  the regula- 
tion of gallbladder contraction after m t r a d u o d e n a l  fat.
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SUMMARY
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SU M MARY
Cholecystokinin together with secretin and gastrin consti- 
tute the classical triad of gut hormones. While the roles of 
secretin and gastrin have, in the meantime, been well establish- 
ed, the physiological and pathophysiological roles of CCK have 
remained speculative, mainly due to the lack of specific and re- 
liable radioimmunoassays for CCK. Several reasons discussed in 
chapter I may account for this situation, like size and species 
h eterogeneity, similarity between the biologically active part of 
CCK and gastrin, labelling problems and suspected conformational 
changes between different molecular forms of CCK. Furthermore,
CCK is not only present in the small bowel mucosa, but also in 
nerves in the gastrointestinal tract, introducing the possibili- 
ty that CCK not only acts as a hormone, but also as a neurotrans­
mitter, at least in some regions of the gut.
The aim of the studies presented in this thesis was to de- 
velop a specific and sensitive radioimmunoassay for CCK. Data 
about the production and evaluation of antisera were presented 
in chapter II. Immunization of rabbits with CCK-33 resulted in 
high titer antibodies which could be used in sensitive and spe­
cific radioimmunoassays for CCK.
125
Introduction of I into a polypeptide may result in chan­
ges in immunoreactivity. The evaluation of antisera tested with 
CCK-labels prepared by different techniques was presented in
chapters III and IV. In chapter III it was shown that labelling
125
with I-hydroxyphenylpropionic acid-hydroxysuccinimide ester 
(Bolton-Hunter reagent) resulted in labels with excellent immu- 
noreactivity when tested with non-carboxyl-terminal CCK-antibo­
dies, but extremely low binding to carboxyl-terminal antibodies, 
while in chapter IV it was shown that different CCK-labels bound 
to different binding sites in the same antiserum (antibody hete­
rogeneity) . The pattern of immunoreactivity of the antiserum to 
CCK-peptides was dependent on the type of label used. Therefore, 
antisera raised against CCK should be characterized employing 
different CCK-labels.
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It appeared that one of the antisera was specific for the 
triacontanonapeptide of CCK (CCK-39). Using this antiserum in a 
sensitive and specific radioimmunoassay for CCK-39, CCK-39-like 
immunoreactivity was demonstrated in extracts of porcine brain. 
These data were presented in chapter V.
The reliability of highly sensitive and specific radioim­
munoassays for measurement of CCK in human tissue and blood us­
ing two antibodies (1703 and T 2 0 4 ) , was extensively evaluated 
in chapter VI. The binding between label and antibody was inhi- 
bited by 50% (IDj-q ) at a concentration of 2.8 pmol/1 CCK-33 for 
antibody 1703, and at a concentration of 3.3 pmol/1 CCK-33 for 
antibody T204. The detection limit of the assay was between 0.5 
and 1.0 pmol/1 plasma. Plasma samples were extracted in 96% e­
thanol prior to assay. Infusion of exogenous CCK-33, resulting 
in plasma CCK-levels slightly lower than those measured during 
administration of fat, induced pancreatic enzyme secretion and 
gallbladder contraction. The reliability of these radioimmuno- 
assays for measurements in human plasma was extensively evalu­
ated.
In chapters II and IV it was shown that oral and intradu­
odenal administration of fat stimulated plasma CCK secretion.
In chapters VII and VIII the effect of other stimuli for pan­
creatic enzyme secretion on plasma CCK concentrations were stu- 
died. In chapter VII the effect of insulin-hypoglycaemia was 
studied. It was demonstrated that activation of vagal choliner- 
gic mechanisms by insulin-hypoglycaemia induced a significant 
rise in plasma pancreatic polypeptide. However, plasma CCK con­
centrations did not significantly change during insulin-hypo- 
glycaemia. In chapter VIII the effect of bombesin on plasma CCK 
was studied. Bombesin is a tetradecapeptide with stimulatory ac- 
tions on antral gastrin release. Infusion of bombesin in normal 
subjects and gastrectomized patients showed that bombesin releas- 
ed CCK in man by a gastrin and gastric acid independent mecha- 
nism.
The molecular forms of CCK in plasma during infusion of 
bombesin in man were reported in chapter IX. Fractionation by
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Sephadex G 50 SF column chromatography revealed 4 molecular 
forms of CCK in BBS-stimulated plasma. Peak I eluted in the 
void volume and comprised 0-7% of total CCK-like immunoreacti- 
vity. Peak II eluted at 35% and comprised 8-41% of total CCK- 
like immunoreactivity. Peak III eluted at 50% and comprised 
44-61% of total CCK-like immunoreactivity. Peak IV eluted at
7 5% and comprised 15-27% of total CCK-like immunoreactivity.
In chapters X and XI plasma CCK was measured in patients 
with clinical conditions, in whom previously abnormal CCK va- 
lues have been suggested. In chapter X patients with pancrea­
tic insufficiency due to alcohol or cystic fibrosis were stu­
died. It was shown that CCK concentrations in fasting plasma 
were very low, that oral fat induced significant increases in 
plasma CCK, and that in patients with pancreatic insufficiency 
plasma CCK levels were not increased. In chapter XI the effect 
of intraduodenal fat on plasma CCK and on gallbladder contrac- 
tion in patients with coeliac disease was reported. In patients 
with untreated coeliac disease intraduodenal instillation of 
fat did not increase plasma CCK concentrations and did not in- 
duce gallbladder contraction, whereas coeliac patients on a 
gluten-free diet showed normal increases in plasma CCK accompa- 
nied by contraction of the gallbladder. These studies pointed 
to an important role for CCK in the regulation of gallbladder 
contraction.
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SAMENVATTING
Cholecystokinine (CCK), secretine en gastrine zijn de drie 
r.ieest bekende maag-darmhormonen. De functies van gastrine en se­
cretine zijn inmiddels grotendeels achterhaald, maar de fysiolo­
gische en pathofysiologische betekenis van CCK is nog vrijwel on­
bekend. Dit komt hoofdzakelijk omdat er tot voor kort geen be ­
trouwbare en specifieke radioimmunologische bepalingen voor CCK 
bestonden. Hiervoor zijn verschillende oorzaken aan te wijzen 
waarvan de belangrijkste in hoofdstuk I werden besproken. Vooral 
het voorkomen van CCK in moleculaire vormen van verschillende 
grootte (heterogeniteit in molecuulgrootte); verschillen in amino- 
zuursamenstelling van CCK tussen diverse species (speciesheteroge- 
ni teit); overeenkomst in structuur van het biologisch actieve ge­
deelte van CCK en gastrine; problemen bij het maken van radioac­
tief gemerkt CCK en vermeende vormveranderingen in tertiaire struc­
tuur tussen verschillende moleculaire vormen van CCK zouden hier­
voor verantwoordelijk kunnen zijn. Bovendien is CCK niet alleen 
aanwezig in het slijmvlies, maar ook in het zenuwweefsel van het 
maag-darmkanaal, waardoor de mogelijkheid bestaat dat CCK niet al­
leen als hormoon, maar ook als neurotransmitter in sommige delen 
van het maag-darmkanaal actief is.
Het doel van dit onderzoek was een specifieke en gevoelige
radioimmunologische bepaling voor CCK te ontwikkelen. Gegevens
over de productie en evaluatie van antisera werden in hoofdstuk II
beschreven. Immunisatie van konijnen met CCK-33 resulteerde in de
productie van antilichamen met een hoge titer, die gebruikt konden
worden in gevoelige en specifieke radioimmunologische bepalingen
125
voor CCK. Koppeling van I aan een polypeptide kan veranderingen 
in immunoreactiviteit van dat polypeptide teweeg brengen. Evalua­
tie van de binding van antisera aan CCK dat met behulp van verschil-
125
lende technieken radioactief is gemerkt met I werd in de hoofd­
stukken III en IV beschreven. In hoofdstuk III werd gevonden dat
125
er na conjugatie van CCK-33 met de succinimide ester van I-hydro- 
xyphenylpropionzuur (Bolton-Hunter reagens) radioactief gemerkt 
CCK-33 ontstond dat uitstekend bond aan antilichamen die niet ge­
richt waren tegen het biologisch actieve COOH-terminale gedeelte
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van CCK, maar dat zeer slecht bond aan antilichamen gericht tegen
het COOH-terminale gedeelte dat CCK gemeen heeft met gastrine. In
hoofdstuk IV werd beschreven dat CCK, waaraan op verschillende ma-
12 5
nieren I was gebonden, zich bond aan verschillende antilichamen 
binnen hetzelfde antiserum (antilichaamheterogeniteit). De binding 
van een antiserum aan verschillende moleculaire vormen van CCK was 
afhankelijk van het gebruikte type radioactief gemerkt CCK. Daarom 
behoren antisera opgewekt tegen CCK getest te worden met op ver­
schillende manieren radioactief gemerkt CCK, teneinde de meest ge­
schikte antigen-antilichaam combinatie op te sporen.
Het bleek dat een van de antisera specifiek gericht was tegen 
CCK-39. Gebruik makend van dit antiserum kon een gevoelige bepaling 
worden ontwikkeld specifiek voor CCK-39, waarmee voor het eerst 
CCK-39 in de hersenen kon worden aangetoond. Deze gegevens werden 
in hoofdstuk V  beschreven. De betrouwbaarheid van gevoelige en spe­
cifieke radioimmunologische bepalingen gebruikmakend van twee anti­
lichamen (1703 en T204), voor het meten van CCK in het menselijk 
weefsel en bloed werd uitvoerig beschreven in hoofdstuk VI. 2.8
pmol/1 CCK-33 was in staat de binding tussen antiserum 1703 en de 
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met I-Bolton-Hunter reagens gemerkte CCK-33 label met 50% te 
verlagen. Voor antiserum T204 was hiervoor 3.3 pmol/1 CCK-33 nodig. 
De kleinste hoeveelheid CCK-33 die nog betrouwbaar gemeten kon w o r ­
den lag tussen 0.5 en 1.0 pmol/lplasma. Plasma monsters werden al­
vorens gemeten te worden eerst behandeld met een dubbel volume 96% 
ethanol, teneinde eiwitten te precipiteren. Infusie van CCK-33 tot 
plasmawaarden die iets lager lagen dan die gemeten na toediening 
van vet, stimuleerde pancreasenzymsecretie en galblaascontractie.
De betrouwbaarheid van deze radioimmunologische bepalingen voor 
het meten van CCK in menselijk weefsel en plasma werd uitvoerig 
o n d e r z o c h t .
In de hoofdstukken II en IV werd beschreven dat orale en in- 
traduodenale toediening van maisolie het plasma CCK gehalte deed 
stijgen. In de hoofdstukken VII en VIII werd het effect van andere 
stimuli van de pancreasenzymsecretie op het plasma CCK gehalte be ­
studeerd. In hoofdstuk VII werd het effect van insulinehypoglycae- 
mie bestudeerd. Aangetoond werd dat stimulering van het cholinerg-
ische systeem door insulinehypoglycaemie een duidelijke stijging 
van het plasma pancreas polypeptidegehalte gaf. Het plasma CCK 
gehalte veranderde tijdens insulinehypoglycaemie echter niet sig­
nificant. In hoofdstuk VIII werd het effect van bombesine (BBS) 
op het plasma CCK gehalte bestudeerd. BBS is een uit 14 aminozu­
ren bestaand polypeptide, dat in staat is gastrine uit het an- 
trum van de maag vrij te maken. Infusie van BBS bij gezonde vrij­
willigers en bij patienten met een maagresectie toonde aan dat 
BBS in staat was CCK vrij te maken onafhankelijk van gastrine- en 
maagzuursecretie.
De moleculaire vormen van CCK die in het plasma vrijkomen 
tijdens infusie van bombesine werden beschreven in hoofdstuk IX.
Na scheiding van BBS-gestimuleerd plasma op een Sephadex G 50 SF 
kolom konden bij 3 proefpersonen tenminste 4 verschillende mole­
culaire vormen van CCK worden aangetoond. De eerste vorm elueerde 
in het zogenaamde "void-volume" en bevatte 0-7% van de totaal ge­
meten hoeveelheid CCK. De tweede vorm elueerde op 35% tussen het 
"void-volume" en het "totale-volume" van de kolom en bevatte 8-41% 
van de totaal gemeten hoeveelheid CCK. De derde vorm elueerde op 
50% tussen het "void-volume" en het"totale volume" (dit is ook de 
plaats waar CCK-33 en CCK-39 elueren) en bevatte 44-61% van de to­
taal gemeten hoeveeleid CCK. De vierde vorm elueerde op 75% tus­
sen het "void-volume" en het "totale-volume" en bevatte 15-27% 
van de totaal gemeten hoeveelheid CCK.
In de hoofdstukken X en XI werden de resultaten beschreven 
van studies verricht bij patienten waarbij door andere onderzoe­
kers een gestoorde CCK secretie werd verondersteld. In hoofdstuk
X werden patienten met pancreasinsufficientie ten gevolge van 
alkoholmisbruik of mucoviscoïdose bestudeerd. Bij deze patienten 
werden lage nuchtere CCK-waarden gemeten. Na orale toediening 
van vet trad er een duidelijke stijging van het plasma-CCK-gehalte 
op. Zowel basale als gestimuleerde plasma CCK-waarden bij patient­
en met pancreasinsufficientie waren niet significant verschillend 
van de waarden gevonden bij gezonde vrijwilligers. In hoofdstuk
XI werd het effect van intraduodenaal toegediend vet op het plas­
ma CCK-gehalte en de galblaassamentrekking bij patienten met
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darmspruw bestudeerd. Bij patienten met onbehandelde darmspruw 
ontstond na intraduodenale toediening van vet geen stijging van 
het plasma CCK-gehalte en trad er ook geen galblaassamentrekking 
op, terwijl bij patienten met darmspruw die goed reageerden op 
behandeling met een glutenvrij dieët normale stijgingen van het 
plasma CCK-gehalte werden gevonden in combinatie met galblaas- 
contractie. Deze onderzoeken wezen op een belangrijke rol voor 
CCK bij het reguleren van galblaascontractie.
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WOORDEN VAN WAARDERING
Allen, die hebben bijgedragen aan het tot stand komen van 
dit proefschrift wil ik van harte danken.
De praktische vaardigheden voor het verwerken van de meer 
dan 200.000 reageerbuizen, die nodig waren voor het verrichten 
van de studies beschreven in dit proefschrift, leerde ik van de 
heer W Roeffen.
De heer J Koedam van het Centraal Dierenlaboratorium (hoofd: 
Dr WJI vd Gulden) was behulpzaam bij het immuniseren van konijnen 
en cavia's.
Mevr M  Huybregts-vd Manaker bestelde het radioactieve jodium 
waarmee op het Ir R e i c h e r t l a b o r a t o n u m  (hoofd: Dr FMH Corstens) 
cholecystokinine werd gelabelled. De deskundige adviezen van de 
heer W  vd Broek waren nodig om steeds minder sporen van deze la- 
belling achter te laten. Evenmin mag de bereidwillige hulp die 
ik kreeg van de heer G Grutters (I s o t o p e n l a b o r a t o n u m  van het 
Centraal Dierenlaboratorium) bij de praktische uitvoering van 
een aantal experimenten onvermeld blijven.
Mevr M  Hessels van het Klinisch Chemisch Laboratorium van 
de Kliniek voor Inwendige Ziekten (hoofd: Prof Dr A Jansen), be ­
paalde met veel zorg pancreasenzymactiviteiten.
In het bijzonder gaat mijn dank uit naar patienten en gezon­
de vrijwilligers, die bereid waren aan het onderzoek mee te wer­
ken. Collega W Hopman en de medewerksters van de afdeling Radio­
diagnostiek (hoofd: Prof Dr G Rosenbusch) ben ik zeer erkentelijk 
voor de nauwkeurige echografische metingen en berekeningen van 
galblaasvolumina.
De medewerkers van de afdeling Klinische Farmacie waren be­
hulpzaam bij het bereiden van bombesine-infusaten.
De geringe hoeveelheden van verschillende polypeptiden die 
voor vele experimenten nodig waren werden op uiterst nauwkeurige 
wijze afgewogen door de heer J Diersmann (Faculteit W  & N ) .
Kolomchromatografie bij de juiste temperatuur was mede moge­
lijk door het bereidwillig beschikbaar stellen van de daarvoor 
geschikte ruimte in de koude kamer van het Oogheelkundig Labora­
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torium (hoofd: Dr RM Broekhuyse).
De heren H Berris en C Nicolasen van de afdeling Medische 
Illustratie vervaardigden met veel zorg de tekeningen voor dit 
proefschrift, die vervolgens door de afdeling Medische Fotogra­
fie (hoofd: ATA Reynen) drukklaar werden gemaakt. De medewerk­
ers van de Medische Bibliotheek (hoofd E de G r a a f f } , waren be ­
hulpzaam bij het verzamelen van de literatuur.
Het snelle en accurate typewerk van mevr Pat Mey-Fullroth, 
secretaresse van de afdeling Maag-, Darm- en Leverziekten, is 
reeds in vele proefschriften geroemd. Ook haar delegerende 
kwaliteiten, waardoor ik de indruk heb gekregen dat noch Tine 
Reintjes noch Els Teunessen zich aan typewerk van een van de 
versies van enig artikel hebben kunnen onttrekken, dienen niet 
onvermeld te blijven.
Alle (oud-)medewerkers van het Laboratorium voor Maag-,
Darm- en Leverziekten bedank ik voor de prettige samenwerking.
Het belang van stelling X uit het proefschrift van Dr HTM Cuy- 
pers, dat het instellen van een "verplicht" uurtje rikken in de 
middagpauze in plaats van een "discussie"uurtje bijdraagt tot 
een prettige werksfeer, dient hierbij nog eens benadrukt te wor­
den .
De uitgave van dit proefschrift werd mogelijk gemaakt door 
financiële steun van de firma SK&F.
Helaas laat het promotieregelement van deze universiteit mij 
niet toe, hem, die door zijn vele bijzondere kwaliteiten het meest 
aan het tot stand komen van dit proefschrift heeft bijgedragen, op 
deze plaats te bedanken.
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CURRICULUM VITAE
De schrijver van dit proefschrift werd op 23 augustus 1948 
te Aarle-Rixtel geboren.
In 1967 behaalde hij aan het Dr. Knippenbergcollege te 
Helmond het einddiploma HBS-B.
Vanaf 1967 studeerde hij geneeskunde aan de Katholieke 
Universiteit te Nijmegen. In 1973 werd het doctoraalexamen en 
in 1975 het artsexamen behaald. Daarna begon zijn opleiding tot 
internist bij Dr. M. van Zoeren, in het Militair Hospitaal 
"Dr. A. Mathijsen" te Utrecht (hoofd opleiding destijds: D r . C. 
van B e l l e ^ ) . In 1977 werd deze opleiding voortgezet aan de Uni­
versiteitskliniek voor Inwendige Ziekten van het Radboudzieken- 
huis te Nijmegen (hoofd destijds: Prof. Dr. C.L.H. Majoor^, hui­
dig hoofd: Prof. Dr. A. van 't Laar). In november 1980 werd hij 
ingeschreven in het specialistenregister.
Van 1 maart 1980 tot 1 september 1983 was hij als weten­
schappelijk medewerker in dienst van de Stichting Zuiver Weten­
schappelijk Onderzoek (FUNGO) verbonden aan de afdeling Maag-, 
Darm- en Leverziekten, tijdens welke periode het onderzoek 
plaatsvond dat resulteerde in dit proefschrift. Vanaf 1 septem­
ber 1983 is hij als wetenschappelijk medewerker in dienst van 
het Koningin Wilhelmina Fonds verbonden aan de afdeling Maag-, 
Darm- en Leverziekten van het Radboudziekenhuis te Nijmegen.
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